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The research work described in this thesis, the environmentally 
friendly novel ―Microwave Assisted Sub-Critical water (MASCW)‖ technology 
for particle engineering of active pharmaceutical ingredients and excipients 
was developed. The present novel technology MASCW process is described 
as green technology as water is used as the solvent medium and microwave 
energy as external source of heat energy for generation of a particle with 
different morphological and chemical properties. 
In MASCW process supersaturated solution of APIs is prepared by 
dissolving solute in water at high temperature and pressure conditions. Upon 
rapid and controlled cooling, based on the aqueous solubility of solute, 
solute/solvent concentration and dielectric constant of water rapid 
precipitation of API with narrow particle size distribution occurs.  
 Using paracetamol (pca) as API moiety understanding of the 
mechanism of MASCW crystallisation process was investigated. The effect 
of different process and experimental parameters on crystallisation pathway 
and end product attributes were analysed. Correlation between the degree of 
supersaturation concentration of pca solution against temperature and 
pressure parameters was explained by generating binary phase diagram. 
Determination of polymorphic transformation pathway of pca from form I 
(stable) to form II metastable polymorphs in solution was analysed using 
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Raman spectroscopy. The difference between conventional heating and 
subcritical treatment was explored by determining the change in the solvent 
dielectric constant and solubility of hydrophobic API molecule. 
Based on the process understanding results, this technology was 
further implemented to explore its application in generating phase pure 
stable and metastable cocrystal phase. Based on the solubility of API and 
cocrystal former congruent (CBZ/SAC, SMT/SAC, SMZ/SAC) and 
incongruent (CAF/4HBA) cocrystal pairs were selected. For the first time 
generation of anhydrous phase of CAF: 4HBA cocrystal in 1:1 stoichiometric 
ration was reported and generation of metastable cocrystal phase of CA 
CBZ: SAC form II was reported. 
The application of this technology was explored in generating phase 
pure metastable polymorph of paracetamol which retain higher 
compressibility and dissolution rate. The potential of MASCW micronisation 
process, theophylline is used as the model component to produce micro-
sized particles for pulmonary drug delivery system via dry powder inhaler 
(Foradil inhaler). The results demonstrate that the THF particles generated 
using MASCW process displayed greater aerodynamic performance 
compared to conventional spray-dried THF sample. 
In the final chapter, synthesis of inorganic biomaterial (nano-
crystalline hydroxyapatite) was reported for the first time and the prospects of 
combining API like ibuprofen (IBU) with a biologically active component like 
nano-crystalline hydroxyapatite (HA) through hydrogen bonding was 
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Chapter 1: Introduction 
1.1 Introduction 
Active pharmaceutical ingredients (APIs) are frequently delivered to the 
patients in the solid state form (e.g., tablets, capsules, pellets) as part of an 
approved dosage forms as during storage of API or drug formulations solid 
state provides the most compact, convenient and generally stable state. In 
drug development and processing industry, understanding and controlling 
the solid-state chemistry of API, both as pure drug and in the formulation is 
the important challenge to be considered (Morissette et al., 2004). Recently, 
due to increased interest in the field of crystal engineering high throughput 
screening (HTS) is implemented to elucidate different physical and chemical 
properties of APIs. Based on recent finding of HTS about 30-40% of all 
identified APIs are hydrophobic in nature. The bioavailability of these 
insoluble drugs is highly based on its aqueous solubility and therefore to 
enhance the solubility and dissolution property  is an important challenge for 
pharmaceutical processing and development industry (Maniruzzaman et al., 
2013). As it is not feasible to substitute poorly soluble drugs with highly 
soluble drugs so large proportions of academic researchers and 
pharmaceutical industries are focused in developing new crystallisation or 
processing technologies to enhance their physicochemical properties like 
solubility, stability, rate of dissolution, bioavailability and compressibility by 
altering chemical and morphological properties of chemical components. 
There are various process technologies reported targeting the followings 
requirements in crystal engineering of APIs: 1) product purity to retain quality 
standards, 2) isolation of chosen crystal form, 3) generate targeted uniform 
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particle size and shape which will significantly affect bioavailability and 
processability, 4) high yield and 5) reasonable cycle time (Variankaval et al., 
2008). Most traditionally used crystallisation technique is solution state 
crystallisation method in which based on the solubility of the solute in the 
organic solvent; a saturated solution is prepared and left for the solvent to 
evaporate when concentration between solute and solvent increases than 
the crystal starts inducing out. The main disadvantage of this method is use 
of an organic solvent which may cause toxicity side effects, formation of 
phase impurities (formation of solvates, hydrates) and time required for the 
crystallisation varies from days to weeks (Bruni et al., 2012). Sonic energy or 
Ultrasound assisted crystallisation is implemented in crystal engineering this 
is also referred as sonochemical crystallisation which includes sonic energy 
to induce crystal from supersaturated solution or slurry. Limitations of this 
technology includes the use of organic solvents, no phase pure crystals are 
formed, this technology is lacking in scalability (Aher et al., 2010) (Dejan-
Kresimir Bucar et al., 2015 ). Another technique which includes use of 
organic solvents or aqueous solvent mixtures in particle crystallisation is 
Spray drying technique; this involves production of dry powder by rapid 
evaporation of solvents due to presence of hot air stream. Limitations of this 
technique are generation of impure crystal phases, less yield percentage, 
high static charges  and use of organic solvents (Alhalaweh and Velaga., 
2010). Freeze drying technique is used for generation of co-crystals, it is the 
technology where crystallisation occurs from amorphous state due to 
sublimation of solvent, the limiting factors are use of organic solvents, 
stability issues due to presence of residual solvent molecules, drying step is 
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long lasting and cost of processing is not economical (Eddleston et al., 
2013). Solvent free technologies like Hot-melt extrusion (Choy 2003; Yang et 
al., 2007) are developed to eradicate the use of organic solvents, HME is the 
process where external shear and temperature is used to dissolve the 
ingredients by forming melts and generate co-crystals or amorphous solid 
dispersions of API and excipients (polymers, co-formers), the limiting factor 
in this technology is due to use of high temperature and shear conditions 
thermal degradation of drugs and polymers takes place  (Dhumal et al., 
2010) and due to use of polymer the stable drug load for formulation is less 
between 20-25%w/w between API and polymer. Recently supercritical fluid 
technology is developed to process non-polar bioactive and thermally labile 
components; this technology includes the use of supercritical carbon dioxide 
at high stress conditions as solvent system for the generation of particles. 
Due to its high capital cost, difficulty in controlling crystallisation pathway and 
use of solvent modifiers hindered its application in pharmaceutical 
processing industry (Revelli et al., 2014). Chemical vapour deposition (CVD) 
is the recent technology developed in crystal engineering; this technology 
involves dissociation of gaseous reactants in the activated heat, light, plasma 
environment which is followed by generation of powdered samples of solid 
products. The limiting factor is use of large volume of toxic, corrosive 
precursor gases, high temperature and pressure conditions, difficulty to work 
with multi-component materials, impurities in the final product and use of 
very sophisticated reactors which are not economically feasible (Choy 2003). 
Based on the above mentioned limitations of exiting technologies a novel 
green technology as Microwave assisted sub-critical water processing 
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(MASCW) technology for particle engineering was developed. Sub-critical 
water-process technology is a widely applied technology in biomass 
processing industry and extraction of biological active components from 
natural sources (Gbashi et al., 2016). As the longevity and lifestyle of 
humans has been profoundly impacted by modern pharmaceutics, since last 
few years this sub-critical water technology has been implemented in the 
field of pharmaceuticals to enhance the pharmacokinetic properties of 
pharmaceutical ingredients particularly hydrophobic drugs (Carr et al., 2011) 
but the experiments are performed in milligrams scale lacking commercial 
importance. In the present thesis upon considering all the limiting factors and 
challenges in the crystallisation and pharmaceutical processing technologies, 
scalable MASCW crystallisation technology has been reported for the first 
time, where water is acting as the green solvent system used for 
crystallisation and complex formation, microwave energy is used as external 
energy source to speed up the reaction by retaining chemical integrity of the 
components. This technology in my thesis is further explored for the 
generation of cocrystals (congruent and incongruent pairs), metastable 
polymorphs, API micronisation process for pulmonary drug delivery system 
and synthesis of biomaterials like hydroxyapatite and API loaded biomaterial 
complexes. 
The present thesis work is categorised based on two major objectives: First 
objective, is process understanding and validation of different experimental 
and process parameters, secondly includes investigation the application of 
this technology for generation of cocrystals, polymorph, micro, and nano-
sized particles for inhalation drug delivery system and complex formation 
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between API with inorganic biomaterials (hydroxyapatite). A brief description 
of individual chapters is explained below (Refer Section 1.2). 
This technology is based on micronisation process where pharmaceutical 
ingredients are crystallised into micron or nano sized particles with altered 
smooth crystal habit. By micronising API particularly poorly soluble drugs, the 
rate of dissolution can be enhanced prominently which will aid in the drug 
distribution to the site of reaction (Clarke et al., 2011). Reduction in the 
particle size of the drugs the effectiveness of the drug can be increased, 
which could reduce the required drug dose, reducing cost and risk of side 
effects caused due to excessive use of drugs. 
Various process parameters of the crystallisation process determine different 
chemical and physical attributes of crystal products such as size, shape, 
purity and polymorphic form, these properties affect the different 
physicochemical properties of individual drugs or drug formulations (Yu et al., 
2007). The positive aspects of this technology are: 
 Pathway of crystallisation and specifications of the end products can 
be monitored easily by controlling different process parameters. 
 It is a single continuous process where reaction kinetics is continuous 
and quick. 
 Based on the dielectric constant of water and level of supersaturation 
metastable phases of co-crystal pairs and polymorphs can be 
generated with enhanced physical and chemical properties. 
 It includes water as the only green solvent system for the formation of 
a non-covalent interaction between APIs and excipients; therefore the 
risk of residual organic solvent is eliminated. 
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 Heating and cooling steps are well controlled retaining bioactivity of 
APIs. There is no degradation of the API taking place as it is not 
subjected to large shear conditions. 
 Due to the use of microwave energy uniform heat transfer occurs 
between solute and solvent molecules which prevent product 
impurities and reduce the processing duration add reference. 
 Most importantly, this technology is scalable from small scale to 
industrial processing scale; these experiments were performed by our 
industrial partner. 
Microwave energy is used as the heating source for the water to enable 
faster and effective heating of water molecules to achieve the desired 
processing conditions and to retain solute chemical stability. The main 
principle on which the water at sub-critical level works is the change in 
dielectric constant of water at elevated temperature and pressure conditions, 
as it is well known fact that at high temperatures the dielectric constant of 
water decreases and the polarity increases, hence solubilisation property of 
water increases.  The temperature range between 100°C – 374°C is referred 
as sub-critical temperature and the water in this range is referred as 
subcritical water. The water molecule in this temperature conditions has the 
properties to retain its elastic property (liquid state) upon cooling step 
(Adachi 2009) and when treated above this temperature than it is referred as 
supercritical water where the elastic property of water is lost in this region. 
The clear mechanism of this sub-critical water is pictographically represented 




Figure 1.1 Phase diagram of water at elevated temperature and 
pressure conditions (Asl and Khajenoori 2013) 
In MASCW technology volumetric and homogenous heating of water is 
involved which aid for the homogeneous nucleation process to take place 
during cooling step. Different properties of MASCW processed 
pharmaceutical ingredients are studied like surface properties, kinetic 
property, aerodynamic performance, solubility, dissolution rate and stability. 
While exploring this technology for cocrystallisation and polymorphism the 
challenges associated with thermal degradation, hydrate formation and effect 
of different process parameters on the end product was considered.  
1.2 Research objectives 
The main focus of this thesis is to investigate the potential applications of 
MASCW process technology in the field of crystal engineering for generation 
of micro and nano-sized API particles with enhanced physicochemical 
properties.   
1. Understanding the physical and chemical properties of water at the 
subcritical level and proposing the mechanism of crystallisation.  
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2. Explore understanding regarding crystallisation kinetic of API using 
MASCW process. 
3. Explore this novel technology in the field of crystal engineering for the 
generation of stable and metastable phases of both congruent and 
incongruent cocrystal pairs. 
4. To understand the correlation between process and experimental 
parameters for the synthesis of stable and metastable polymorphs of 
API. 
5. To develop commercially potential technology for transformation from 
small scale to large scale. 
6. To investigate the use of this process for development of drugs with 
high compressibility for tableting process and aerodynamic 
performance for inhalation drug delivery system. 
7. To investigate the use of the MASCW process for complex formation 
between API and biomaterials. 
1.3 Thesis outline 
Chapter 2 – includes literature review and background, literature review 
includes three sections 1) brief description regarding supramolecular 
chemistry, different solid form, 2) include description regarding cocrystal 
complex, mechanism of cocrystallisation, its applications, challenges and 
different technologies used for cocrystallisation, 3) this section includes  
description regarding polymorphism, rules for predicting pathway of 
polymorphism and applications.  
Chapter 3 – includes background description of subcritical water process, its 
applications, the structure of water and effect of different process parameters 
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on subcritical water process. A brief discussion of the chemical structure of 
water, the effect of microwave energies and application of microwave reactor 
is described. The description regarding present work and proposed 
mechanism of microwave assisted subcritical water (MASCW) is 
schematically described. 
Chapter 4 - includes the materials and methods section, this section is 
further categories into three sections. Section one includes the structural and 
chemical description of all the drugs, excipients and solvents used in this 
research work. Section two includes the summary of different experimental 
designs and conditions implemented to study and understand the technology 
and the final section includes the brief description regarding the general 
working principles of different analytical tools and software versions used to 
analyse the data. 
Chapter 5 - includes process understanding and validation of MASCW 
process, for this, different process and experimental conditions were 
considered to understand and validate MASCW process technology. Based 
on the solubility, physical and chemical properties paracetamol was selected 
as a model compound to investigate the correlation between supersaturation 
solution concentration and crystallisation time using MASCW process and 
further comparing the results with conventional heating process. Correlation 
between the paracetamol solubility and temperature-pressure parameters is 
explored. Effect of process temperature and pressure conditions on the 




Crystallisation kinetics of MASCW treated a supersaturated solution of 
paracetamol is monitored using Raman spectroscopy over 22hrs. Different 
solvent mixtures of methanol-water, ethanol-water, acetonitrile-water and 
acetone-water at 10, 20 and 30% v/v concentration were selected to 
understand the effect of the solvent mixture on the dielectric constant of the 
solution, equilibrium solubility of paracetamol in solvent mixtures, physical 
state and chemical stability of paracetamol.  
Below Figure 1.2 represents the schematic diagram to summarise different 
experiments performed to explore the application of the MASCW process in 
crystal engineering and complex formation.  
 
Figure 1.2 Schematic representation of research work 
Chapter 6: After process validation in this section the application of MASCW 
technology for generation of stable and metastable cocrystal pairs was 
explored. Carbamazepine (CBZ) and saccharine (SAC) cocrystal pair were 
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considered for the production of stable form I and metastable form II 
cocrystals of CBZ-SAC cocrystal in 1:1 stoichiometric ratio, along with this 
pair sulfamerazine and sulfamethazine cocrystals were produced using SAC 
as co-former. Effect of process parameters like temperature, energy, solvent 
concentration, and solute (API)-solute (coformer) concentration on phase 
purity of end product is investigated. All the above pairs for cocrystallisation 
are congruent pairs based on their solubility in water. For the first time, the 
effect of solvent mixture for the product of incongruent pair cocrystal of CAF: 
4HBA in 1:1 stoichiometric ratio was explored (Aher et al.,2010). 
Chapter 7: This section is further divided into two section, the first section 
includes generation of stable and metastable polymorphs is investigated 
using paracetamol as the lead API for production of paracetamol form I 
stable and paracetamol form II metastable polymorph. Equilibrium solubility, 
intrinsic dissolution rate and surface properties of this MASCW treated 
paracetamol form I and form II is investigated keeping raw paracetamol form 
I as a reference. In this section, the scalability of this technology is explored 
by performing the experiment on the large-scale manufacturing unit by our 
industrial partner.  
In the second section, MASCW technology is used to explore its application 
for the generation of micron-sized stable particles for inhalation drug delivery 
route using dry-powder inhaler device. Anhydrous theophylline (THF) is 
selected as a model component for inhalation drug delivery route and 
aerodynamic performance of MASCW treated THF is investigated against 
conventional spray-dried THF.  
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Chapter 8: In this final chapter this technology is implemented in the 
synthesis of phase-pure hydroxyapatite (nano-crystalline) and further 
complex material is formed between the synthesised nano-crystalline HA and 
ibuprofen as API. Mechanism of the hydrogen-bonded complex formation 
between IBU and microcrystalline HA is studied using infra-red spectroscopy 
and computational simulations were performed to understand the 


















Chapter 2: Literature review 
2.1 Introduction 
The drug discovery and processing industries are facing considerable 
challenges as they progress through development stages due to increase in 
processing cost, a decrease in productivity, side effects caused due to use of 
chemicals during processing pharmaceutical products. Most of the 
biopharmaceutical industries are facing challenges due to decrease in output 
in comparison with the enormous increase in pharma R&D spending. Most of 
the big pharma companies had prodigiously invested a huge amount in novel 
technologies such as combinatorial chemistry, structural based design of the 
drug, high-throughput screening (Rodrıǵuez-Spong, 2004) and genomics but 
all failed in generating productivity. US companies have invested $100 
million dollars in HTS technology with the promise of enhancing drug 
productivity but so far it has been successful with very few products. This 
challenge of cost, productivity issues, challenges from generics and ever-
increasing regulatory issues has forced many drug developers to become 
more creative in finding new applications of present drugs, to develop new 
novel green technologies for processing pharmaceutical drugs and to 
develop new versions of existing drugs with enhanced physicochemical 
properties (Ashburn and Thor, 2004). 
Due to present trend of mixed models of drug discovery and development, it 
has driven great opportunity for the different collaboration partners of 
different expertise to contribute unitedly in the field of pharmaceutical drug 
discovery and processing industry. Academic research has traditionally 
proved to be the powerhouses for the discovery of innovative drug 
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processing technologies and understanding the science and applications of 
the technology (Tralau-Stewart et al., 2009). The main objective of the 
pharma industries is to develop and discover medicines which are 
acceptable by regulatory authorities, patient healthcare bodies and 
healthcare providers. They expect to reduce the cost of the drug processing, 
maintain process drugs safely and improve patients quality of life,  thus 
based on the current challenges cost of processing drugs, quality of drugs 
and speed of processing has become the potential requirement for all the 
drug discovery and development activities (Elebring et al., 2012).  
Pharmaceutical product development is proprietarily driven by rigorous and 
continuous innovation in the fields of drug discovery, process engineering, 
drug polymorph design and dosage form design fulfilling regulatory 
standards. About 90% of the new APIs are having low aqueous solubility so 
micromeritic properties and solubility of APIs has become very prevalent in 
the research and development of new drugs. Thus primary aim of the 
pharmaceutical industry is to generate new pharmaceutical material 
engineering technologies to design pharmaceutical particles and dosage 
forms which results in an increase in efficiency of the manufacturing process, 
resulting the high degree of functionality to the drugs and pharmaceutical 
excipients (El-Zhry El-Yafi and El-Zein 2015).  
In the present thesis, the proposed new technology is implemented to 
manipulate the physical properties and chemical form of pharmaceutical 
ingredients and excipients to enhance their chemical stability, 
thermodynamic and kinetic performance. Earlier drug discovery is based on 
serendipitous discoveries or through traditional ways but since last two 
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decades due to increasing in the number of unknown diseases and 
development of drug resistance by the microbes,  the development of new 
rational remedies for the design and processing of drugs is highly in demand 
(Thakuria et al., 2013b). Various drug processing technologies like high-
throughput screening and combinatorial chemistry were developed to 
enhance the solubility and dissolution rate of lipophilic drugs. Various studies 
have been proposed to understand the molecular association and molecular 
chemistry of chemical ingredients.  
2.1.1 Supramolecular chemistry  
Supramolecular Chemistry is firstly proposed by Jean-Marie Lehn (Chiou, 
1969) which deals with the study of molecular association and intramolecular 
bonding involved between the reactant molecules. This involves the study of 
the non-covalent interaction between two chemical entities where one is 
referred as a host molecule and the other is referred as a guest molecule. 
Currently, supramolecular chemistry has further extended its understanding 
of molecular assembly, molecular recognition and self-assembly. 
Supramolecular chemistry has become interdisciplinary study as it includes 
nano-chemistry and certain complex materials (Ismael Rafols., 2010).  
 
Figure 2.1 Pictographic representation of a comparison between 
molecular chemistry and supramolecular chemistry (Kumar 2014) 
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2.1.2 Solid State chemistry 
Due to vast variations in the chemical properties of the solid materials, it is 
not understood completely. To understand the solid-state chemistry it is very 
important to have the knowledge regarding the physical, chemical properties 
of the solid materials and the interactions which are responsible for holding 
the solid materials together. The study of the solid state generally deals with 
the synthesis of organic and inorganic materials, its characterisation, crystal 
structure properties and applications in various medical devices. Recently a 
new branch of chemistry has taken birth from solid state chemistry which is 
termed as “Materials Chemistry” which deals with the non-molecular and 
molecular materials. These materials are increasing the interest of the 
researchers as it has improved the understanding of structure-property 
relationships. Generally, X-ray diffraction technique is used to study the 
molecular motions in the lattice, lattice arrangement of the molecules, and 
the extent of crystallinity. Crystal Engineering is the newly evolved section of 
solid state chemistry which deals with the design and modeling of new 
crystal structures with similar or different molecules which act as building 
blocks. This study demands the detailed understanding of the molecular 
structure and interactions between the molecules which act as a building 
glue for the crystal. This study gained importance when Bragg‘s discovered 
X-ray crystallographic study of naphthalene and anthracene. 
Most of the pharmaceutical industries are concerned with the optimisation of 
API to attain required therapeutic activity. During formulation, certain physical 
properties like dissolution rate, solubility, physical and chemical stability and 
hygroscopicity are considered (Jones.W, 2006). Most of the API dosage 
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forms are solid dosage forms which exist in the crystalline or amorphous 
forms, but due to instability under storage and processing conditions they get 
converted into different forms which are responsible to induce adverse 
effects or desired effect is not attained. This diversity is due to non-covalent 
interactions between the components and the interplay between the enthalpy 
and entropy (Duarte, 2006). To surmount this hurdle various substituted 
forms like API hydrate, solvate, salts, polymorphs were generated and 
analysed using single crystal data and advanced analytical tools but recently 
pharmaceutical co-crystal has brought into focus which has given positive 
results in optimising physical and chemical properties of various API‘s 
(Jones. W, 2006). Various studies and process technologies were developed 
to produce API with improved physicochemical properties out of which 
cocrystal generation displayed improved physicochemical properties of API 
displaying good stability.  
2.1.3 Classification of Solid forms  
Solids are defined as the form of matter with definite shape and volume due 
to their rigid molecular arrangements. Intermolecular forces in the solids are 
strong interactions so they don‘t possess translatory motion, they can only 
vibrate from their positions until an external force or stress is applied. Based 
on the above properties of the solids there are mainly classified into two 
categories amorphous and crystalline solid forms (Sekhon, 2009). Figure 2.2 
illustrates the classification of different solid forms of API into its substituent‘s 
based on its chemical structure composition and molecular arrangements. 
Co-crystals come under the category of multicomponent crystalline forms 
which consist of two or more chemical components fused together in a single 
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crystal lattice. Polymorphs are categorised under the single component 
system as they occur within the same molecule. 
 
Figure 2.2 Classification of solid forms based on structure and 
composition 
Amorphous solid forms are also referred as non-crystalline solid forms as 
they lack arrangement in long-range order which is characteristic of a crystal. 
The molecules in the amorphous solid are not arranged in the particular 
order so they lack crystallinity. Other materials which come under amorphous 
solid forms are gels, polymers.  Crystalline solid forms based on the number 
of components are further classified as a single component when only one 
chemical component is involved in representing the crystalline structure and 
multicomponent system when two or more chemical components are 
involved in the formation of single components through different covalent and 
noncovalent interactions. Polymorphs are categorised under the single 
component system as this polymorphs keep the ability to retain similar 
molecular structure but vary in molecular conformations. In multicomponent 
system is referred as hydrates when the crystal lattice consists of a bonded 
water molecule. In a multicomponent system if there are molecules with 
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ionisable acid and base functional groups than these are referred as salts. 
APIs which undergo ionisation are included in this class of solids, there are 
very few salts like sildenafil sodium salt, piroxicam salt exists in zwitterion 
form (Mahajan and Sharma 2011). Salts, hydrates, and solvates are 
multicomponent systems which are similar to cocrystals but different in 
intermolecular bonding, stability, crystal structure and molecular arrangement 
(Newman 2009). Cocrystals are the multicomponent solid form which 
consists of two solid molecules which form a single complex through 
intermolecular bonding, which is attained in the presence or in absence of 
solvent system (Sekon 2009).   
 
Figure 2.1 Possible multicomponent systems: cocrystals, salt 
cocrystals and derived multicomponent systems (Newman 2009) 
Multicomponent system is referred as solvates when the solvent molecules 
retain the capacity to interact with the API and form the complex (Figure 2.3) 
(Aitipamula et al., 2012). It is analysed that about one third of the 
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pharmaceutical materials and formulations are sensitive to humidity 
conditions as they undergo hydrate formation during storage or when 
exposed to atmospheric moisture (Andrew V. Trask, 2005). Cocrystals gain 
advantage over amorphous material due to its low Gibbs free energy and 
stability to maintain its crystalline structure and they retain the phase purity 
whereas amorphous materials undergo phase transformation to crystal state 
during storage due to its molecular rearrangement.  
2.2 Cocrystal  
2.2.1 Introduction  
The term ―cocrystal‖ originates from ―a composite crystal‖ (Rahul Banerjee, 
2005), over the last decade, the co-crystallisation has become prominent and 
gained importance in the pharmaceutical processing sector. This increase in 
importance is due to the ability of the co-crystals to enhance the 
physicochemical properties like solubility, chemical stability, physical stability, 
dissolution rate, and  bioavailability without altering the therapeutic properties 
of active APIs (Clarke, 2011) or without modifying the bioactivity of APIs 
(Newman, 2009). In the process of co-crystallisation involves molecular 
rearrangement and interaction between two or more chemical components 
which are responsible to sustain the fundamental physical properties 
(Newman, 2009). This new technique of cocrystallisation has gained the 
support of FDA on intellectual property right for developing and patenting 
new forms from ―old drugs‖ (Duarte, 2006). According to FDA guidelines of 
2013, the cocrystals are defined as ―Molecular association of two or more 
ingredients in the same chemical crystal lattice‖ . Pharmaceutical cocrystal is 
defined as the crystalline complex of two or more chemical molecules 
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arranged in a three dimensional crystal lattice which are held together by 
non-covalent interactions generally hydrogen bond, halogen bond or π-π 
interactions (Jones. W, 2006). As discussed before that cocrystal molecular 
lattice consists of two components, one of the components is referred as 
Active Pharmaceutical Ingredient and other as cocrystal former (CCF, 
pharmaceutical excipient) (Clarke et al., 2011). This excipient (CCF) is 
responsible for the formation of weak non-covalent interactions with the API ( 
Jones .W, 2006). As most of the API‘s exists in the crystalline form, a small 
modifications in its crystal structure may alter its physical and chemical 
properties, based on the similar hypothesis co-crystals are designed where 
the weak non-covalent bonds would exist between the API and CCF, which 
can alter chemical and physical properties without altering the therapeutic 
properties of the API (Sekon, 2009). To design cocrystal complex between 
two chemical components is not an easy task as various factors such as 
individual component solubility, lattice-free energy, Pka values are 
considered before forming cocrystal complex. Due to reported enhancement 
of physical and chemical performance of APIs through cocrystallisation 
process gained interest of various researchers, they  have developed various 
methods for preparation of cocrystals, which include liquid assisted grinding 
(Trask et al., 2006), solution crystallisation, spray drying (Mehta, 2013), hot-
melt extrusion (Kelly et al., 2012), ultrasound assisted crystallisation (Aher et 
al., 2010), supercritical crystallisation (Bala Subramaniam, 1997). In all these 
technologies, there are certain challenges which proved to be negative such 
as the use of large amount of solvents, process temperature is very high so 
degradation percentage is more, time consuming processes, non-uniform 
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ratios of API and co-formers are processed and very limited control over the 
process parameters (Daurio et al., 2011).The new technique introduced by 
research group from University of Bradford (UoB), omitted the use of solvent 
and the cocrystals were prepared from the solid-melt using hot-melt 
extrusion technology. UoB have introduced new solvent-free technology 
which is twin screw extrusion technology and titled it as SFCC (Dhumal et 
al., 2010). 
2.2.2 Design of cocrystal 
Cocrystallisation process is induces due to result of competing molecular 
association between two similar (homomers) or two different molecules 
(heteromers)  through intermolecular non-covalent interactions such as 
hydrogen bond, Van-der-Waals forces and π-π interactions (Jampilek and 
Dohnal 2012). The two components in a cocrystal may exist in different 
stoichiometric ratios like 1:1, 2:1, 1:2. Crystal structure of cocrystal complex 
is different from original starting materials and as such they often exhibit 
different physical and chemical properties than the starting materials. Design 
and preparation of cocrystals of pharmaceutical ingredients is a multistage 
process as described schematically in Figure 2.4 (Qiao et al., 2011). 
 




For the process of cocrystallisation to take place knowledge regarding the 
chemical nature of the coformer is very important because the chemical 
nature of the co-former decides the type of bonding between the API and 
coformer. Desiraju and co-workers have postulated that the selection of 
coformer is based on the ―synthon‖ approach which is responsible for the 
interaction of specific fragments of API for the formation of ―supramolecular 
synthon‖. The functional group present on the drug and the coformer should 
be complementary to each other to form co-crystals. This association is 
based on the type and bonding properties of the functional groups present on 
the API and coformer. Some typical supramolecular synthons are carboxylic 
acid-acid synthon, amide-amide synthon, the acid-pyridine heterosynthon 
and acid-amide synthon are shown in below Figure 2.5 (Thakuria et al., 
2013a). 
 
Figure 2.5 Types of hydrogen bonding between two synthons (a) acid-
acid, (b) acid-amine, (c) acid-amide, (d) acid-imide, (e) amide-amide and 
(f) alcohol-ether.(Thakuria et al., 2013a) 
The limitations of the synthon approach are that the steric hindrance, 
molecular arrangement, steric density around the functional groups and 
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competition between them are not considered. Later, Fabian and Fayos  
considered the polar density and crystal shape which are the important 
factors for the generation of co-crystal (Khuwijitjaru, 2014). The 
computational prediction is done by Hunter, Sally Price and coworkers for 
predicting cocrystal formation, this method is accepted and brought into 
practice by various researchers (Thakuria et al., 2013a). According to US-
FDA guidelines, the selection of API and cocrystal former for cocrystallisation 
are based on its pKa value between the acidic and basic conjugates. This 
enables us to study the interaction between API and coformer is either ionic 
or non-ionic interactions. 
If ∆pKa value is less than zero, where very less proton transfer take place 
than the reaction is driven to form cocrystals   
                                    𝐀 − 𝐇 + 𝐁 ↔ 𝐀−𝐇… . .𝐁    (Properties) 
If the ∆pKa value is greater than three, proton transfer is expected then the 
reaction results in salt formations.  
                                     𝐀 − 𝐇 + 𝐁 ↔ 𝐀− 𝐁+  𝐇−             (salts) 
If ∆pKa is > 0 < 3 then it becomes difficult to predict the degree of ionisation. 
2.2.3 Challenges in cocrystallisation process 
There are various obstacles in the co-crystallisation process such as 
scalability, reproducibility, stability, purity and other physical and chemical 
properties. Apart from various advantages for the co-crystallisation, there are 
certain factors need to be considered as process parameters, selection of 




2.2.3.1 Incongruent co-crystal pair 
Technologies like solution crystallisation spray drying, slurry crystallisation, 
solvent evaporation, cooling crystallisation and anti-solvent crystallisation 
include the use of the solvent system for the generation of co-crystal. So it is 
very important to consider the solubility of two components in the solvent, if 
they are miscible then they are referred as a congruent pair and if the two co-
crystallisation components are having a large variation in the solubility 
parameter in the given solvent then this type of pairs are referred as an 
incongruent pair. In incongruent pair as the solubility of the two components 
vary largely, the level of supersaturation in the selected solvent system will 
not be achieved and as a result crystals of API or co-former or their solvates 
or hydrates induce as an impurity (Rager and Hilfiker 2010). Example for the 
incongruent pair is caffeine and maleic acid, recently Mehta and group 
(Alhalaweh et al., 2013) proposed the diversities obtained in stoichiometric 
ratio when caffeine and maleic acid in aqueous solutions were spray dried.  
Different approaches are been adopted by various researchers to for stable 
cocrystal complexes of incongruent pairs: (1) preparation of a supersaturated 
solution of two components using a solvent mixture, the solvent mixture will 
further reduce the dielectric constant of the solution compared with the 
individual solvent system. This promoted the increase in solubility of the two 
components in the solvent mixture (Childs et al., 2008; Rager and Hilfiker 
2010),Sander and group selection of two components in different 
stoichiometric ratios to prevent stoichiometric diversity (Sander et al., 2010) 
(Porter et al.,2008), (Aher et al., 2010) used surfactants to enhance the 
solubility of sparingly soluble pharmaceutical compounds. 
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2.2.3.2 Spring-parachute effect 
The spring-parachute effect is implemented to increase the bioavailability of 
poorly soluble APIs by enhancing their solubility. This effect is used in 
formulations like amorphous formulation (solid dispersion), salts, self-
emulsifying formulations and co-crystals (Childs et al., 2008). It has been 
derived based on the solubility curve generated by the API formulations. 
Spring represents the sudden increase in the solubility of the API in the 
media and parachute indicates the time interval where the desired 
therapeutic concentration has been attained. These two effects occurring 
simultaneously are important to attain desired therapeutic effect. If parachute 
effect is missing, the drug release is very fast and quick that the desired 
therapeutic effect is not attained. In the field of co-crystals, this effect is seen 
when the crystalline API gets transformed into an amorphous form which is 
spring effect and this amorphous form over a period of time gets converted 
into insoluble crystalline API which is parachute effect. Nangia and group 
have proposed the importance of selection of coformers to obtain this effect 




Figure 2.6 Graphical representation of spring-parachute effect. (Babu 
and Nangia 2011) 
Velaga group has demonstrated the spring without parachute effect in case 
of indomethacin/saccharin co-crystals with less in vivo bioavailability. 
Recently to enhance the bioavailability of API in the dissolution media, 
certain biocompatible polymers are used which enhances the solubility and 
bioavailability (Childs et al., 2013). 
2.2.4 Mechanism of cocrystal formations 
Understanding the molecular interactions responsible for the formation of 
molecular complexes is very important not only in understanding the ability to 
control pharmaceutical properties by monitoring covalent bonds but also it is 
used to design new pharmaceutical materials. In the recent years, advances 
in the field of crystal engineering and supramolecular chemistry have gained 
the interest of many scientists to perform advanced research on 
pharmaceutical materials to form cocrystals ( Jones.S., 2006).  
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Different technology and methods were developed to produce and 
understand the mechanisms of cocrystallisation. The proposed mechanisms 
are solution state reaction crystallisation, thermal fusion method, the eutectic 
and vapor phase method and deliquescence methods. 
2.2.4.1 Solution state crystallisation mechanism; is an ancient method of 
crystallisation where the solute based on the solubility it is dissolved in the 
solvent and kept in the ambient conditions for the solvent to evaporate and 
based on solute/solvent supersaturation level crystals starts inducing out. 
This reaction crystallisation mechanism is based on the chemical association 
between the solute and the solvent molecules, this molecular association 
acts as the driving force for the crystallisation to take place. The theory 
states that difference between the individual solubility of the chemicals at the 
equilibrium and at the supersaturated state is an important factor to be 
considered to predict the rate of crystallisation. 
If a binary phase cocrystal pair of 1:1 molar stoichiometric ratio is dissolved 
in the pure solvent system into its individual components with no further 
complexation to form a saturated solution, the molar mass balance of 
individual components in the solution system can be explained in terms of 
molar solubility of cocrystals (S). 
                          𝐀 = 𝐒 𝐚𝐧𝐝  𝐁 = 𝐒 (𝐞𝐪𝐮𝐚𝐭𝐢𝐨𝐧.𝟏)                
The solubility product of the cocrystal components 
                          𝐊𝐬𝐩 = 𝐒
𝟐 𝐚𝐧𝐝 𝐒 = (𝐊𝐬𝐩 )
𝟏/𝟐 (𝒆𝒒𝒖𝒂𝒕𝒊𝒐𝒏.𝟐) 
The above solubility product is derived for the solutions where the two 
cocrystal components are added in the equimolar ratios to form saturated 
solution but if non-stoichiometric solution component is selected with excess 
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amount of cocrystal component or ligand is added (C), then the molar 
solubility becomes 
                           𝐀 = 𝐒 𝐚𝐧𝐝  𝐁 = 𝐒 + 𝐂 (𝐞𝐪𝐮𝐚𝐭𝐢𝐨𝐧.𝟑)          
                          therefore 𝐊𝐬𝐩 = 𝐒 𝐒 + 𝐂  (𝒆𝒒𝒖𝒂𝒕𝒊𝒐𝒏.𝟒)    
If excess amount of cocrystal former or ligand is present C>>S, then 
                                    𝐒 = 𝐊𝐬𝐩/𝐂 (𝒆𝒒𝒖𝒂𝒕𝒊𝒐𝒏.𝟓) 
The derived quadratic equation is: 
𝐒 =
−𝐂 +  𝐂𝟐 + 𝟒𝐊𝐬𝐩
𝟐
        (𝐞𝐪𝐮𝐚𝐭𝐢𝐨𝐧.𝟔) 
The above-proposed equation predicts that excess addition of cocrystal 
component or ligand reduces the solubility of the cocrystal in the solvent 
system under ambient conditions. The equilibrium constant for this reaction 
is proportional to the thermodynamic activity product of the API and co-
former. The co-crystal solubility can, therefore, be predicted by the solubility 
product if the activity of the solid is constant or equal to 1. 
This relation is explained with the help of solubility phase diagram in Figure  
2.7 ( J. Sarah., 2006). 
 
Figure 2.7 Solubility phase diagram of three components A, B, and 
cocrystal AB in the single solvent system.  
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The subscript ‗T‘ is a total concentration of components and [B]tr is the 
transition concentration. The four different zones in the phase diagram is 
referred as I-IV. The above phase diagram is based on the following 
assumptions: 1) Component A is less soluble than component B, 2) A is less 
soluble than component cocrystal AB in the stoichiometric solution, 3) there 
is no complexation or ionisation of the cocrystals in the solution, and 4) 
solubility of component A is independent on solubility of B in the solution 
system. [B]tr is the transition temperature where the solubility of the cocrystal 
AB is equal to the solubility of component A. 
Zone I in the phase diagram is the region where the component A is 
supersaturated and undersaturated with respect to cocrystal AB. In Zone II 
both AB and A is supersaturated and undersaturated in zone III. Zone IV is 
supersaturated with respect to AB and undersaturated with respect to A. The 
intersection point between the solubility of component A and AB cocrystal 
refers to the eutectic point and the solubility of the cocrystal can be 
calculated by using concentration of drug and coformer used. Group of (J. 
Sarah., 2006) proposed the above phase diagram to explains phase 
transformation occurring between the crystal and cocrystal in the solution. 
They have explained the effect of nonstoichiometric concentration of the two 
cocrystal components causing a reduction in the solubility of the cocrystal 
due to increase in the concentration of coformer and thus promote cocrystal 
crystallisation. 
2.2.4.2 Heat fusion mechanism; is a thermal method where the external 
thermal energy is used to fuse two cocrystal components for the formation of 
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cocrystals. Recent years mixed Kofler method is used as the screening tool 
to visualise the cocrystal formation of different pharmaceutical components  
(Berry 2008). David and group have implemented this thermal fusion 
technique as the screening tool for visualisation of cocrystal formation of 
nicotinamide as coformer and different API containing carboxylic acid chain, 
they proposed that this technique is used to understand the thermodynamic 
properties of individual components and cocrystal. They visualised the 
formation of cocrystal under glass slide induced with temperature. The basic 
mechanism of Kofler technique is illustrated in Fig 2.7. Component A is the 
highest melting point component and component B is the low melting point. 
These components are subjected to temperature and allowed to melt and 
then the boundaries of the two melt components are brought in contact 
where the mixing of the two components takes place and cocrystallisation 
occurs at this contact zone. 
 
Figure 2.8 Zone of mixing in fusion mechanism for cocrystal formation 
In the above Figure illustrates the pathway of cocrystal formation using 
thermo fusion mechanism using hot stage microscopy (HSM). Using HSM 
the eutectic melting profile of binary mixtures can be observed and maped. In 
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the above Figure higher melting component A is melted first and solidifies 
and then low melting component B is melted and brought in contact with 
component A, in the contact zone the solidified component A gets dissolved 
in liquid B producing a mixing zone and further when the sample is quenched 
cocrystals start inducing out. When these crystals are again heated till it 
melts a new cocrystal phase exhibiting birefringence can be observed 
(Nicole et al., 2012). 
2.2.4.3 Eutectic or vapor phase mechanism; this theory explains the 
formation of cocrystals during mechanical grinding. This method has been 
implemented in the recent years, by the use of co-grinding of API and 
coformer either as dry solids (neat grinding) or by solvent drop grinding 
(liquid assisted grinding) (Chadwick., 2007). This technology gained the 
interest of the researchers as this method requires less or no solvent system 
for cocrystallisation so it is environmentally friendly and secondly this 
mechanism can be used as a screening aid to generate novel cocrystal 
phases which are not formed from conventional solution crystallisation. 
Despite evident use of this technology very little study is performed to 
understand the mechanism of cocrystal formation. Rastogi and group worked 
with solid state grinding of picric acid complexes for the formation of 
complexes, they postulated that vapor diffusion as mass transfer mechanism 
during solid-state grinding (N.B.Singh.,1965). During solvent drop grinding on 
the basis of the additional degree of freedom due to the molecular collision 
occurring during grinding seed of cocrystal is generated (Shan et al., 2002). 
A further mechanism of grinding is proposed explaining the eutectic effect is 
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the reason when the two components undergo molecular migration, the 
molecules can undergo gas-solid, solid-solid and solid-liquid reactions.  
Recently eutectic effect is explained implementing mechanical grinding 
technology that during initial grinding experiment liquid phase is formed due 
to melt of the solid components and on further grinding this liquid and solid 
phase come in contact with each other and facilitate the formation of 
cocrystal seed (Chadwick ., 2007), binary phase diagram is also reported to 
explain the eutectic effect between two solid components during grinding. 
2.2.4.4 Deliquescence mediated cocrystallisation; this method is based 
on the hygroscopic property of the cocrystal component. In this method 
deliquescence, mediated crystallisation has been proposed to describe the 
formation of cocrystals in the solution phase. Different cocrystals have shown 
phase transformation in presence of humidity which will further affect the 
stability of the API.  
When two components containing deliquescent materials are selected the 
driving force for the cocrystallisation reaction to take place is the amount of 
moisture uptake by the deliquescent material at specific relative humidity, 
level of supersaturation of the two components and dissolution rate of the 
deliquescent component. Mechanism of moisture induced cocrystal is 





Figure 2.9 Pictogram of the mechanism of moisture in cocrystallisation, 
Ds deliquescent material, dissolution of cocrystal component and 
generation of a cocrystal of two components A and B (Jayasankar et 
al., 2007). 
In this method, one component is highly hygroscopic in nature such as 
sugars, organic and inorganic salts. This component readily uptake the 
surrounding moisture and gets solubilised further this solution interacts with 
the second cocrystal component forming a thin layer, thus solution-mediated 
nucleation occurs due to the dissolution of the cocrystal component in the 
deliquescent solution (Jayasankar et al., 2007).  
2.2.5 Applications of cocrystals 
Various researchers based on the experimental evidence have stated that 
due to co-crystal formation there is an enhancement in physical and 
chemical performance of pharmaceutical ingredients. Applications of 
cocrystal formation are as follows: 
A. Solubility enhancement - Cocrystallisation gained importance due to 
its capacity to monitor or enhance the solubility of pure APIs. This 
effect is observed by (Nehm, 2005) who demonstrated the phase 
solubility of CBZ/NIC cocrystals, which is higher than individual pure 
API (Rodríguez-Hornedo et al.,2008), they have studied the effect of 
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cocrystallisation used to enhance the solubility of poorly soluble 
ibuprofen. Fast dissolving curcumin is produced by this 
cocrystallisation approach by producing fast soluble polymorphs of 
curcumin (Sanphui et al., 2011). (Goud et al., 2014) group modulated 
the solubility parameters of sulfacetamide using cocrystal approach. 
B. Improved physical stability - Caffeine, and piracetam as API are very 
sensitive towards moisture, they readily uptake the moisture under 
storage conditions and form hydrates. To enhance the physical 
stability of such components (Jones W, 2006),( (Aitipamula et al., 
2012) generated cocrystals of caffeine and piracetam with different 
cocrystal formers respectively.   
C. Enhancement of bioavailability - (Dwayne T. Friesen 2008) used this 
process of cocrystallisation to increase the bioavailability of quercetin 
than pure quercetin API. (Xi Xu, 1996) used the cocrystallisation 
approach to enhance the bioavailability of baicalein. 
D. Improvement of mechanical and compressibility of crystalline 
materials– Paracetamol in the commercial form I is very difficult to 
compress into tablets or granules so to improve this compressibility 
(Karki et al., 2009) produce cocrystals of paracetamol with a 
carboxylic acid to improve its compressibility. Mechanical properties of 
ibuprofen and fluriprofen were improved using cocrystallisation 
approach (Chow et al., 2012). 
E. Enhancement of photostability -  Vangala improved the photostability 
of nitrofurantoin (antibacterial API) which undergo degradation when 
exposed to sunlight by implementing the approach of cocrystallisation 
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with hydroxyl substituted benzoic acids (Vangala et al., 2012). 
Rodriguez- Hornedo used the process of cocrystallisation of CBZ/SAC 
to improve its photostability (Rodríguez-Hornedo et al.,2008). 
F. Improving chemical stability -  There are various APIs which are 
chemically unstable like andrographolide which gets converted into 
inactive metabolite during the chemical process so to overcome this 
hurdle (Suresh et al., 2013) used the approach of cocrystallisation to 
inhibit the chemical instability of andrographolide. 
G. Enhancement of therapeutic activity - Due to the short residence time 
of APIs in the body, therapeutic activity is not reached to required 
amount. The example of such drug is sulfacetamide which is an 
antibiotic drug used for eye infection due to its low residence time in 
the eye region less therapeutic activity is achieved. To improve the 
residence time of sulfacetamide (Goud et al., 2014) and the 
researchers have used the process of cocrystallisation to increase its 
residence time in the eye region. 
H. Colour tuning pigments - (Bucar et al., 2013) group analysed the 
mechanochemical cocrystallisation of fluorescein to synthesise new 
colored cocrystals. 
Apart from these, cocrystallisation process has delivered various 
advantages to the science of solid-state chemistry by altering various 
physical and chemical properties of APIs. 
2.2.6 Synthesis of cocrystals 
Due to thermodynamic and kinetic challenges existing in formulating different 
APIs formulations, pharmaceutical manufacturers have started implementing 
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the technique of modulating crystalline API into different solid states 
(polymorphs, amorphous, solvates, salts, and cocrystals) to enhance 
physicochemical properties of individual API formulations. Screening of 
cocrystals has been recently a part of solid form development and design of 
active pharmaceutical ingredients (Clarke et al., 2011). Due to the 
heteromeric structure of cocrystal complex, it is very difficult to generate 
thermodynamically stable cocrystal moiety. The choice of cocrystal 
techniques is influenced by a not only number of experiments but also with a 
number of potential hits (Sladkova et al., 2014). Presently very few 
techniques are evaluated on the basis of efficiency of generation of 
cocrystals. As the process of cocrystallisation consists of molecular 
complexes between two or more components, various physical and chemical 
properties such as solubility, stability, and dissolution of the cocrystal 
components needed to be considered. Different cocrystal techniques are 
been reported by different research group globally to enhance the physical 
and chemical properties of active pharmaceutical ingredients. 
Reported methods for cocrystallisation are: Solution crystallisation is the 
traditional method used for the generation of co-crystals based on the degree 
of supersaturation of the solute concentration in the solvent. This technique 
is also referred as solvent evaporation method (Bruni et al., 2012). Vangala 
and co-scientists have successfully generated the co-crystals of 
nitrofurantoin with substituted hydroxybenzoic acids. Ultrasound-assisted 
crystallisation technique sonic energy is implemented for the generation of 
cocrystals; it is also referred as a sonochemical reaction (Aher et al., 2010). 
Spray drying technique this technique involves the production of dry powder 
38 
 
by rapid evaporation of solvent due to the presence of hot air stream 
(Alhalaweh and Velaga 2010). Freeze drying technique cocrystals are 
formed from an amorphous state where the solvent gets sublimed (Eddleston 
et al., 2013). Mechanochemical method (Jones and Eddleston 2014,Hasa 
Dritan et al.,2017) Solvent-free continuous co-crystallisation (SFCC) (Dhumal 
et al., 2010), Thermal microscopy technique (Berry 2008) and Supercritical 
fluid technology (Revelli et al., 2014). In all the above-mentioned processes 
there are certain limitations in every technique but the common factor is the 
existence of external energy for the generation of co-crystals, the energy 
may be in the form of shear heat, sonic crystallisation, mechanochemical 
crystallisation and the involvement of solvent. Recently, solid state shear 
milling process was involved for generation of cocrystal, the limiting factor is 
generation of phase impurity occurs and optimisation of process parameters 
is difficult (Korde et al., 2018) 
Various advance analytical tools like Powder X-ray diffraction (PXRD), 
thermal analysis- differential scanning calorimetry (DSC), thermogravimetric 
analysis (TGA), scanning electron microscopy (Jouyban et al.,2004), FT-IR 
and Raman spectroscopy are used to understand the mechanism and 
formation of cocrystals.  
2.3 Polymorphism 
In the recent years due to advances in the field of crystal engineering and 
supramolecular chemistry apart from drug cocrystallisation the subject of 
drug polymorphism has gained extensive academic and industrial attention 
due to the early reports presented by Aguiar and colleagues regarding the 
enhancement of drug dissolution and bioavailability due to drug 
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polymorphism of chloramphenicol palmitate (Singhal and Curatolo 2004). 
The structural perspective is based on the range of molecular arrangement 
and order of structure, in crystalline state molecules are repeatedly arranged 
in a definite crystal order and have similar extended molecular arrangement 
while in amorphous state or disordered solids they retain the similar local 
molecular assemblies but don‘t have extended range of molecular order, 
thus both crystalline and amorphous states exhibit similar intermolecular 
assembly but different in the order or arrangement of molecules. 
Polymorphism is defined as the crystalline material with similar chemical 
composition but differs in molecular conformation (Novoa 2008). Many 
scientists have tried to define polymorphism but in 1965, McCrone defined 
polymorphism as ‗it is a solid crystalline phase of a given compound resulting 
from the possibility of at least two different arrangements of the molecules of 
that compound in the solid state (Lee, 2014). 
Polymorphism generally occurs due to the propensity of changing the 
molecular arrangement in the crystal lattice, its flexibility in the conformation 
of the molecules and the competition in supramolecular synthons. There are 
various chemical and physical properties which are affected by 
polymorphism such as solubility rate, dissolution properties, physical and 
chemical stability and bioavailability. Based on the arrangement of the 
molecules in the crystal lattice, the molecular flexibility, and supramolecular 
synthon arrangement, the process of polymorphism is further classified as 
conformational and pseudopolymorphism respectively. 
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Different analogies of polymorphism based on the supramolecular 
arrangements are described in the below Table 2.1 ( Rodrıǵuez-Spong et al., 
2004) 
Table 2.1 Definitions incorporating terms used in polymorphism 
Polymorphism -a substance with similar chemical composition but 




-formed by the molecules which adopt different 
confirmation in the different crystal structure 
Pseudo-
polymorphism 
-this includes crystal molecules having a solvent 
molecule or solvates and are classified in terms of 
structure as lattice channels, lattice sites, metal ions 
Quantitative relationship between the mechanism of crystallisation and effect 
of factors responsible for polymorphism were not explored (Hulme et al., 
2005). Kitamura and group based on crystallisation method and type of 
solvent system used , grouped these factors into two sections primary and 
secondary (Yu et al., 2000). Both these factors influence the thermodynamic 
and kinetic properties of polymorphic crystallisation. Primary factors include 
operational factors like temperature, supersaturation, seeding, stirring rate, 
cooling rate, the rate of addition if antisolvent, mixing rate of reactants on the 
other hand, secondary factors include interfaces, additives, solvent systems.   
2.3.1 Thermodynamics and rules to predict polymorphism 
When a compound exists in two or more solid forms, two factors needed to 
be addressed: relative thermodynamic stability of the entity or the pathway of 
phase transformation and factors affecting transformation and secondly the  
time required for the phase transformation to reach an equilibrium state 
(Brabander  et al., 2002). The thermodynamic study will explain the pathway 
of polymorphism and kinetics will predict the time required to reach phase 
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equilibrium. They are different factors that govern solid-state phase 
transformation, below schematic diagram describes regarding different 
factors which govern solid-state phase transformation.  
 
Figure 2.10 Different thermodynamic and kinetic properties governing 
solid states (Rodrı́guez-Spong et al., 2004) 
Different rules and phase diagram were postulated to understand the 
thermodynamic stability and kinetics of polymorphism. 
Phase rule 
Based on the thermodynamic principle Gibbs (1876, 1878) formulated phase 
rule as:  
𝐅 = 𝐂 − 𝐏 + 𝟐    
 Where, F- degrees of freedom in the system, C- number of components and 
P- the number of phases. 
A system which is homogeneous and physically separated from the other 
system by a specific definite boundary then that homogenous system is 
referred as phase pure system. For instance, water and gas are totally 
homogenous and separate system so they have one phase number 
individually. Two different solid polymorphs which are homogeneously 
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distributed or form an alloy are referred to contain one phase in the solid 
state. Various scientists have raised certain controversies regarding 
homogenous systems in the field of crystal engineering when they started 
analysing X-ray diffraction patterns of a single crystal; they reported that the 
single crystals are generally inhomogeneous mixed crystals or 
inhomogeneous racemic mixtures (conglomerates). Others stated that in 
crystal two polymorphs co-exist with each other in a definite molecular 
arrangement. A number of components are defined as the number of 
individual species present in the system which may exist in the liquid, solid or 
gaseous state, an example for this is water that is a single component 
system which exists in different phases. 
A number of the degree of freedom or variance is referred as the number of 
components like temperature, pressure and concentrations are fixed to 
maintain the system at equilibrium. For example, gas has two degrees of 
freedom and single phase whereas gases in two phase‘s liquid phase and 
gaseous phase have one degree of freedom. A system with one component 
and three phases have no degree of freedom, these relationships are often 
stated as bi-variant, mono-variant and invariant. 
To control the polymorphic crystallisation thermodynamic and kinetic 
properties are essential properties to be considered. They are used to 
understand the nucleation process, crystal growth and phase conversion 
occurring during crystallisation process (Datta and Grant 2004). These 
properties are based on Gibbs free energy ΔGc of a crystallisation process 
considering temperature and pressure constant (equation 1). 
∆𝐆𝐜 =  ∆𝐇𝐜 − 𝐓 ∆𝐒𝐜     (𝐞𝐪.𝟏) 
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Where, ΔH and ΔS are related as a change in enthalpy and entropy during 
crystallisation process respectively. In thermodynamic point of view, a 
system with minimum Gibbs free energy is acting as a driving force for the 
formation of stable polymorphs (equation 2). Increase in rate of entropy is 
irreversible thermodynamics which leads to the formation of the less stable 
form (Brabander et al., 2002). 
                                      ∆𝐆𝐓 =  ∆𝐇𝐓 − 𝐓 ∆𝐒𝐓     (𝐞𝐪.𝟐)                                
The thermodynamic system of polymorphs and the driving force responsible 
for the phase transformation when temperature and pressure are kept 
constant can be determined by the difference in Gibbs free energy. Change 
in the enthalpy and entropy is referred to change in lattice energy and 
disorder in the lattice structure respectively. In thermodynamic if ΔGT <0, 
then the phase transformation occurs spontaneously as very less energy is 
consumed, ΔGT =0 then the free energy between two polymorphs is similar 
and when ΔGT>0 then the polymorphs are stable and spontaneous 
transformation is not possible (Venugopalan 2009). According to 
thermodynamic studies, polymorphic transformation can be considered to be 
enantiotropic and monographic based on the transformation of phases. 
There are various rules postulated by various scientists for the prediction of 
polymorphs and its transformations. 
2.3.2 Rules for predicting polymorphs 
Since entropy cannot be determined experimentally, free energy isobar 
cannot be predicted. Burger and Ramberger have proposed various rules for 
understanding and predicting the stability and nature of polymorphic systems 
considering temperature and free energy as parameters (Venugopalan 
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2009). Polymorphism as discussed before can exist in monotropic and 
enantiotropic systems. The most stable polymorph has lowest Gibbs free 
energy.  
 
Figure 2.11 Correlation of energy and temperature of polymorphs to 
determine enantiotropy and monotropy (Venugopalan 2009). 
In Figure, 2.11a represents a thermodynamic system with two polymorphs 
where form II has less Gibbs free energy till it reaches transition point (Tp) 
thus it is more thermodynamically stable as it crosses this transition point the 
Gibbs free energy of form II is higher than form I and becomes unstable up to 
its melting. At transition point (Tp) the two polymorphs form I and II are 
thermodynamically stable with equal Gibbs free energy. ΔHt represents the 
enthalpy of transition where the conversion of form II to form I occurs to 
retain its stability .ΔHf,I and ΔHf,II represents the fusion enthalpy for forms I 
and II, respectively. Figure 2.10c represents the energy/temperature diagram 
for tedisamil dihydrochloride which shows three polymorphs exhibiting 
enantiotropic behavior. Figure 2.11b represents the monotropic system 
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where the Gibbs free energy of form II is greater than form I and remains 
unstable until melting. There is no transition point present in this system so 
the transformation of unstable form II to stable form I occurs but this 
conversion is not reversible. Figure 2.11d represents energy/temperature 
diagram for fluriprofen reflecting monotropic polymorphic system. 
Below Table 2.2 briefs out different rules reported understanding the 










   Table 2.2 Rules to understand the relationship between polymorphs and single component system 
Heat of transition 
rule 
The system is said to be enantiotropic when an endothermic phase transformation takes place 
between two crystals at a particular temperature and if that transition temperature lies below the 
melting temperatures of two polymorphs. The system is said to be a monotropic system when 
there is no thermodynamic transition point below the melting temperatures of polymorph 
(Venugopalan 2009). 
Heat of fusion rule 
 
The heat of fusion rule states that the polymorph with a high melting point will have a lower 
enthalpy of fusion then it is the enantiotropic system. If the enthalpy of fusion of higher melting 




The system is an enantiotropic system when enthalpy of sublimation is low than high melting point 
polymorph. In monotropic system, high melting point polymorph show higher enthalpy of 
sublimation (Venugopalan 2009). 
Heat capacity rule For a pair of polymorph if heat capacity of high melting point peak is high then the system is 
referred as enantiotropic and if the system shows low heat capacity for high melting peak 
polymorph then it is monotropic (Venugopalan 2009). 
Entropy of fusion 
rule 
 
According to this rule, melting point is the region where the liquid state is in equilibrium with solid 
state and the difference in Gibbs free energy is zero. Polymorphs with high melting point peak 
having low entropy of fusion are the enantiotropic system. In monotropic system polymorphs with 
low melting point have a low entropy of fusion (Venugopalan 2009). 
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2.3.2 Properties of polymorphs 
In the process of polymorphism has left prominent benchmark to understand 
the chemical and physical properties of solid state materials. They are useful 
in pharmaceutical industry, pigments, agrochemicals, explosives and fine 
chemicals in the industry (Venugopalan 2009). 
 Packing properties are considered such as mass volume, density, 
refractive index, optical properties, electrical properties, thermal and 
hygroscopicity. 
 Mechanical properties: Tensile strength, hardness, friability, 
compactability, tabletability, flow rate and blending. 
 Surface properties: Surface free energy, the heat of sorption, crystal 
habit. 
 Thermodynamic properties: Internal energy, enthalpy, melting and 
sublimation property, heat capacity, and the heat of fusion. 
 Kinetic properties: Stability, dissolution rate, the rate of solid-state 
reactions. 
2.4 Summary 
Most of the R&D formulations are failing in the final development stage due 
to lack of knowledge regarding solid state chemistry, crystal attributes, 
supramolecular chemistry and crystal engineering. To develop a solid 
formulation understanding the physical and chemical properties of the solid 
pharmaceutical component is very important to make the formulation 
commercially successful. The major challenge that pharmaceutical 
manufacturing and processing industry facing are solubility of hydrophobic 
components; around 60% of the identified API molecules are reported to be 
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hydrophobic in nature. Thus to overcome this challenge new field of solid 
state chemistry has evolved. This filed is crystal engineering which deals with 
the design of API component with different morphological and crystal habits 
so that their physicochemical properties can be enhanced.  To process the 
solid crystalline material or to manipulate the morphological properties 
different crystallisation and processing techniques are been postulated. In 
the present chapter brief introduction regarding solid state chemistry and 
supra molecular chemistry is explained.  Introduction of multicomponent 
systems such as cocrystals and mono-component system such as 
polymorphs is elucidated. Definition to cocrystals, mechanism of 
cocrystallisation, designs of cocrystals, their applications, and different 
techniques of cocrystallisation their challenges are explained in brief. 
Definition to polymorphism and polymorphs their molecular arrangements is 
explained which was supported by explaining different thermodynamic rules 









Chapter 3: Sub-Critical Water 
3.1 Introduction 
Water is referred as a universal solvent due to its proportionality during 
heating, its high dielectric constant and high polarity. Subcritical water (SCW) 
is the physical state of the water that has been heated between 100°C and 
374°C (critical temperature) with sufficient pressure applied to retain the 
liquid state of water (Asl and Khajenoori., 2013), when water is heated above 
the critical temperature under high pressure and when water molecules can 
no further retain its liquid state than this state of water is referred as 
supercritical water. Water in the subcritical state is used as a tunable solvent 
in the food processing, extraction of chemicals from natural sources, 
nutraceuticals. The reason for selection of water as a solvent over other 
solvent system is that it is harmless and the polarity of water can be 
controlled by altering process conditions such as temperature and pressure. 
Thus this typical property of water refers it as tunable solvent (Ibanez, 2003). 
As the polarity of water can be monitored by controlling process parameters 
like temperature and pressure this water can be used for the extraction of 
different components with different polarity and dissolve various hydrophobic 
components (Ibanez, 1999). 
Apart from the change in polarity of water at subcritical state the change in its 
surface tension, viscosity, the dielectric constant is also observed, this 
change in these physical properties of water enhances the effective capacity 
of penetrability or miscibility of water which is used to dissolve different 
hydrophobic components. In the present study the dielectric constant of 
water was tuned under high temperature and pressure conditions to alter the 
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morphological and induce hydrogen bonding capacity of various organic 
molecules which includes production of complexes molecules (cocrystals, 
solvates and hydrates), altering morphological properties of insoluble APIs to 
increase its kinetic properties (solubility, dissolution, stability) example 
lactose, theophylline, generation of metastable polymorph of API 
(paracetamol) and forming complexes between organic and inorganic 
molecules (API loaded hydroxyapatite). Below Figure 3.1 represents the 
phase diagram representing different states and regions of water at different 
temperatures and pressure conditions. 
 
Figure 3.1 Representation of phase diagram of water as the function of 
temperature and pressure  
In the above Figure different physical state of water is represented by different 
temperature and pressure conditions. From the above Figure, the subcritical 
region of water is between 100°C - 374°C where the vapor pressure is 1bar 
and 220 bars respectively. In this region due to sufficient pressure, the water 
retains the capacity to stay in liquid state than only this region is referred as a 
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subcritical region. The Figure 3.2 below represents the change in various 
properties of water at subcritical temperatures. 
 
Figure 3.2  Properties of water at various conditions (Toor et al., 2011) 
3.2 Water structural properties at subcritical state 
The life-supporting process in the evolution is based on the water due to its 
unique physical and chemical properties. Water structural properties are 
most controversially discussed in the condensed matter research. Several 
experiments and studies are carried out to decipher the structural orientation 
of water at elevated temperatures and pressure conditions (Sahle et al., 
2013).  
 
Figure 3.3 Chemical structure of water molecule. 
The water stays in the liquid form when  the attraction forces between the 
water molecules is around 23.3 kJmol-1 this is the enthalpy of water when it 
is in liquid form at 25°C, the minimum energy required to break the water 
hydrogen bond is equal to the heat of enthalpy the water molecule at 25°C. 
This separation energy is equal to half of the enthalpy of vaporisation (44 
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kJmol-1 at 25°C), this indicates that when water gets vaporised less than two 
hydrogen molecules are broken. Thus based on above interpretation the 
minimum energy required to break the water molecule in such a way that it 
can retain its structural electrostatic interaction is equal to 25% of hydrogen 
bond enthalpy (23.3 kJmol-1) which is recently calculated to be 6.3 kJmol-1 
(Smith 2006). Muller,1988 and his co-author‘s has proposed that if the 
excess heat capacity over the steam is assumed to be responsible factors for 
the hydrogen bond breaking this attractive energy is calculated to be 9.80 
kJmol-1 this additional energy is due to the influence of extra energy of 
polarisation, cooperatively and covalence of hydrogen bond (Muller,1988). 
 
Figure 3.4 Schematic representations of dipole moments of water 
molecule 
The most important factor which play role in understanding the polarity of 
water is the dielectric constant of water. As the temperature increases the 
polarity of water decreases and the dielectric constant or permittivity constant 
decreases which make water at elevated temperature to behave as organic 
solvents. In the subcritical region the dielectric constant of water is similar to 
that of organic solvents. Water at 100°C the dielectric constant is similar to 
organic solvent DMSO so water can solubilise all the solute molecules which 
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are soluble in DMSO at room temperature (Champion et al., 2007). This ability 
to mimic the dielectric constant of water with various organic solvents has 
gained importance in extraction of various hydrophobic compounds from 
natural sources (Charoenchaitrakool et al., 2000). Figure 3.5 represents the 
relationship between temperature sensitive dielectric constant of water with 
various organic solvents. 
  
Figure 3.5 Comparison between the dielectric constant of water and  
organic  solvents at elevated temperatures (Maghsoodi et al., 2008) 
The most prominent analytical tools used to measure the site to site variation 
in the water structure and density fluctuations is by using X-ray or neutron 
scattering involving isotopic substitution (P. Postorino 1993). The 
spectroscopic data provided a controversial discussion regarding the local 
atomic structure of water (Wernet et al., 2004), this study has raised an 
discussion whether the structure of water at ambient conditions retain 
homogenous density or inhomogeneous mixture of two structural states 
where hydrogen bonding distorted structure surrounding less denser 
tetrahedral structure of water. Water is generally consists of four weak 
hydrogen bonds normally weaker than covalent bond but stronger than 
natural thermal energy. Water is generally tetrahedral structure where the 
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local cluster is flexible. If the hydrogen bond formed are strong than the local 
cluster expands leading for the decrease in the density of water resulting in 
increase in volume of water molecule.  Optical Raman spectrometry is used 
by (Frantz et al., 1993) proposed that the significant tetrahedral structure of 
water is still retained at elevated temperature and pressure conditions. 
(Vasconcelos et al., 2007) had proposed that at elevated temperature and 
pressure number of water monomers are formed at supercritical regime, they 
also reported the presence of remaining higher coordinated of water like 
dimer and trimers. (Sahle et al., 2013) and group had investigated the 
microscopic structure of water at high temperature and pressure conditions 
using X-ray scattering experiments, they have compared the practical data 
with initio molecular dynamic simulations and reported that at ambient 
conditions the tetrahedral structure of water where four hydrogen atoms are 
surrounded by five oxygen motifs within the distance of 3.6 A°, with increase 
in temperature and pressure the number of hydrogen bonds per molecule 
decreases which causes decrease in the density and polarity of the water 
molecule, further based on the molecular simulations and experimental 
spectra they reported that there is clustering of motifs taking place at 
elevated temperature and pressure thus the water molecule is 
homogeneously separated at super and sub critical regime. 
3.2.1 Process taking place at SCW level 
They are two processes which dominate this sub-critical water process positive 
heat and negative heat (Duarte et al., 2006). Positive heat is driving force 
which is used for the formation of cavities in the media. Negative heat is used 
for the formation of hydrogen bonds between the solute and water molecules 
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where energy is consumed ―ice berg formation step‖. If the negative heat 
generated due to increase in temperature dominates over positive heat than 
the solubility of organic molecules in water decreases and when positive heat 
dominates over negative heat than the solubility of solute molecule in the water 
system increases (Reverchon and Della Porta 1999). Below Figure 3.6 
demonstrated the effect of solubility with increase in temperature correlating 
with dielectric constant of water. 
 
Figure 3.6 Trendline of solubility data of anthracene (diamond shape), 
p-terphenyl (square shaped) and 1, 8-cineole (triangle shape) in SCW. 
The effect of dielectric constant of water with increase in temperature 
(Reverchon and Della Porta 1999) 
From the above interpretation it is suggested that after 150˚C the solubility of 
various hydrophobic compounds increase drastically this is related to 
domination of positive heat (cavity forming) over negative heat (ice-berg 
forming) process (Vemavarapu et al., 2002). If there is no precipitation or ice-
berg formation observed in the solution it doesn‘t mean that no hydrogen 
bonds are formed, it is due to hydrogen bonding between the water is beyond 
the critical point and no bonding is formed between the solute molecules in the 
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solvent system. Pressure as a parameter of the process has negligible effect 
on the solute and solvent in sub-critical levels. 
3.3 Factors effecting Sub-critical water process 
There are various parameters such as structure of the solute component, 
temperature and pressure conditions, interaction between the solute and water 
molecule and level of supersaturation influencing SCW process. 
3.3.1 Effect of solvent conditions 
The thermodynamic dissociation ability of water is based on hydrogen bonding 
capacity at ambient conditions and elevated temperatures (Rabinow 2004). In 
water hydrogen bonds of one water molecule is influenced by hydrogen bonds 
of other water molecule grouped around it, they are self-associating molecules. 
Heat of vaporisation, and change in dielectric constants are generally 
regulated by change in hydrogen bonding of water (P. Alessi 1996), thus little 
change in the hydrogen bond of water changes the entire volume of water. At 
low temperatures the dielectric constant of water is high and retains high 
hydrogen bonding capacity (P. Alessi 1996), as the temperature of water is 
raised the increase in thermal agitation of molecules causes reduction in the 
hydrogen bond strength which leads to reduction in dielectric constant of water 
(Duarte et al., 2006). This reduction in hydrogen bond strength and reduction 
in polarity leads increase in the solubility of hydrophobic compounds in water. 
This same principle is applied in our Microwave assisted sub-critical water 
process. Trend between the solubility of chemical components vs temperature 
is not linear as some complex molecules like benzene, toluene display liner 
relationship between temperature and solubility when water is heated up to 
150°C under applied pressure beyond this temperature the solubility graph 
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shoots up drastically which is referred to further breaking of hydrogen bonds of 
water molecule and this region is called as ―solubility minima‖. 
3.3.2 Effect of nature of solute 
Behaviour of solute greatly affects the solubility of solute molecule in SCW 
(sub-critical water). Degree of conjugation, position of hydrogen bonding 
groups on side chain, presence of number of aromatic ring and groups on the 
side chain are structural factors of solute considered during SCW process. 
The solute with small size increases the solubility than the complex size solute, 
an organic molecule with a high degree of conjugation results in higher 
solubility. With the increase in a number of aromatic rings in the structure 
increases the solubility with an increase in temperature than the molecule with 
linear hydrocarbon structured molecules. Complex aromatic ring structures 
show an increase in solubility than linear aromatic ring structures. This effect is 
due to the availability of delocalised pi electrons in the complex aromatic 
structure which results in greater interaction between SCW than hydrocarbons 
and cluster hydrocarbons chain structured molecules.  Presence of oxygen 
group on the side chain increases the solubility as it takes part in hydrogen 
bonding process (P. Alessi 1996).  
3.4 Computational model to study solubility parameter of solute in SCW  
The most important parameter which is considered in SCW process is 
solubility of the solute in the solvent system. In particle engineering or 
extraction process, the material should be completely soluble in the solvent 
system. Very limited test and study are performed to analyse and study this 
solubility parameter.  Some researchers proposed certain tools or model to 
study this solubility parameter in SCW process. Initially, Miller and group 
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proposed the model for solubility prediction based on the characterisation of 
solute and solvent but this model failed as it cannot work under elevated 
temperature conditions. 
 Empirical model 
This model generated the solubility study of solid materials at room 
temperature and constructed 1st, 2nd and 3rd order equations which can be 
used for the prediction of solubility in SCW process. General equation 
proposed in the empirical model is as follow: 
    ln 𝑥2(𝑇) =  
𝑇0
𝑇
 In𝑥2(𝑇0).............................. (1) 
Where X2 is solubility of solid material (in moles) at temperature T (Kelvin), X0 
(T0) is the solubility of same solid material at ambient room temperature. (Carr 
et al., 2011b) 
 Hansan solubility model 
This model does not predict the solubility of solid materials but instead it 
reveals the information regarding onset of solubility of both polar and non-polar 
solid materials. Onset of solubility is governed by the change in hydrogen 
bonding, polar and dispersive forces involved in solubilising of materials in the 
solvent. Solubility of organic compounds is predicted by (Srinivas et al., 2008) 
using this model. 
Modified Universal Function Activity Coefficient (M-UNIFAC) model 
This is most widely used model for prediction of solubility of solid materials in 
the solvent during SCW process. This study deals with the activity coefficient 
which is determined by considering the presence of functional groups on the 
solute side chains and the solvent system in the solution. Once the activity 
coefficient is predicted than the fraction of solubility is determined by 
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calculating the material melting properties and fugacity ratio between 
solute/solvent (Karásek et al., 2006). This model is applicable at elevated 
temperature which is positive point of implementing this model. Later on 
Fornari proposed the modified M-UNIFAC model in which the dielectric 
constant relationship between the interaction between solute and solvent 
systems is considered. 
 Dielectric constant model:  
This is recently proposed model which deals with the dielectric constant of 
water at room temperature and at elevated temperature. It give the accurate 
result of the change in dielectric constant of water at elevated temperature 
which can be correlated with the amount of solute gets solubilised in it. If a 
solute molecule is completely gets solubilised in water, were the molar 
concentration of solute varies with temperature than it becomes very easy to 
predict the solubility of solute in the solvent mixture like water/organic 
solvent, organic solvent mixture (Carr et al., 2011b). 
Carr and group had worked with budesonide using SCW process, initial 
stages of experiment they have observed that budesonide is not soluble in 
water at sub-critical level (200°C) so to prevent further degradation of solute 
they have implemented the use of solvent mixture to further reduce the 
dielectric constant of water. They used 20% alcohol-water mixture to form 
clear solution of budesonide using SCW process. Due to presence of alcohol 
in the solvent system the morphology of the crystal can be altered which 
brings change in physical properties of the crystal. This change in 
morphology is observed in case of supercritical extraction process. As we 
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are dealing with melt induce crystallisation process it is very important to 
form a clear solution to obtain phase pure crystal structures. 
3.5 Applications of SCW process 
Particle engineering 
Carr and grouped produce narrow sized particle of greseofulvin, budesonide 
by this process. This process took place in two steps, first is solubilising the 
solute in water at elevated temperature and pressure conditions and secondly 
spraying the saturated solution under ambient conditions. Fosters and group 
proposed the application of SCW process in pharmaceutical and particle 
engineering field. Richier et al have used this SCW process to enhance the 
solubility of nifedipine for tabletting formulations.  
Extraction 
This process is used for the extraction of hydrophobic materials from natural 
sources. Various studies have been performed to analyse the extraction 
capacity of SCW. (Smith 2006) have used for extraction of flavonoids from 
herbs. In this process at high temperatures and pressure conditions the 
diffusion rate of water increases across the cell walls of herbs and thus 
promotes extraction (Asl and Khajenoori, 2013). This method has proved 
advantage over conventional extraction process in terms of purity and extent of 
extraction, time of process and use of organic solvents which are toxic. 
Chromatography 
SCW has proved advantageous in chromatography in separation of polar 
and non-polar solvents. As the SCW process the dielectric constant of water 
is tunable various polar and non-polar components are separated using 




Subcritical water at elevated temperatures and pressure act as catalyst as it 
gets ionised and used for hydrolysis process by (Yung et al., 2004). Water in 
ambient conditions has very less ionising capacity so it cannot break the 
hydrogen bonds so at elevated temperature it causes breakdown of 
hydrogen bonds and increase in ionisation which leads for the release of 
proton. 
3.6 Microwave Assisted Sub-Critical Water process 
Microwaves is an attarctive tool used for extraction and chemical synthesis 
and various studies are performed based on microwave assited organic 
synthesis (Giguere et al., 1986). Microwaves are the electromagnetic 
spectrums which occur in the frequency range of 0.3 to 300GHz and 
wavelength between 1mm to 1m. These microwave frequencies are used in 
telecommunications, microwaves and various radar instruments (Kappe 2004). 
Microwave quantum energy can reach up to 0.0016eV, this energy is 
insufficient to break any covalent bonds and additionally the energy lies below 
the Brownian motion (Kappe 2004, Giguere 1986). Below Figure 3.7 
represents the region of microwave and the relative frequency range. 
 




There are various advantages of microwave heating: 
 By the use of microwave heating the reaction time is reduced and 
further contamination of products is reduced and the yield is high. 
 In the microwave reactor principle of bulk heating occurs where every 
molecule will simultaneously act as heat source, this kind of heating 
provide productive heating profile which will produce different 
distribution of reaction products and minimises degradation. 
 The distribution of energy mass transfer is significantly high, the 
energy doesn‘t emerge equally with reaction vessels, the microwave 
energy only infiltrated the reacting molecules and increases heat 
transfer. 
 Use of microwave energy in crystallisation reduces the use of solvent 
drastically and this is considered more environmentally friendly as 
compared to other technologies (Pagire et al, 2013). 
Dielectric constant plays a significant role in controlling thermal behaviour of 
dipole carrying materials under the influence of microwave radiations. The 
dielectric constant is referred as physical property which changes with 
change in inter atomic and intermolecular interaction. The efficiency of 
solvents to separate electrolytes into ions is determined by calculating 
dielectric constant (Jouyban et al., 2004). A dielectric supports the charge by 
inducing polarisation in a particular electric field, like one surface develops 
positive charge and the other develops opposite net negative charge. This is 
taking place due to development of electric dipole moments between the two 
oppositely charged surfaces which are separated by a certain distance on a 
molecular level. Solvents with high dielectric constants have greater 
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dissociation property and solvents with low dielectric constant have capacity 
to form ionic pairs. Recently in most of the pharmaceutical and analytical 
industries there are vast studies on determining the dielectric constant of 
mixed solvents and their effect on the solubility of the solute molecule. Irani 
et al., 2017 have used the solubility of xanthine derivatives using solvent 
mixtures and correlating with dielectric constant (Anthony, 1966). Dielectric 
constant of water at room temperature is low so they have fewer ions forming 
capacity and water at high temperature has less dielectric constant and high 
polarity so its capacity of solubilising insoluble materials has enhanced 
(Kenneth, 1983). 
3.6.1 Microwave heating mechanism 
The mechanism in which material are heated is referred as microwave 
dielectric heating. Dielectric heating reflects the potential of the materials to 
consume microwave energy and transfer it into thermal energy. It is reported 
that only the electric part of the electromagnetic field is responsible factor for 
microwave heating (Strass et al., 2000, Woodward et al., 1997). Microwave 
heating is the coordinate mechanism originated from the overall molecule. 
For example, according to Debey 2013, the combination between microwave 
and polar molecules increases the rational speed causing an elevation in the 
friction forces and hence generating heat (Gabriel et al., 1998). The dielectric 
heating mechanism is controlled based on two main mechanism; Dipolar 
Polarisation and Ionic Conduction. 
1. Dipolar polarisation: The dipolar polarisation required in a molecule 
to obtain dipolar moment such as water. When the microwave irradiations 
pass through the dipolar material, the dipole group start to respond to the 
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electric part and orient according to the electric field oscillation (Lidstrom et 
al., 2001, Kappe, 2004). When the electric field changes its direction, these 
groups will rearrange themselves according to that direction. During this 
reorientation process part of the energy is lost by the electric field which is 
absorbed by the dipole group and transformed into thermal energy. This 
transformation is controlled by several factors such as molecular friction and 
dielectric properties. 
2. Ionic conduction:  Tap water produces more temperature than 
distilled water during microwave heating; this is because of the presence 
solubilised ions in tap water. These ions will gain kinetic energy under the 
influence of microwaves and will produce more collision between molecules. 
This event will increase kinetic energy loss, which will transform into thermal 
energy. 
3.6.1.1 Key attributes of microwave heating over conventional heating  
There are different key attributes of microwave heating compared to 
conventional heating: 
 Due to microwave irradiations can significantly enhance the heating 
process resulting in rapid crystallisation and generation of reduced 
particle size. In case of conventional heating longer time is required to 
reach the target temperature conditions, which may result in further 
hydrothermal degradation of organic components. 
 In microwave irradiations offers rapid and volumetric heating, without the 
need of heat transfer surfaces or heat transfer fluids. This process is 
absent in conventional (conductive) heating. 
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 Additionally in microwave heating the microwaves directly couple with 
the molecules (polar) of the solution, the heat transfer is immediately 
stops when the magnetron is turned off, thus minimising the thermal 
inertia. But in conventional heating the heat transfer is continued for 
certain period of time even after the external heating source energy is 
stopped. 
 In microwave heating, heat transfer is not based on thermal conductivity, 
which is less for conventional solvents like water, methanol or ethanol. 
Rather it depends on the dielectric property of the solution (Radacsi et 
al., 2013). 
Based on the above advantages of microwave heating, microwave 
irradiations are used as the external heating source in the present research 
work. For the first time in the present research work scalable microwave 
assisted Sub-critical water process technology is proposed for particle 
engineering of pharmaceutical components. Microwave energy is used as 
the external heating source to treat the water from ambient conditions to 
subcritical temperature and pressure conditions. The scalability of this 
technology was performed by our industrial partner where conventional 
heating source was used as heating source. Due to microwave heating in the 
small lab scale reactor this technology was used as screening tools for 
different chemical components and process understanding.  
RotoSYNTH microwave reactor is used as heating source for water, the  
instrument (Figure 3.8) is equipped with quartz tube with 30 and 50ml 
capacity, these tubes are covered by external covering made up of peek. 
The reactor tubes are coonnected by temperature and pressure valve. This 
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protective shield can withshand the temperature and pressure up to 250°C 
and 30-40 bars respectively. The complete setup is kept over magnetic 
stirrer which is present inside the instrument. The reaction is processed in 
closed container with temperature and pressure valve. Below Figure 3.8 
ellustrated the design of RotoSYNTH microwave reactor with different probes 
and vessels. 
 
Figure 3.8 RotoSYNTH microwave reactor with pressure vessel for sub-
critical water processing. (Adopted through digital camera)  
In recent years various novel technologies implemented in the field of crystal 
engineering and process industries  include the use of organic solvents 
which is a drawback in terms of toxicity, contamination of pharmaceutical 
components and non-economical. Recently Paradkar and co-workers have 
developed, a green pathway of crystallisation which is Solvent Free 
Continuous Co-crystallisation (SFCC) using hot melt extrusion, they have 
proved the commercial feasibility of this technology (Kelly et al., 2012), the 
only drawback of this technology is the thermal degradation of 
pharmaceutical components as they are subjected to high  temperature and 
shear conditions. Based on the previous trials performed by various 
researchers on subcritical water technology they concluded that water at 
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subcritical level can be used as green tunable solvent to enhance the 
solubility of hydrophobic components. As we know pharmacokinetic effect of 
API formulations is potentially influenced by crystal morphological properties 
like particle size, shape and surface roughness, thus the present research is 
focussed on crystal engineering of pharmaceutical ingredients by using 
MASCW technology. This technology was implemented to understand the 
influence of various process parameters like temperature, pressure, solvent 
and solute concentration over morphological and kinetic properties of 
pharmaceutical ingredients. As discussed before change in particle 
morphology significantly alter various physical and chemical properties such 
as its solubility, stability, degradation profile, drug dissolution rate, flow 
property, and compressibility. For example, paracetamol is an analgesic drug 
and by altering the size of the particle, dissolution, flow and compressibility 
properties can also be changed (Champion et al., 2007). MASCW process is 
based on antisolvent based top-down micronisation crystallisation process. 
Use of water as subcritical water has various applications and advantages 
over conventional crystallisation technologies: 
3.6.2 Advantages of subcritcal water process 
 Tuning the morphological and chemical properties of particles is very 
easy by adjusting the process parameters like temperature, pressure, 
ratio of solute to solvent, type of solvent (Ibanez et al., 2003). 
 In this process no high shear is applied when compared to 
extrusion.Thus the thermal degradation of the pharmaceutical 
ingredients is prevented (Bala Subramaniam 1997). 
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 In this process the nuceiation of the particles takes place from the 
molecular level up to nano/micro and macro sized particles which 
avoids the influence of high shear which is involved in breaking the 
granules into smaller particle size (Bala Subramaniam 1997). 
 More efficient in terms of unit operations. 
3.7 Mechanism of MASCW process 
Based on the experiments performed by us a tentative mechanism of MASCW 
process was postulated, Figure 3.9 schematic representation of MASCW 
process mechanism. Initially solute solid materials are added in water 
according to supersaturation solubility of solute in water. Microwave energy is 
subjected to the solution and the temperature is raised based on the heat rate 
adjusted in the instrument.  As the temperature increases clear solution is 
formed and then the saturated solution is subjected for gradual cooling. During 
the elevated temperature conditions the hydrogen bond strength of water is 
reduced and the molecules start vibrating. 
 
Figure 3.9 Summary of mechanism of molecular association of 
particles in MASCW process 
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The complete assembly is subjected to magnetic stirring using magnetic 
beads in the solution. During cooling or by rapid cooling conditions the 
change in the polarity of water can induce change in supersaturation of 
solution leading to rapid precipitation of the solute. The yield of precipitation 
is generally based on the solubility parameters of solute in water. The effect 
has been observed in the present study, when metastable cocrystals and 
polymorphs were generated by rapid cooling so supersaturation level of 
solute is solvent is altered and the precipitation starts inducing. 
Previously they are few research work is reported based on subcritical water 
process. Adam Carr and group implemented subcritical water process for the 
generation of micronised budesonide, analysing solubility of griseofulvin using 
chromatographic oven made up of stainless steel, they have used SCW as the 
tunable solvent for crystallisation process (Carr et al., 2011). Recently group of 
Jian-Feng Chen has used this subcritical water process for generation of 
ultrafine clarithromycin and beclomethasone dipropionate via antisolvent 
precipitation mechanism (Pu et al., 2017). The instrument used them is high 
pressure micro reactors as heating source for water, they have used very low 
supersaturated solution (6 mg of beclomethasone solute in 6 ml water) for the 
generation of nano particles.  All the studies performed on subcritical water 
process are performed on small scale level thus these technologies failed to 
gain importance commercially.  In the present work using MASCW process it 
was successfully reported commercial feasibility of this technology by 
performing scaling up experiments.  
The MASCW process was used for generation of cocrystal of carbamazepine, 
sulphamerazine and sulfamethazine as API and saccharine as cocrystal 
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former, carbamazepine and saccharine as novel cocrystal pair was selected 
for understanding the influence of various process parameters on cocrystal 
form and were successful in generating metastable carbamazepine saccharine 
form II cocrystal, further caffiene and para-hydroxybenzoic acid was selected 
as incongruent cocrystal pair and successfully generated CAF: 4HBA 1:1 
cocrystal. This MASCW process was applied in the field of polymorphism, it 
was found that successsful generation of metastable form II of paracetamol 
with greater solubility and compresability was reported. This MASCW process 
was used  to generate microsized particles less than 5 micron of theophylline 
and further analysed the enhanced aerodynamic property of MASCW treated 
theophylline. Further to its feasibiltity in organic molecules this MASCW 
technology was implemented to treat inorganic compounds like hydroxyapatite.  













 Chapter 4: Materials and Methods 
This chapter includes detailed explanation of various chemical materials, 
methods and different characterisation tools used throughout this research 
work. The method section include summary of different methods used for 
crystallisation experiments and the brief description regarding the working 
principles and software details of different characterisation instruments. 
4.1 Materials  
4.1.1 Active pharmaceutical ingredients (APIs) and excipients 
Standard samples of different APIs and pharmaceutical excipients are used 
for the present work; phase purity of all APIs and excipients is further 
confirmed using X-ray diffraction technique.  Below Table 4.1 includes the 
brief description of different APIs and excipients used in the present 
research. 
 Table 4.1 Summary of list of raw materials  
API name Source / Lot no Chemical structure 
Carbamazepine 




Chemical formula: C15H12N2O 
Molecular weight:  236.27 g/mol 
Melting point:        191-192°C 






a) Ibuprofen monomer, 
b)  b) ibuprofen dimer 
highlighting the hydrogen 
bonds between carboxyl 
groups 
Chemical formula: C15H12N2O 
Molecular weight:  236.27 g/mol 




Reagent Plus, is 
purchased from 
Sigma Aldrich, UK 
 
Chemical formula: C8H10N4O2 
Molecular weight:  194.19 g/mol 
Melting point:         235°C 
Theophylline 
anhydrous (THF) 
HPLC grade purity 
≥99% is purchased 
from Sigma Aldrich 
 
Chemical formula: C7H8N4O2 
Molecular weight:  180.16 g/mol 
Melting point:         270-274°C 
Paracetamol form 
I (PAR)  
Sigma Aldrich 
 
Chemical formula: C8H9NO2 
Molecular weight:  151.163 g/mol 






HPLC grade purity 
≥99.0% is 
purchased from 
Sigma Aldrich  
Chemical formula: C11H12N4O2S 
Molecular weight:  264.30  g/mol 
Melting point:         236°C 
Sulfamethazine 
(SMT) 
HPLC grade purity 
≥99.0% is 
purchased from 
Sigma Aldrich  
Chemical formula: C11H14N4O2S 
Molecular weight:  264.30  g/mol 





(chemical purity of 
these chemicals is 
>99.9%) 
 
Chemical formula: C7H5NO3S 
Molecular weight:  183.18 g/mol 




Reagent Plus, (≥ 
99.0%) purchased 
from Sigma Aldrich, 
UK 
 
Chemical formula: C7H5NO3S 
Molecular weight:  183.18 g/mol 




99.995% trace metal 
basis is purchase from 
Sigma Aldrich, UK 
Molecular weight:  74 g/mol 




4.1.2 Chemicals and solvents 
 Phosphoric acid solution, 85 wt. % in H2O, FCC, and FG is purchased 
from Sigma Aldrich. 
 Methanol (HPLC grade purity >99%) purchased from Sigma Aldrich, 
UK.  
 Acetonitrile (HPLC grade, purity >99%) is purchased from Sigma 
Aldrich, UK. 
 De-ionised water used for experiments is collected from ELGA 
purelab ultra system providing water with purity of 18.2 MΩ / cm. 
 Potassium dihydrogen phosphate, AR grade is purchased from Sigma 
Aldrich, UK. 
 Sodium hydroxide, AR grade is purchased from Sigma Aldrich, UK 
 Sodium phosphate monobasic, AR grade is purchased from Sigma 
Aldrich, UK. 
4.1.3 Characterisation analytical instruments 
Table 4.2 includes the summary of equipments used for this research work. 
Table 4.2 Equipment specification 
Equipment Manufacturer Specifications 






Spray Dryer LabUltima  LU-228 
Scanning electron 
microscopy  
FEI, UK Quanta 400SEM 
Diffraction scanning 
calorimeter (DSC) 
TA Instrument, UK Q 2000 






Bruker, USA D8 powder 
diffractometer 
Raman Spectroscopy Renishaw, UK Thermo Scientific 
FTIR  Perkin Elmer, USA ATR Frontier 
Nuclear Magnetic 
Resonance (NMR) 
Bruker 400 Multi-nuclear Bruker 




LabIndia, India USP type II paddle 
test apparatus 
UV-spectroscopy Jasco, UK V-730 UV-visible 
HPLC  Waters e-2695 
Surface Energy Analyser  SMS, London, UK SMS-iGC 2000 
Laser diffractometer  Sympatec 
Instruments, UK 
HELOS (H2419) & 
RODOS dispersion. 
Rotavapor BUCHI Rotavapor R210 et 
R215 





Different software used for analysis data are listed in Table 4.3 
Table 4.3 List of software used for data processing 
Software Application 
TA universal analysis Thermal analysis (DSC, TGA) 
PowDLL converter PXRD pattern analysis 
EVA PXRD pattern analysis 
GRAMS AI- Spectroscopy 
Software 
Spectroscopic analysis (Raman 
and FTIR spectra) 
ID NMR processor NMR spectra 
Cirrus Software IGC graphical software 
ACD/ Chem Sketch Chemical structure drawing 
Mercury Chemical structure analysis 
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Origin 8.1 Graphical analysis of excel data 
PCP Disso Dissolution study 
CITDAS Aerodynamic properties analysis 
 
4.2 Experimental methods 
The method section is further categorised into two sections, experimental 
method and analytical characterisation method using different analytical 
tools. Initially process validation experiments is performed to understand the 
correlation between process parameters (temperature, pressure, 
supersaturation and solvent mixture) and end product physical and chemical 
state. 
Once the process was validated further experimental designed was 
performed to explore the application of MASCW technology in crystal 
engineering. 
Based on the objective to investigate the application of this new technology 
further experiments are categorised as below: 
 Application of MASCW process for generation of congruent and 
incongruent stable and metastable cocrystals pairs. 
 Application of MASCW process for particle engineering which includes 
generation of micron sized particles and analysis of kinetic and 
aerodynamic properties of active pharmaceutical ingredients. 
Investigation of MASCW technology for synthesis of metastable 
polymorphs  
 The final study includes mechanistic understanding of hydrogen 
bonding between Ibuprofen and nano crystalline hydroxyapatite. 
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Crystal structure, polymorphic form and calculated PXRD patterns of all 
pharmaceutical ingredients are retrieved from Crystal Structure Database 
(CSD) 
4.2.1 Process understanding and validation method 
In this section investigation of the influence of different process parameters 
like temperature, pressure, solution supersaturation and dielectric solvent 
mixture on crystal state of end product was done. Paracetamol was selected 
as the model component to validate different parameter of MASCW 
technology. This is further categorised as below: 
4.2.1. A) Investigation of effect of supersaturated concentration of 
paracetamol and process temperature/pressure parameters: In this 
study different concentrations (w/v) of paracetamol solutions in water were 
selected. Based on the minimum volume requirement of the instrument 
container, 10ml volume of water is considered as lower limit of solvent. 
Based on solubility of paracetamol in water different w/v supersaturated 
solution concentration 5%, 10%, 15%, 20%, 25% and 30% w/v of 
paracetamol in water were selected. All the samples were weighed 
accurately and processed using MASCW processes until clear solution is 
observed. Once the clear solution was formed the corresponding 
temperature and pressure conditions were recorded. Correlation between 
supersaturation and solubilising temperature and pressure conditions was 
plotted graphically using binary phase diagram. As the samples are treated 
at high temperature and pressure conditions percent essay of individual 
powdered samples, supersaturated solutions and filtered solutions was 
analysed using HPLC analyser. Different parameters including pH of the 
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supersaturated solution and percent yield is calculated for all the 
experiments. Once the crystal started inducing out samples were vacuum 
filtered using Whatmann filter paper (0.04 micron size) and air dried under 
ambient conditions. There were further analysed to investigate crystal form 
using analytical tools like PXRD, DSC and Raman spectroscopy. 
4.2.1. B) Crystallisation time: In this experimental design the main objective 
was to prepare a saturated solution of paracetamol (similar to above 
experiments) using MASCW process and monitor the time required to induce 
crystallisation. Concentrations of paracetamol solution selected for sub-
critical and conventional heating are 5%, 10%, 15%, 20%, 25% and 30% in 
10 ml deionised water. Using MASCW process all the samples are 
processed at 140°C with heating rate of 7°C/minute at variable pressure (4.0-
5.0bars) until clear solution is formed; further on cooling the time required for 
the crystals to induce is recorded. The experimental results was compared 
with the conventional heating experiments were similar supersaturated 
solutions of paracetamol were prepared in 10ml of water and subjected to 
heating and stirring using water bath at 90°C-95°C and magnetic stirrer 
beads respectively for four hours. The solubility and percent essay of these 
saturated solutions are reported. PXRD, DSC and Raman data was 
analysed. 
4.2.1. C) Crystallisation kinetic studies: In this section the crystallisation 
kinetic studies of paracetamol solution using off line Raman spectroscopy 
have been described. Homogenous supersatured solution of 10%w/v of 
paracetamol is processed using MASCW technology and drop of this 
solution is placed on the sample slide and analysed using Raman 
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spectroscopy at 785nm laser power at different accumulations and time 
points over 24hrs. This experiment is performed to tract the crystallisation 
kinetics and phase identification using spectroscopy. Spectra over lay of 
Raman spectra are graphically plotted for every three hours‘ time point.  
4.2.1. D) Effect of solvent mixture on dielectric constant of solution and 
solubility of paracetamol: In this section use of solvent mixture apart from 
pure water for crystallisation of API was investigated. Four different organic 
solvents like methanol (MeOH), ethanol (EtOH), acetone (ACE) and 
acetonitrile (ACN) all HPLC grade were selected to prepare 10%, 20% and 
30% v/v concentration with water. Initially dielectric constant of water and 
solvent mixture of water-methanol, water –ethanol, water- acetone and 
water- acetonitrile from 0%v/v concentrations to 100%v/v concentrations was 
analysed. Later 10%, 20% and 30% v/v solution concentrations was selected 
and added 1g of paracetamol and processed using MASCW process at 
130°C with heating rate of 13°C/minute under variable pressure conditions 
until clear solution is formed. Once these saturated solutions are cooled at 
room temperature change in the dielectric constant of paracetamol solutions 
was reported.  
The equilibrium solubility of paracetamol raw in all these solvents for 24 hrs 
was checked at 25±3°C in triplicates. Amount of paracetamol dissolved in the 
respective solvent system was quantitatively determined using HPLC 
analyser. Based on the solubility of paracetamol in the solvent selected 
1500mg of paracetamol in the solvent mixture and processed using MASCW 
technology was selected. Further this saturated solution was left for stirring 
at 300rpms for 24hrs under room temperature conditions. All the samples are 
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treated at 150°C with heating rate of 15°C/min at variable pressure 
conditions. Change in dielectric constant, pH of the solution and equilibrium 
solubility of paracetamol in these solvent mixtures using MASCW technology 
was notified and reported. Percent purity and amount of dissolved 
paracetamol in all the solvent mixtures is analysed quantitatively using HPLC 
analyser.  
4.2.2 Application of MASCW process in cocrystallisation process 
Under this section elucidation of the application of MASCW process in 
generation of stable cocrystal pairs was explored. This section is divided into 
three sections;   
Section 1 includes the generation of CBZ: SAC (1:1) form I and form II 
cocrystals using MASCW process, further in this section the correlation 
between process parameters on cocrystal phase is reported. 
Section 2 demonstrates the screening experiment used to analyse the 
formation of cocrystals using MASCW process, in this section SMT, SMZ as 
API molecules and SAC as cocrystal former was selected.  
Section 3: this section included the cocrystallisation of incongruent pair; CAF 
and 4HBA in different stoichiometric ratios was selected and further the 
application of MASCW process in incongruent pair cocrystal formation was 
investigated. 
4.2.2.1 Cocrystallisation of CBZ: SAC cocrystals 
This study includes experimental design for co-crystallisation of CBZ: SAC 
stable form I and metastable form II cocrystal pairs using MASCW process, 
further methods for quantitative analysis of CBZ: SAC cocrystals using 
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HPLC, solubility profile of cocrystal pairs and surface properties of the 
powdered samples are described. 
4.2.2.1.1 Crystal Structure data prediction 
A) Crystal structure data of CBZ and SAC 
Carbamazepine anhydrous form III (CSD Refcode CBMZPN10) 
Polymorphic forms of CBZ are ranging from I to V, out of which form III 
anhydrous CBZ which is monoclinic crystal form is selected for the present 
study. This crystalline phase consists of space group P21/n, unit cell 
dimensions are, cell length a = 7.53Å, b = 11.15Å and c = 13.91Å and the 
angles are α = γ = 90 and β = 92.86. The computationally calculated PXRD 
pattern and crystal structure of CBZ III are displayed in Figure 4.1 and 4.2 
respectively. This PXRD pattern reflects the characteristic peaks at 2θ (°) = 
13.173 and 15.32. 
 





Figure 4.2 Crystal structure of CBZ III (retrieved from CSD) 
B) Carbamazepine dihydrate (CSD Refcode: FEFNOTO2) 
The crystal structure of CBZ dihydrate (CBZD) compromises one CBZ and 
two water molecules. The hydrogen bond is formed NH…O bond by 
inversion of crystallographic centre, the amido groups are contributing in 
hydrogen bonding activity (Robin K. Harris and Caiyun Ma 2005). CBZD is 
present in monoclinic with space group space group P21/c, the unit cell 
dimensions are, cell lengths a = 10.06 Å, b = 28.71 Å, c = 4.83 Å, and angles 
α = γ = 90 and β = 103.45. Calculated PXRD pattern and crystal structure 
of CBZD are displayed below Figure 4.3 and 4.4 respectively. 
 
Figure 4.3 Calculated PXRD pattern of carbamazepine dihydrate 




                     Figure 4.4 Crystal structure of CBZD (obtained from CSD) 
C) Saccharin (CSD Refcode: SCCHRN) 
Saccharin (CSD Refcode: SCCHRN) is arranged in planar and monoclinic 
crystal lattice with cell parameters as, lengths a= 9.55 Å, b = 6.91 Å, c = 
11.80 Å and angels as α = γ = 90° and β = 103.9° and space group P21/c. 
The crystal structure represents the centrosymmetric dimer where hydrogen 
bond NHO is present between nitrogen molecule of imide group and 
oxygen molecule of keto group (Rahul Banerjee 2005). The below Figure no 
4.5 and 4.6 represent the PXRD pattern and crystal structure of saccharin. In 
the calculated PXRD pattern characteristic reflections are observed in 2θ (°) 
= 15.99 and 25.2. 
 




Figure 4.6 Crystal structure of saccharin (obtained from CSD) 
D) CBZ/SAC cocrystal Form I (CSD Ref code: UNEZAO) 
CBZ/SAC form I is triclinic crystal entity with space group of P-1 and the unit 
cell parameters are a = 7.514 Å, b = 10.4538 Å, c = 12.6826 Å, and angles α 
=83.642, γ = 75.411 and β = 83.642. They are arranged in 1:1 
stoichiometric ratio, this form is addressed as the stable form of CBZ/SAC 
1:1 cocrystal. This exhibits homosynthon between the N-H site of SAC and –
COOH site of CBZ the second hydrogen bond i. e. formed between anti N-H 
group of CBZ and -S=O group of SAC (Porter et al., 2008). The distance of 
these two hydrogen bonding are d=1.75Å and d=2.47Å respectively. In the 
calculated PXRD pattern of this cocrystal characteristic reflections are 
observed at 2θ=6.88°, which is distinctive peak from CBZ/SAC form II 
cocrystal. Below is the schematic representation of the hydrogen bonding 




Figure 4.7 Calculated PXRD pattern of CBZ/SAC 1:1 cocrystal FI 
(retrieved from CSD) 
 
                     Figure 4.8 Crystal structure of CBZ/SAC 1:1 cocrystal  
 
Figure 4.9 Schematic representation of CBZ/SAC 1:1 cocrystal motif 
(Hickey et al., 2007). 
E) CBZ/SAC cocrystal Form II (CSD Ref code: UNEZAO01) 
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This form II structure consists of monoclinic space group C2/c with a = 35.72 
Å, b = 6.84 Å, c = 16.11 Å, and β = 98.03°. This exists in the form of 
heterosynthon between CBZ and SAC. Hydrogen bond is observed between 
N-H group of SAC and C=O group of CBZ at d=1.76Å and second bond is 
observed between N-H group of SAC and carboxylic group of CBZ at 
d=1.97Å, the differentiating bonding is observed between the –N-H site on 
urea region of CBZ and S=O group of SAC at d=2.00Å. There is a 
characteristic distinctive peak of CBZ/SAC form II reflected at 2θ = 4.80 ° 
which is lacking in form I. The morphology of this form is confirmed to be 
needle shaped (Porter et al., 2008). 
 
Figure 4.10 Calculated PXRD pattern of CBZ/SAC 1:1 cocrystal FII 
(CSD) 
 





Figure 4.12 Difference between homosynthon (FI) and heterosynthon 
(FII) of CBZ/SAC cocrystals. 
4.2.2.1.2 Crystallisation method of CBZ/SAC cocrystals 
Microwave assembly used for the crystallisation is RotoSYNTH (Analytix) 
which consists of quartz reacting vessel with total capacity of 30mL. It has 
the temperature and pressure valve and the limits are up to 350˚C and 30 
bars pressure respectively. Molar weight of CBZ and SAC in 1:1 
stoichiometric ratios is weighed accurately using analytical balance and 
deionised water is used as the solvent media for cocrystallisation process. 
The total molar weight of CBZ /SAC 1:1 cocrystal pair is 350 mg and it is 
kept constant throughout the experiment. This saturated mixture solution is 
subjected for stirring using magnetic stirrers. 
Different experiments were performed to study the effect of process 
parameters and concentration of solvent in the final product. For the purpose 
of comparison CBZ: SAC cocrystals were crystallised from methanol using 
conventional solution crystallisation technique. CBZ: SAC (2mmol) each is 
weighed and dissolved using methanol (40ml) till clear solution is formed and 
then the saturated solution is left for solvent evaporation to induce solution 
mediated crystallisation process.  Below Table 4.4 represents the 
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experimental design where different process parameters like energy, 
temperature, heating rate, concentration of solvent and effect of solvent 
mixture as selected as variable parameters and amount of solute mixture in 
water as constant parameter. Microwave energy is used to increase the 
temperature and pressure of the solution, the solution is treated until 
homogenous solution of solute and solution is obtained. Once the clear 
solution is obtained it is further treated to confirm homogeneity and further on 
sudden quenching or controlled cooling crystals starts inducing out. During 
the cooling stage the crystals started inducing out which are vacuum filtered 
using wattmann filter paper (grade 1) and air dried at ambient conditions and 
further characterised using different analytical tools. 














Rate of heating 
(mins) 
350 (1:1) 110 10 300 5 
350 (1:1) 115 10 300 5 
350 (1:1) 120 10 300 5 
350 (1:1) 115 10 300 5 
350 (1:1) 115 12.5 300 5 
350 (1:1) 115 15 300 5 
350 (1:1) 115 10 200 5 
350 (1:1) 115 10 300 5 
350 (1:1) 115 10 400 5 
350 (1:1) 115 10 300 5 
350 (1:1) 115 10 300 2.5 
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350 (1:1.5) 115 12.5 300 5 
350 (1:1.5) 115 15 300 5 
350 (1:2) 115 12.5 300 5 
350 (1:2) 115 15 300 5 




4.2.2.1.3 HPLC method for analysis of CBZ: SAC cocrystals 
For quantitative and qualitative analysis of the raw and processed samples 
HPLC method is developed. In MASCW process as the samples are 
subjected to high temperature and pressure conditions so for quantitative 
analysis of CBZ in the final cocrystal samples degradation study using HPLC 
is performed. Based on USP standards carbamazepine further undergoes 
degradation to iminostilbene. The degradation study is performed using 
Waters e-2695 system integrated with a PDA detector (PDA 2998) 
connected with degasser. Waters symmetry C18 column with dimensions 4.6 
x 250 mm and the particle size of the packing material is 5μm. Concentration 
of injection volume used is 10μL. The mobile phase selected for the 
separation is the combination of acetonitrile with 0.1% v/v formic acid 
solution, flow rate selected is 1.2 mL per minute. The temperature of the 
column and sample is maintained at 25˚C±2 throughout the experiment. The 
UV wavelengths used for detection of CBZ and iminostilbene are 219 nm, 
253 nm and 285 nm. The chromatographic data is analysed using Empower 
3, analysis software. 
Development of calibration curve for iminostilbene 
Calibration curve for iminostilbene is generated using six known standard 
concentrations of iminostilbene. Area under the curve is integrated and 
90 
 
calibration plot is plotted against concentration and area under curve. This 
graph is used to generate the slope equation. The concentrations of 
iminostilbene selected were 10, 20, 30, 40, 50 and 60μg/mL in acetonitrile as 
the solvent media. The slope equation is used to calculate the unknown 
concentration of iminostilbene in MASCW processed samples. 
Sample preparation 
Analysis of the unknown iminostilbene in MASCW processed carbamazepine 
is performed dissolving 250mg of processed sample in 10mL acetonitrile and 
subjected for stirring till clear solution is formed. The resultant solution is 
injected into HPLC assembly after passing through 0.45 μM nylon membrane 
filter. The quantification of iminostilbene in these samples is done using 
calibration curve equation. 
4.2.2.1.4 Surface Energy Analysis method 
Surface energy analysis is performed to understand the change in the 
surface properties of initial and final dry powdered samples. This analysis 
explains the change in specific surface area and surface heterogeneity which 
is attributed to change in particle morphology and crystal form. The 
instrument used for analysis is Surface Energy Analyser (SEA), UK Ltd.  
CBZ/SAC form I and form II obtained from MASCW processed is analysed 
and in comparison with this CBZ/SAC form I obtained from solution 
crystallisation is used. To compare the results obtained by different batches 
and forms, the iGC experiments were performed at specific and constant 
probe surface coverage. Fixed probe surface coverage approach is applied 
to SEA which is next generation system.  
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Three separate salinised glass columns were packed with the cocrystal 
samples using glass wool and these are subjected for SEA analysis. 
 Column temperature maintained at 30°C 
 Relative humidity conditions are 0% 
 The conditioning of samples to nullify the vacuum present is done for 
4hrs using inert helium gas. 
 Conditioning of the column before and after the experiment is done 
using methane injection. 
 Amount of samples used are 
 CBZ/SAC Form I solution crystallisation: 135 mg 
 CBZ/SAC Form I MASCW processed    : 110 mg 
 CBZ/SAC Form II MASCW processed   : 139 mg 
Initially, BET surface area of the cocrystal samples were calculated and 
further based on the surface area of the sample further surface heterogeneity 
is calculated using different solvent probes. 
BET surface area is calculated by injecting octane gas at different surface 
coverage‘s, area under curve (peak max) is determined using Dorris and 
Gray equation. Below Table 4.5 describes the experimental details used for 
calculating BET specific surface area. Cirrus Plus software is used to 
analyse the dispersive surface energy of the materials. 
Based on the specific surface area results different alkanes (hexane, 
heptane, octane, nonane), polar and nonpolar injections were injected in the 
sample column to determine the surface heterogeneity of the sample. Detail 
description regarding the experimental conditions and solvent system for 
analysing surface heterogeneity of the sample is described in Table 4.5.  
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Table 4.5 Experimental design used to analyse the specific surface area 
 
Below Table 4.6 illustrated the method used to analyse surface 
heterogeneity of the samples. 
Table 4.6 Experimental design to analyse surface heterogeneity 
 
4.2.2.1.5 Solubility studies 
Solubility profile curves were generated based on the solubility of CBZ-SAC 
FI and FII in the deionised water at different temperatures ranging from 10 °C 
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to 45 °C. The solubility of FI and FII were measured in terms of concentration 
of CBZ using high performance liquid chromatography (HPLC), Waters e-
2695 equipped with PDA detector (PDA-2998). The HPLC analysis is 
performed using Waters symmetry C18 column with 5µ column packing 
material and 4.6x 250mm column dimensions. The HPLC method used is an 
isocratic and mobile phase comprises of 30%water and 70% acetonitrile 
containing 0.1% trifluroacetic acid, flow rate and injection volume used is 1 
mL/min and 10µL respectively. 
4.2.2.2 Cocrystallisation of SMT: SAC and SMZ: SAC cocrystal pairs 
MASCW technology was further explored as a screening tool for the 
generation of different cocrystal pairs. In the screening experiments 
cocrystals of SMZ: SAC and SMT: SAC is synthesised in 1:1 molar 
stoichiometric ratios. 
4.2.2.2.1 Crystal Structure data prediction  
A) Crystal structure data of SMZ (CSD Refcode- 2209208-COD) 
Sulfamerazine exists in three polymorphic forms, form I, II and III (Ravindra 
Acharya et al., 1982) . All the three polymorphs of SMZ is a dimer via a pair 
of intermolecular N-H…N hydrogen bonds between two SMZ molecules. 
Furthermore one of the hydrogen atoms of the amide group associated with 
dimer is engaged in single intermolecular N-H….O hydrogen bond with the 
oxygen of sulfonyl group. Thus as a result of molecular association structure 
with extended two dimensional (2D) hexagonal networks is present in form I 
polymorph and one dimensional (1D) ladder network is in form II and form III. 
In the present study form I polymorph of SMZ with space group of P 21/c with 
cell length a 11.097, b 8.315, c 13.964 and cell angles (α 90.00 β 99.327 γ 
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90.00) have been used. There is no crystal structure data reported for the 
sulfamerazine and saccharine cocrystal pair. Below Figure 4.13 and 4.14 
describes the crystal structure and calculated PXRD pattern for SMZ form I 
 
Figure 4.13 Crystal structure of: sulfamerazine (CSD -2209208-COD) 
 
Figure 4.14 Calculated PXRD pattern of sulfamerazine form I polymorph 
B) Crystal structure data of SMT and SAC cocrystal (CSD Refcode 
g150513a)  
As the crystal structure data for sulfamethazine is not reported, therefore the 
calculated crystal structure data for SMT: SAC cocrystal has been used as 
reference. SMT: SAC in 1:1 stoichiometric ratio exists in monoclinic crystal 
lattice with space group of P21/n, bond length (a/ A
° 8.0729, b/ A° 17.6015, c/ 
A° 14.4311) and bond angle (α/° 90, β/° 104.488, γ/° 90). Below Figure 4.15 
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and 4.16 represents the crystal structure of SMT: SAC 1:1 cocrystal and 
calculated PXRD pattern respectively (Fu et al., 2016). Crystal structure data 
of saccharine is described in the above section (4.2.1.1.1. a – structure-C). 
 
Figure 4.15 Crystal structure of: SMT: SAC 1:1 cocrystal (CSD Refcode 
g150513a)  
 
Figure 4.16 Calculated PXRD pattern of SMT: SAC 1:1 cocrystal 
4.2.2.2.2 Crystallisation method for screening experiment 
Equimolar concentrations of APIs SMT (278mg, 1mmol), SMZ (264 mg, 
1mmol) and cocrystal former SAC (183 mg, 1 mmol) were added to 10ml of 
water and were subjected to high temperature and pressure under the 
influence of microwave energy (300watts) using MASCW technology till clear 
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solution is obtained. The clear solution is further aged at the targeted 
subcritical temperature for 1 minute to attain homogenous solution and then 
the solution is cooled down, upon cooling the solution is subjected for shear 
via stirring using magnetic stirrer and based on the supersaturation level 
crystals started inducing out. Below Table 4.7 explains the experimental and 
stoichiometric conditions of the experiment. The material is filtered using 
0.22 µm PTFE syringe filter paper, dried at ambient conditions and analysed 
using PXRD and thermal analysis (DSC and TGA) to confirm the cocrystal 
formation. 
Table 4.7 Experimental conditions for SMT/SAC and SMZ/SAC 
cocrystals 
Wt. of API 
(mg)(1mmol)  








SMT (278)  183 mg 1:1 135 27°/min 
SMZ (264) 183 mg 1:1 135 27°/min 
 
4.2.2.3 Application of MASCW process for generation of incongruent 
pair cocrystal pair (CAF: 4HBA 1:1)  
In this study based on the aqueous solubility of individual component CAF 
and 4HBA is selected as incongruent cocrystal pair. They are process at 
different stoichiometric ratios using MASCW process. 
4.2.2.3.1 Crystal structure data of CAF and 4HBA 
A) Caffeine anhydrous (CSD Refcode NIMFEE03)  
They are two polymorphs of caffeine anhydrous but one of the anhydrous 
crystal form is reported (Habgood and Price 2010). Caffeine anhydrous (CSD 
Refcode NIMFEE03) - xanthine derivative and caffeine consists of two fused 
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rings pyrimidinedione and imidazole. Caffeine anhydrous undergo 
crystallisation with five independent molecules in a monoclinic C-centered 
unit cell with dimensions a=43.0390 Å, b=15.0676Å and c=6.95314 Å and 
beta angle of 99.027° (Lehmann and Stoisser 2007). In the below Figures 
4.17, 4.18 represents crystal structure and calculated PXRD pattern of t 
anhydrous caffeine. 
 
Figure 4.17 Crystal structure of: caffeine anhydrous (CSD Refcode 
NIMFEE03). 
 
Figure 4.18 Calculated PXRD pattern of caffeine anhydrous. 
B) 4-Hydroxybenzoic acid (CSD Refcode JOZZIH) 
4-Hydroxybenzoic acid (4-HBA) exists in two polymorphic forms but one of 
the polymorphs crystal structure reported, it is the monoclinic crystal 
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structure with space group P21/a, and unit cell dimensions are a= 18.508 Å, 
b = 5.228 Å, c = 6.342 Å and angels as α = γ = 90° and β = 93.22°. This 
structure has hydrogen bonding site at the -OH functional group. Figure 4.19 
and 4.20 represents the crystal structure and calculated PXRD pattern of 4-
HBA. 
 
Figure 4.19 Crystal structure of 4-hydroxybenzoic acid (CSD Refcode 
JOZZIH). 
 
Figure 4.20 Calculated PXRD pattern of 4-hydroxybenzoic acid. 
4.2.2.3.2 Experimental method of cocrystallisation 
MASCW process is performed initially using water 10 mL as solvent system, 
microwave energy is 300W and rate of heating is 5 minutes. Molar quantity 
of CAF and 4HBA were weighed in different stoichiometry and subjected to 
99 
 
MASCW process, under the influence of elevated temperature and pressure 
till clear solution is obtained and the resulted supersaturated solution is 
further cooled using ice-water bath where the temperature is reduced 
suddenly. 2.5 mille moles of each starting solute components were selected 
based on supersaturation in the solvent system. The below Table 4.8 
illustrates the brief description of experimental design of CAF/4HBA 
cocrystals and results obtained. 
Table 4.8 Experimental design of: CAF-4HBA cocrystallisation using 
MASCW process. 
Wt. of CAF (mg) 
(2.5mmol) 
Wt. of 4HBA 
(mg)(2.5mmoll) 
Ratio Solvent system 
(10 mL) 
Temp (˚C) 
485 345 1:1 water 135 
485 690 1:2 water 135 
970 345 2:1 water 135 
485 345 1:1 5mLMeOH +5mL 
H2O 
135 
The cocrystal obtained is vacuum filtered using 0.22µm PTFE syringe filter 
paper and dried in the ambient conditions for 1 hr and further analysed using 
PXRD, DSC, TGA and NMR. 
4.2.2.4 Application of MASCW process in particle engineering of 
paracetamol. 
In this section MASCW process was implemented to explore its application in 
the field of particle engineering. This section is divided into two sections 
based on the application. 
Section 1: In this section paracetamol was selected as lead molecule and 
MASCW process was implemented for generation of metastable polymorphs 
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of paracetamol to enhance the compressibility and kinetic properties of 
paracetamol powder and tablet.  
Section 2: MASCW process was further explored for generation of macro 
sized anhydrous theophylline and analysed their aerodynamic performance 
using Next Generation Impactor (NGI). 
4.2.2.4.1 Crystal structure database (CSD) of paracetamol 
A) Paracetamol form I (CSD Refcode: HXACAN01) 
Paracetamol is antipyretic drug which exists in three polymorphic forms. 
Paracetamol form I and II are well studied crystal structures than III which is 
still elusive. This is stable monoclinic form which is placed in space group 
P21/a with unit cell dimensions cell length a = 12.930Å, b = 9.400Å and c = 
7.100Å and the angles are α = γ = 90 and β = 115.9. Below Figure 4.21 and 
4.22 represents the crystal structure of Paracetamol and computationally 
calculated PXRD pattern of paracetamol form I (monoclinic). 
 




Figure 4.22 Calculated PXRD pattern of paracetamol Form I. 
B) Paracetamol form II (CSD Refcode HXACAN23) 
Paracetamol form II is referred as metastable phase with orthorhombic 
crystal structures. It is crystallized in the space group of Pcab with unit cell 
dimensions a = 7.406 Å, b = 11.837Å and c = 17.162Å and the angles are α 
= β = γ = 90. Figure 4.23 represents the calculated PXRD pattern of 
Paracetamol form II. The crystal structure is similar in all forms as they are 
polymorphs they differ only in the cell dimensions and space group. 
 
Figure 4.23 Calculated PXRD pattern of paracetamol Form II. 
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4.2.2.4.2 Processing method of Paracetamol 
MASCW process was used to process commercially available form I 
polymorph of paracetamol. In this process the paracetamol was subjected to 
high temperature and pressure conditions until clear solution was obtained 
and further left it for cooling. Based on the level of supersaturation and 
aqueous solubility of paracetamol the crystals started inducing as the 
temperature decreases and the crystalline material is vacuum filtered using 
wattmann filter paper. The concentration of solute in the solvent system is 
selected considering the solubility of paracetamol in water to maintain high 
supersaturated concentration of paracetamol in water. Based on the 
literature review the solubility of paracetamol in water at 25°C is 
approximately 14mg/ml so initially smaller quantity of solute was used but 
after process due to less supersaturation concentrations crystals failed to 
induce, based on this observation solute concentration was optimised  to 1g 
and based on the capacity of instrument and observations in cocrystallisation 
experiments 10 mL of water is considered. The supersaturation 
concentration is 14 times higher than the normal solubility of paracetamol in 
water. The heating rate to reach the target temperature is optimised to 5 
minutes and is further treated at that temperature for 1 minute. At 140°C no 
decolouration or degradation of paracetamol took place, but when the 
temperature is further increased to 150°C there is decolouration of the solid 
materials taking place this is due to the degradation of paracetamol under 
the influence of high temperature and pressure conditions. Below Table 4.9 




Table 4.9 Experiment conditions used to process paracetamol using 
MASCW process. 
Amt. of raw 
paracetamol 
Experimental conditions during cooling step 
1g Controlled cooling without stirring 
1g Controlled cooling with stirring 
1g Sudden cooling with stirring 
1g Sudden cooling without stirring 
 
4.2.2.4.3 Quantitative analysis of paracetamol using HPLC 
As the samples of paracetamol are exposed to high temperatures and 
pressure conditions degradation analysis of paracetamol was performed 
using HPLC. Paracetamol in solution state undergoes oxidation to give rise 
to 4-aminopenol as potential degradant product. The degradation study is 
performed using Waters e-2695 system which is integrated by PDA detector 
(PDA2998) connected with degasser. The column used is waters symmetry 
C18 column with dimensions 4.6*250 mm and the particle size of the packed 
material is 5µm. Concentration of injection volume used is 10 µL. 
Method: The method used to study the degradation calibration of 
paracetamol is gradient method where solvent A = 20mM phosphate buffer 
and solvent B = Acetonitrile HPLC grade. Column and the sample 
temperature were maintained at 25±2°C. The wavelength used to analyse 
paracetamol is 245nm where retention time is 3.9 and wavelength for 4-






Table 4.10 Summary of HPLC method (gradient) 
Time (minute) Flow rate (mg/ml) %A Solvent %B Solvent 
0 1.50 90% 10% 
10 1.50 70% 30% 
12 1.50 90% 10% 
15 1.50 90% 10% 
Development of calibration curve for 4-aminophenol 
Standard calibration curve is plotted for 4-aminophenol and paracetamol 
using same HPLC method of analysis. Area under the curve is integrated 
and the calibration plot is plotted between different concentrations and area 
under curve. From the slope value generated concentration of 4-
aminophenol present in MASCW process paracetamol and percent purity of 
paracetamol present in the process samples was calculated. The 
concentrations used for calibrations are 5, 10, 20, 30, 40 and 50µg/mL. 
Phosphate buffer and acetonitrile were used for dilution of the standards and 
solvent to dissolve standard solute respectively. 
4.2.2.4.4 Analysis of surface properties (SEA) 
Surface properties like specific surface area, surface heterogeneity and acid-
base values are analysed using Surface Energy Analyser (SEA). The 
procedures and methods used for analysis are similar to methods described 
in the Table 4.5 and 4.6. The analysis of the samples is performed at infinite 
dilutions. Approximately 100 mg of paracetamol form I and II MASCW 
processed and raw commercial form I is filled into salinised glass column 
(4mm diameter) and series of alkane gas is passed through the column to 
measure the change in elution obtained from all solvent systems. Fixed 
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probe surface coverage approach is applied to SEA which is next generation 
system.  
4.2.2.4.5 Solubility study of paracetamol 
Solubility study is performed to understand the kinetic properties of MASCW 
processed paracetamol samples. Paracetamol form I and II MASCW process 
and raw paracetamol form I is selected for this study. The particle sizes of 
the three samples are determined using Sympatec particle size analyser. 
The equilibrium solubility of the paracetamol samples were performed at 
constant temperature 20°C±3 against different time points using deionised 
water as solvent system. The time points selected for the study are 1, 2, 3, 4, 
6, 12 and 24hrs. Approximately 200mg of each sample is added to 5ml of 
water under 300rpm stirring using magnetic stirrer. The temperature is 
monitored using temperature sensor on the hot plate. At every time point the 
supernatant liquid sample is filtered using wattmann filter paper with pore 
size 0.45microns and the quantitative analysis of the samples is analysed 
using HPLC analyser. The method used to study the concentration of the 
dissolved paracetamol in water is similar to the method used in quantitative 
analysis of paracetamol. The concentration of the dissolved paracetamol is 
calculated based on the slope equation derived from the calibration curve of 
paracetamol. All the readings are performed in triplicates. 
4.2.2.4.6 Dissolution study 
Intrinsic dissolution experiments were performed using a UPS II type 
LabIndia dissolution tester (Labin-09, India). Tablets of 500mg each 
paracetamol samples were prepared using IR –press at 1tones pressure for 
30secs. Paracetamol raw and MASCW processed from I and from II samples 
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were placed at the bottom of the dissolution vessel (at least four repeats) 
containing 900 ml phosphate buffer (20mM) maintained at 37 ± 0.5 °C and 
stirred with a paddle at 50 rpm. Samples were collected periodically and 
further filtered. Quantification of paracetamol is performed 
spectrophotometrically at a fixed wavelength of 243 nm using a Jasco-V630 
spectrophotometer. The percent release rate of paracetamol is calculated 
using PCP disso software. 
4.2.2.5 Application of MASCW process for inhalation drug delivery 
system 
In this present work MASCW process was in the field of crystal engineering 
for the generation of micro sized particles of anhydrous theophylline (THF) 
for inhalation drug delivery system. The aerodynamic performance of the 
MASCW process THF and spray dried THF as reference was reported. 
4.2.2.5.1 Crystal Structure Data 
A) Crystal structure data of Theophylline (CSD Refcode- 4505532-COD) 
Theophylline is widely used antiasthmatic drug which is also known for its 
phase transition during pharmaceutical processing.  Based on the storage 
conditions THF exists either as anhydrous THF or gets converted into THF 
monohydrate. Crystal structure of anhydrous and monohydrate THF is 
orthorhombic and monoclinic crystal systems respectively. In the present 
study anhydrous theophylline was used, this exists in two forms, stable form I 
anhydrous THF and metastable form I anhydrous THF (Phadnis and 
Suryanarayanan 1997).  Crystal lattice of anhydrous THF consists of space 
group Pna21 , cell length (A°) of a 13.087, b 15.576, c 3.863 and cell angles 
(°) of α90 β90 γ90 respectively. Below Figure 4.24 and 4.25 represents the 
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crystal structure and calculated PXRD pattern for anhydrous form I stable 
theophylline. 
 
Figure 4.24 Crystal structure of: anhydrous theophylline (CSD Ref- 
4505532-COD) 
 
Figure 4.25 Calculated PXRD pattern of: anhydrous THF 
4.2.2.5.2 Preliminary crystallisation experiments of THF 
Crystallisation of theophylline is performed using various experimental 
conditions. Anhydrous THF (1g) in 10ml of distilled water was selected and 
subjected to high temperature and pressure conditions keeping microwave 
power (300 watts) as constant process parameter. The sample is heated till 
clear homogenous solution is obtained and the targeted temperature where 
clear solution is formed is 140°C and the heating rate is 27°C/min and is 
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further aged at this temperature for 1minute to attain homogenous solution 
and left the solution for cooling. 
Different mechanisms of crystallisation were implemented to understand the 
effect of crystallisation techniques over particle size of the precipitated 
theophylline; Table 4.11 described different crystallisation conditions used to 
generate micro sized particles of THF. To study aerodynamic performance of 
any drug the mean particle size distribution (PSD) plays a significant 
importance in the development of inhalation drug delivery system and the 
PSD should be less than 5 micron according to USP standard requirements 
and NGI instrumental requirement. Thus the PSD of the THF samples 
processed using different crystallisation techniques were analysed and the 
one which is fulfilling the requirement for inhalation drug delivery system is 
selected and further large quantity of the samples were prepared to study 
aerodynamic performance of the powder using NGI inhaler. Methods used 
for crystallisation are: 
I. In manual stirring the samples is stirred using magnetic stirrer during 
cooling stage. Based on the degree of supersaturation and shear 
conditions crystals started inducing out 
II. Antisolvent technique is used based on the aqueous solubility of THF 
where MASCW solution of theophylline is poured in 50ml distilled 
water which is kept at ambient conditions under stirring using 
magnetic stirrer due to sudden decrease in the temperature and 
increase of shear conditions micro sized crystals  induced out. 
III. Implemented ultrasound induced crystallisation to produce micron 
sized particles, the MASCW solution of THF during cooling phase is 
109 
 
treated under ultrasound energy which is 100% amplitude for 
3minutes. 
IV. MASCW solution of THF was subjected to Ultraturrax to understand 
the effect of external shear of Ultraturrax over particle size of THF. 
The crystals which are induced are vacuum filtered using 0.45 micron 
wattmann filter paper and kept for drying under ambient conditions before 
analysing for different crystalline properties and aerodynamic performance of 
THF.  
Table 4.11 Experimental description of various batched of theophylline 
Sample Crystallisation techniques used 
THF-S1 Raw anhydrous THF 
THF-S2 Antisolvent techniques 
THF-S3 Ultrasound assisted  
THF-S4 Manual stirring 
Lactose IG Standard 
 
4.2.2.5.3 Synthesis of spray dried anhydrous theophylline 
Spray dryer is conventional technique used for generation of micron sized 
drug particle which are implemented in inhalation drug delivery system. Thus 
anhydrous THF was generated using spray dryer to compare aerodynamic 
performance results of THF obtained from MASCW technology. Based on 
the previous finding 0.02M solution of anhydrous theophylline in methanol 
(HPLC grade) (Alhalaweh et al., 2013) was used. Below Table 4.12 




Table 4.12 Experimental parameters used to crystallise THF using 
spray drying 
Experimental parameters 
Inlet temperature -150°C Outlet high -120°C 
Outlet temperature-130°C Cool temperature -80°C 
Plate temperature -20°C Aspirator Flow rate- 70 Nm3/hr 
Inlet high (°C)- 200°C Feed Pump flow rate- 3ml/min 
 
4.2.2.5.4 Method to setup the Next Generation Impactor 
The Next Generation Impactor is the analytical instrument which is used to 
study the aerodynamic properties of the powdered materials using dry 
powder inhaler. This NGI consists of seven plates with a micro-orifice 
collector. This can be operated at inlet flow rate ranging from 30L/min to 
100L/min based on the inhalation capacity of the patient. The NGI instrument 
consists of arrangement of three different metallic frames; bottom frame 
consists of the impaction cups where the material is deposited, middle plate 
which is sealed frame which holds nozzles and the upper most lid consists of 
inter stage passages which is used for the materials to flow ((United States 
Pharmacopeia Convention. 2004; European Directorate for the Quality of 
Medicines & HealthCare. 2008). Figure 4.26 demonstrated the different 
frames of NGI instrument. The instrument is connected to induction port 
preseperator. The use of pre-separator is recommended according to USP 
conventions, 2004 for dry powder inhaler to retain the active ingredients 
which are attached to larger carrier particles.  
Before initialising the analysis the collection cups were coated with glycerol 
to prevent the bouncing of the powdered samples, the cups were placed in 
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the bottom frame and the NGI lid is closed, 15ml of methanol sample is 
placed in the central cup of pre-separator, further this pre-separator is 
connected to induction port which is also connected to impactor body. A 
suitable mouth piece is connected to the induction port to ensure there is no 
sample loss between the inhaler device and the induction port, a vacuum 
pump is connected to the NGI to attain desired flow rate. The inhalation flow 
rate is determined to be equivalent to 4 KPa pressure drop across the dry 
powder inhaler device (USP convention, 2004). This is equal to the flow rate 
of 60L/min.  Before the use of inhaler device a calibrated electronic flow 
meter is used to measure the flow rate each time. The inhalation time 
required to attain desired flow rate and pressure drop is calculated by the 
following equation (European Directorate for the Quality of Medicines & 
HealthCare. 2008): 
𝑻 =  (𝟔𝟎 𝒔𝒆𝒄 𝒙 𝑽) / 𝑸 
T = Time duration consistent for withdrawal of 4 litres of air from the inhaler 
Q = Airflow which produces a pressure drop of 4 KPa 
V = 4 L to be drawn through the inhaler 
Based on the above equation the required time for attain flow rate of 60L/min 
is 4.0 secs. MASCW processed dry anhydrous THF samples (25mg) is 
loaded into 0.5size gelatine capsules and placed in the Foradil dry powder 
inhaler device, which is then connected to the induction port through an air 
tight connector to prevent the leakage of sample. Before starting the air flow 
the DPI device Foradil is pressed to break the capsule and then the drug is 
injected into the NGI at the flow rate of 60L/min for 4 seconds. Each 
experiment is performed in triplicates. Based on the particle size the sample 
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gets deposited in the different regions of impactor. The deposited particles at 
different stages are recovered by dissolving in the known volume of 
methanol followed by quantitative analysis using HPLC. 
To study the different inhalation parameters of the samples Copley Inhaler 
Testing Data Analysis Software (CITDAS) is used. Using this software the 
fine particle fraction of drug deposited in different stages of NGI has been 
calculated, Mass median aerodynamic diameter and geometric standard 
deviation. 
 
Figure 4.26 Description of the Next Generation impaction (NGI) (Zhu et 
al., 2015). 
1. Fine particle fraction (FPF): It is the percent ration of fine particle dose 
(FPD) and total delivery dose for each run of NGI. 
                    𝑭𝑷𝑭 =  (𝑭𝑷𝑫/𝑻𝒐𝒕𝒂𝒍 𝒅𝒆𝒍𝒊𝒗𝒆𝒓𝒆𝒅 𝒅𝒐𝒔𝒆) ∗  𝟏𝟎𝟎% 
FPD- Fine particle dose is the total amount of dose deposited with particle 
size corresponding to a size less than 5µm. 
Total delivery dose- It is the amount of drug deposited in the induction port, 
pre-separator and stages of NGI (Telko and Hickey 2005). 
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2. Mass median aerodynamic diameter (MMAD) – It is calculated from 
the log of effective cut-off diameter (ECD) corresponding to 50% 
undersized particles (on probability scale). 
3. Geometric standard deviation (GSD) is calculated from the following 
equation (United States Pharmacopeia Convention. 2004):  
                            𝑮𝑺𝑫 =  √((𝒅𝟖𝟒.𝟏𝟑% / 𝒅𝟏𝟓.𝟖𝟕%))    
Where d 84.13%, and d15.87% are the aerodynamic particle size at 15.87% 
and at 84.13% less than the stated size, respectively for the cumulative size 
distribution. 
All the parameter values obtained for each sample are graphically plotted on 
Microsoft excel sheet. 
4.2.2.5.5 Quantitative analysis of THF using HPLC analyser 
As the samples of theophylline were processed using MASCW process due 
high stress conditions degradation can occur therefore quantitative analysis 
was performed to study the degradation of theophylline and develop a 
calibration method for theophylline for analysing various THF sample 
solutions collected from Next Generation Inhaler (NGI). 
HPLC method: The quantitative analysis of THF samples are done using 
isocratic method, this method is based on the US pharmacopeia using 
Waters e-2695 system which is integrated by PDA detector (PDA2998) 
connected with degasser. The column used is waters symmetry C18 column 
with dimensions 4.6*250 mm and the particle size of the packed material is 
5µm. Concentration of injection volume and flow rate used is 10 µL and 
1ml/minute respectively, the solvent system involved are: solvent A = sodium 
acetate trihydrate (1.36g in 1L distilled water + 5ml acetic acid glacial and 
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solvent B = acetonitrile HPLC grade. Column and the sample temperature 
were maintained at 30°C. The wavelength used to analyse THF is 280nm 
where retention time is 5.2 for theophylline. Mobile Phase contains sodium 
acetate buffer and acetonitrile in 93:7 ratios respectively.  
 
Figure 4.27 Graphical representation of calibration curve of THF   
Content uniformity measurements: The content uniformity of THF and 
lactose IG is measured quantitatively using HPLC, as described above. 
Blends of THF (40mg ±0.5mg) and lactose IG is prepared my mixing using 
turbula mixer for 5 minutes. Relative standard deviation calculations were 
performed between the samples and accessed the homogeneity of blends. 
4.2.2.5.6 Setup procedure to analyse surface properties of processed 
THF samples using SEA analyser:  
The surface properties of all the raw and processed theophylline samples are 
analysed using Surface Energy Analyser. Using this instrument specific 
surface area, surface heterogeneity, thermodynamic work of adhesion 
between THF and lactose IG samples and thermodynamic work of cohesion 
within the same moieties was determined. The method used for the analysis 
is similar to the method used previously for the analysis of surface 
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heterogeneity of paracetamol samples (see Section 4.2.2.4.4). Surface 
properties determination was performed at infinite dilutions using Dorris and 
Grey equation (see Section 4.2.2.8).  
Initially before performing the IGC analysis the particle size of the raw and 
processed samples are kept similar and analysed using Sympatec 
diffractometer. All experimental analysis is performed using an IGC-SEA 
analyser and analysis of each sample is performed in duplicate. 
Approximately 100mg of sample is weighed and packed in 4mm iGC 
salinised glass column and is analysed using series of alkanes, polar and 
non-polar solvents at different surface coverage‘s. The retained retention 
time is used to analyse dispersive surface energy (γSD), specific surface 
area, thermodynamic work of adhesion and cohesion. Before performing 
each of the analyses the sample loaded column is preconditioned using 
helium gas for 2hrs at 30°C at 10ml/min flow rate, the dead volume is 
calculated using methane gas purge. Solvents used non-polar solvents- 
heptane, octane, nonane, decane and polar solvents –ethanol, 
dichloromethane, ethyl acetate and chloroform. The surface coverage‘s used 
for analysis are from 0.8%, 1%, 2%, 4%, 6% and 8%. Initially alkane probes 
were injected at different surface coverage‘s to calculate specific surface 
area and based on the surface area results surface heterogeneity, 
thermodynamic work of adhesion and thermodynamic work of cohesion is 
calculated injecting different polar and non-polar solvent probes. 
The effect of different crystallisation techniques are reported in the present 
study, which focused on the particle size and other characteristic properties 
of powdered sample. The  samples generated using MASCW process are 
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further analysed using Sympatec diffractometer, Scanning electron 
microscopy (Jouyban et al.,), X-ray diffraction (XRD), Fourier transform 
infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), and 
differential scanning calorimetry. The quantitative analysis of all the samples 
collected from NGI stages are analysed using High Performance Liquid 
Chromatography (HPLC). 
4.2.2.6 Application of MASCW process in hydrogen bonding between 
nanocrystalline hydroxyapatite and Ibuprofen 
In this section the application of MASCW process in the formation of complex 
molecules was explored, hydroxyapatite (HA) as inorganic biomaterial 
compound and ibuprofen (IBU) as API organic entity was selected and 
mechanism of hydrogen-bonded complex formation between ibuprofen and 
nanocrystalline hydroxyapatite was explained.  
4.2.2.6.1 Nano-hydroxyapatite preparation 
Nanocrystalline HA is prepared based on the method reported previously by 
(Kumar et al., 2004) and group. In brief, calcium hydroxide Ca(OH)2 (3.704g, 
assay ≥96%, Sigma Aldrich) and phosphoric acid (3.459g, 85% wt. in water, 
Sigma Aldrich) were individually dissolved in 100ml of deionised water. 
Peristaltic pump with the rate of 3 ml/min is used to add phosphoric acid 
solution into calcium hydroxide solution at room temperature.  
The above addition of aqueous solution of calcium hydroxide and phosphoric 
acid is performed using two different methods: 1) conventional mixing 
method, continuous addition of aqueous solution of phosphoric acid (3.459 
g/100ml water) at constant addition rate of 3 ml/min using peristaltic pump 
into aqueous solution of calcium hydroxide (3.704g/100ml water) at stirring 
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rate of 300rpms using magnetic stirrer at ambient conditions, 2) MASCW 
process instrument used for synthesis of HA, in this method aqueous 
solution of phosphoric acid is added into aqueous solution of calcium 
hydroxide in similar stoichiometric ratios at addition rate of 3 ml/min with 
rotation speed of 50rpm. The resulting solutions from both the experiments is 
further aged at constant stirring for 2 hours and left overnight for settling. The 
supernatant aqueous solution is removed and the remaining suspension is 
oven dried at 60°C and subsequently ground using an agate motor and 
pestle to form powder. A 25% portion of the sample powder is further 
calcined for 2 hours in a furnace at 1000°C (with a heating rate of 10°C/min) 
in order to evaluate its thermal stability.  
4.2.2.6.2 Ibuprofen and nano-hydroxyapatite complex synthesis 
To synthesise IBU/HA complex using MASCW process following procedure 
is employed. Ibuprofen (200mg) and raw nano-HA (800mg) is dissolved in 
10ml deionised water at treated at 110°C temperature and 1bar pressure 
with heating rate of 28°C/min under constant stirring. This experiment was 
performed at three different concentrations of ibuprofen (5%, 15% and 
20%w/w); based on the limit of detection of complex formation 20% IBU is 
selected for complex formation. The reproducibility of the methods is 
evaluated using ATR-FTIR experiments for each sample to confirm the 
presence of monomeric, dimeric and attached species. An aliquot of the 
paste obtained is used for in situ and ex situ spectroscopic studies, the 
remaining sample is dried at room temperature for 24hrs and used for 
morphological and dissolution examinations. 
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4.2.2.6.3 In-vitro dissolution study of IBU and HA complex 
Dissolution experiments were performed using a UPS II type LabIndia 
dissolution tester (Labin-09, India). Ibuprofen/HA complex, physical mixture 
of ibuprofen and HA or raw ibuprofen powders were placed at the bottom of 
the dissolution vessel (at least four repeats) containing 900 ml phosphate 
buffer (pH 7.2) maintained at 37 ± 0.5 °C and stirred with a paddle at 50 rpm. 
Samples were collected periodically and further filtered. Quantification of 
ibuprofen is performed spectrophotometrically at a fixed wavelength of 221 
nm using a Jasco-V630 spectrophotometer. 
4.2.3 Characterisation of MASCW processed samples  
This section includes the brief description regarding all the analytical tools 
used to characterise various physical and chemical properties of raw and 
process pharmaceutical ingredients. 
4.2.3.1 Powder X-ray diffraction (PXRD) 
X-ray powder diffraction pattern were acquired using a Bruker D8 Advance 
Diffractometer operating at 40kV and 40mA with Cu Kα radiation. All the 
powder samples were analysed in the range of 0 to 30° for all organic 
materials and from 0 to 80° for nanocrystalline HA and ibuprofen complex. 
Analysis of the X-ray pattern is done using EVA programming in DIFRACplus 
XRD commander software. The raw files were converted into excel files 
using PowDLL converter and plated using OriginPro version 8. The PXRD 
patterns obtained were compared with the standard PXRD patterns retrieved 
from Crystal structure database (CSD). 
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4.2.3.2 Differential Scanning Calorimetry (DSC)  
The DSC is performed using DSC Q2000 from TA instruments. 
Approximately 2-4 mg of the sample is heated in the sealed standard 
aluminium pan against an empty aluminium pan as reference. Inert nitrogen 
gas is purged at 50ml/min flow rate. All the samples were heated using ramp 
method with the heating rate of 10°C/min; samples were heated from 25°C 
as lower limit of temperature to 300°C as higher limit of temperature. The 
higher limit of temperature is varied based on the melting point of individual 
and complex samples under analysis. DSC data is analysed using the TA 
Universal analysis software version 4.5A. Excel sheet is exported using TA 
Universal analysis software and the plot is plotted using OriginPro version 8. 
4.2.3.3 Thermogravimetric analysis (TGA) 
Thermo-gravimetric analysis is carried out using Q500 TGA (TA instrument, 
UK) to determine the residual moisture content and decomposition 
temperature of all raw and processed samples. Standard platinum sample 
holders were used and the gas flow is set to 20ml/min. Samples 8-10mg is 
placed in the pre weighted sample holders and subjected for heating. The 
method used for heating is ramp method with heating rate of 10°C/minute 
were lower temperature range is 25°C and higher temperature is 300°C. The 
results obtained were analysed using TA Universal analysis software and 
OriginPro software is used to plot the thermogram. 
4.2.3.4 Scanning electron microscopy   
Scanning electron microscopy is used to analyse the crystal morphology of 
all raw and processed samples. Prior to analysis all the samples were 
mounted on dual adhesive black carbon tapes (pre-mounted on aluminum 
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stud) and coated with gold using sputter coater (BALTECSCD005, Japan). 
The sample images is collected using FEI Quanta 400 scanning electron 
microscope (Cambridge UK) under vacuum and XTM microscope control 
software V 2.3.  
4.2.3.5 Particle size analysis  
Particle size of all the raw and processed samples were analysed using a 
laser diffraction particle size analyser (Sympatec HELOS (H2419)) and 
RODOS dry dispersion unit, Sympatec instruments, UK. Approximately 20-
30 mg of the powdered sample is fed into the analyser by ASPIROS unit, 
using an air pressure of 4bars at the speed of 30mm/sec for all the materials. 
4.2.3.6 Fourier Transform Infrared (FTIR) spectra 
Fourier Transform Infrared (FTIR) spectra were acquired using a 
ThermoFisher Nicolet iS50 FTIR spectrophotometer equipped with a single 
reflection diamond attenuated total reflection (ATR) module. Spectra were 
recorded in the absorbance mode from 4000 to 300 cm-1 at 1 cm-1 resolution 
averaging 64 scans. 
4.2.3.7 Raman spectroscopy 
A Raman spectrum is acquired using Renishaw Raman spectroscope 
(ThermoFisher), the samples were analysed under 100x objective lens and a 
laser radiation of 785nm is focused on the samples. Raman back scattering 
is collected by high numerical aperture and passed through a confocal 
aperture to a detector system. By using laser Rayleigh background with 
notch filter weak signal in the spectra were filtered and then the sample is 
analysed using charged coupled detector. A Renishaw Raman microscope is 
used to observe the samples. Samples were analysed at 50% laser power 
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with the exposure time of 10times/sec and the spectra accumulation of a 1s 
with removal of a cosmic ray. 
The spectral results obtained from FTIR and Raman spectra were analysed 
using GRAMS/ALTM Spectroscope software. 
4.2.3.8 Inverse Gas Chromatography (iGC) 
Inverse gas chromatography is the physical characterisation technique used 
to analyse the surface properties of the solid materials. In iGC the solid 
phase is the stationary phase and mobile phase is the gas or vapor, this 
technique of analysis is inverted version of gas chromatography. In iGC 
chromatography experiment known or constant concentration of gas (probe 
molecule) is injected through the solid column at different surface coverages 
and fixed carrier gas flow rate. The retention time of the probe is calculated 
by gas chromatography detector (flame ionisation detector (FID). In the 
present study surface properties are analysed using Surface Energy 
Analyser (SEA) at infinite dilutions. At infinite dilutions interactions between 
probe-probe is assumed to be negligible and retention is observed due to 
interaction between the probe and solid surface. The retention volume VR° is 
calculated by the following equation: 
                                VR°=
𝑗
𝑚  
𝐹(𝑡𝑟 − 𝑡0 )
𝑇
273.15
      (eq.1) 
Where j= James- Martin pressure drop corrections 
 m= sample mass 
 F= carrier gas flow rate 
 tR = gross retention time for the injected probe 
 t0 = retention time for the interacting probe and  
 T= absolute temperature 
In SMS-iGC SEA helium is used as the carrier gas. Different surface 
properties like specific surface area, surface heterogeneity, acid-base 
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constant, thermodynamic work of adhesion and cohesion is determined by 
injecting different polar and nonpolar solvents at different percent surface 
coverage‘s. Doris-Gray based on the principle that when serious of alkane 
probes are injected than the adsorption dispersive free energy of every 
methylene ∆GCH2 is determined from calculating the slope of the line by 
plotting adsorption free energy -∆Gads of the probes versus carbon number 
n.(Shi et al., 2011) 
                            ∆𝐺𝐶𝐻2 =  −𝑅𝑇. ln(
𝑉𝑁 ,𝑛+1
𝑉𝑁 ,𝑛
)   (eq.2) 
 Where R= gas constant, T= absolute temperature  
  𝑉𝑁,𝑛  = net retention value of n-alkane probes with carbon   number n 
Determination of thermodynamic work of adhesion and cohesion is very 
important factor in post processing and stability determination of 
pharmaceutical ingredients. Thermodynamic work of adhesion can be 
defined as the interactions between two components. These interactions 
may be weak van der Waals interactions, electrostatic and capillary forces. 
The influence of each force in overall adhesion is dependent on several 
physical factors such as surface interfacial free energies, mechanical 
properties, morphological properties and environmental conditions. 
Thermodynamic work of adhesion can be determined from dispersive (γd) 
and specific surface (γsp) energy values for different components: 
                                  WAD  = 2. (γ1
d . γ2d  )
1
2 + 2. (γ1sp . γ2sp  )
1
2   (eq.3) 
Thermodynamic work of cohesion is the interaction between the like 
components. This can be determined dispersive and specific surface energy 
values of the materials. 
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                                 WCOH  = 2. (γ1
d . γ2d  )
1
2 + 2. (γ1sp . γ2sp  )
1
2  (eq.4) 
All the samples are characterised in identical conditions: at 30°C temperature 
of the column and 0% RH (relative humidity). Carrier gas flow rate of 10 
sccm (standard cubic centimetres per minute) is employed in all the 
experiments. 
4.2.3.9 1H- Nuclear magnetic resonance: 
1H-NMR experiments were recorded at 400 MHz using a Bruker Avance III 
400 spectrometer. Measurements were collected at room temperature for 
solution of CAF: 4HBA cocrystal sample in d6-DMSO (NMR grade) and 
scanned for 128 scans. Fitting of the NMR peaks is carried out using Bruker 
Top Spin 3.2 software, and data analysis is carried out by a successive 

















Chapter 5: MASCW process understanding and validation  
In this chapter, the effect of different process parameters like temperature, 
pressure, solute-solvent concentrations and solvent mixture on crystallisation 
of paracetamol is investigated. Further, effect of solvent mixture on dielectric 
constant and equilibrium solubility of paracetamol is reported. 
5.1 Introduction 
Before exploring the application of newly developed MASCW process 
technology, the effect of different process and experimental parameters on 
crystal attributes (morphology, particle size, surface texture and chemical 
phase) was investigated initially. To perform process validation pca raw (form 
I) is selected as the model API moiety as it is less soluble in water (solubility 
13±2 mg/ml). Paracetamol or acetaminophen is very popular drug moiety 
used as an analgesic and antipyretic component.  Paracetamol exists in two 
polymorphic forms, monoclinic form I and orthorhombic form II polymorphs 
recently form III metastable polymorph is characterised by (Etienne Joiris 
1997). Monoclinic form I is the stable commercially available polymorph 
which exhibits poor tabletability under compression thus process scientist 
started implementing novel technologies for generation metastable 
orthorhombic form II polymorph of pca which retains higher tabletability 
under compression. Recently William Jones and team has used the 
sonocrystallisation technique for generation of form II pca with greater 
compressibility property (Dejan-Kresimir Bucar,2017). Marc-Antoine and 
group have elucidated the crystal structure of elusive polymorph form III of 
paracetamol (March-Antoine et al., 20111) 
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For development of robust process in the laboratory knowledge and 
understanding regarding the solubility curve, stability of the supersaturated 
solution at the vicinity of the equilibrium point is required. The crystallisation 
of the crystal phase is explained based on the metastable zone width, which 
is required for process optimisation and scale-up of the crystalliser.  The 
metastable zone width is the point where primary nucleation occurs. Below 
Figure 5.1 describes the between the supersaturated and saturated solubility 
curve. 
 
                           Figure 5.1 Solubility curve and MSZW 
The solute molecule will remain stable in the solution until sufficiently high 
supersaturation level is not developed to induce immediate nucleation. The 
extent of this supersaturation is referred as MSZW. This MSZW is typically 
influenced by the saturated temperature, rate of supersaturation, mixing and 
solution history. Understanding the nucleation mechanism as an indicator of 
metastable zone width is important for scale-up and understanding the 
influence of process parameters (Somnath S. Kadam et al., 2012). In the 
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present study supersaturated solubility curve was generated based on the 
target temperature and pressure where clear solution is formed.  
5.2 Results 
The result section is divided into four sections based on the objective of the 
study. 
5.2.1 Development of temperature and solubility curve using MASCW 
technology. 
The detailed methods and experimental conditions for this study are 
described in (Section 4.2.1.A).  The effect of supersaturation concentration of 
pca in water (10ml) over the solubility of pca in water under MASCW 
treatment conditions was investigated. The change in the pH of the solution 
after processing and percent purity of crystallised solid material is calculated 
using HPLC. Below Table 5.1 summarises the experimental results of 
different saturated concentrations of pca and their melting points.  
Based on the result table it is observed that as the concentration of pca in 
solution increase the target temperature where the clear solution is formed 
also increases along with pressure, thus the temperature and pressure 
conditions where the clear solution of pca is formed is based on pca 
supersaturated solution concentration. Table 5.2 represents the experimental 
images of all batches at different temperatures and marking the temperature 
where the clear solution is formed.  
Decrease in the pH of the pure water pre-treated in the MASCW process 
reactor and pure water at room temperature is observed. This decrease in 
pH can be attributed to the molecular arrangement or hydrogen bonding 
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dissociation of the water molecule in the sub-critical state. Thus once the 
water molecules are treated under sub-critical conditions, for the water 
molecule to retain its structure it takes some time. Slight pink decoloration of 
pca solution is observed after treating under a high temperature above 
140°C and solution concentration above 25%w/v this is due to solution state 
degradation of pca into p-aminophenol.  
Quantitative analysis of the crystallised material is done by calculating 
percent purity using HPLC analyser. It is noticed that range of degradation of 
pca after MASCW treatment is within the acceptable range which is not less 
than 97% and not more than 102% purity according to USP standard 
monograph for pca tablets. As these supersaturated solutions are placed at 
room temperature for 24hrs the total amount of pca solute remaining in the 
solution after filtration was determined, this data is reported in the Table 
below as FSC (filtered solution concentration). In the below Table 5.2 
represents the images of all the experimental batches at different 
temperature conditions, it is observed that the temperature at which clear 
solution is formed increase as there is increase in the concentration of pca in 
water, this is attributed that the solubility of the solute in solution depends on 
solute- solution concentration. Figure 5.2 represents the binary phase 
diagram correlating percent concentration of pca solution, temperature and 









  pH  % Y % P  FSC SC form Image Observation
s 
Exp-plot 
35 - - 6.96 
blank 
- -    - - - 
150 4.2-4.5 - 6.69 - -    - - - 
125 1.6-1.8 500 5.72 71.6 100.25 26.41 462.95 FI 
 
clear solution 





132 3.0-3.1 1000 5.64 68.0 98.98 119.14 982.39 FI 
 
clear solution 





138 3.1-3.4 1500 5.56 70 99.44 129.27 1217.85 FI 
 
clear solution 















is observed  


























T= temperature at which clear solution is observed, P= Pressure at the corresponding temperature, S= solubility of pca  
%Y= percent yield after 24hrs, % P= percent purity of pca, pH= pH of the supersaturated solution  
FSC= filtered solution concentration (mg/10ml water) 
SC= solution concentration- amount of pca dissolved after processing (mg/10ml water)
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Table 5.2 Pictographic representation of: correlation between solubility 
of different pca concentrations vs corresponding temperature 
conditions. 
T(°C) Percent supersaturation (g/ml) 
 5%  10% 15% 20% 25% 30% 
100 
      
110 
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Figure 5.2 Binary phase diagram of concentration of the solution and 
corresponding temperature and pressure 
5.2.1.1 PXRD data  
Based on the PXRD data all the samples process using MASCW process 
are the form I polymorphs as they are rightly similar to form I standard PXRD 
pattern of form I raw pca. As the samples are present in the solution for more 
than 24hrs there is present of hydrate peak at (7.5 2θ°) which is the 
characteristic peak of pca dihydrate (Liming Yang 2008). Further to confirm 
the crystal form Raman spectroscopy is performed. Below Figure 5.3 
represents the PXRD overlay all process samples against pca form I and 





Figure 5.3 PXRD overlay of : a) Raw form I pca, b) form II pca, c) 5% 
pca, d) 10%pca, e)15%pca, f) 20%pca, g) 25%pca, h-30%pca 
5.2.1.2 Raman data 
Below Figure 5.4 shows the overlay of Raman spectra of all pca batches 
against form I raw pca. Based on the presence of characteristic peaks at 837 
cm-1, 1234 cm-1 and absence of a peak at 1220, 1245 and 1623cm-1 it is 
confirmed that the formation of form I and absence of form II polymorph of 
pca. The dome-like spectral pattern of processed samples is due to the 





Figure 5.4 Overlay of Raman spectra of Pca form I raw and MASCW 
processed pca samples of different solution concentrations 
5.2.2 Monitoring crystallisation time and pca supersaturated solution 
concentration using MASCW process 
In this section, the time required for the crystallisation to occur in different 
solution concentrations of pca is monitored. A brief description of 
experimental method is explained in Section (4.2.1.B). Below Table 5.3 
summarises the results obtained from both conventional heating and 
MASCW process.  
It is observed that, when 5%w/v and 10%w/v saturated solution of pca are 
processed using MASCW process at 140°C the time required for the crystals 
to induce out is 30-hrs and 24-hrs respectively, as compared to conventional 
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2-hrs and 8-min respectively. This result is attributed to the eutectic 
molecular association or hydrogen bonding between water and solute 
molecules is very strong and stable that it takes a longer time to crystals to 
induce out. Water when treated at sub-critical state it takes long time to 
retain its molecular dynamics. At sub-critical state of water more number of 
hydrogen bonds are broken therefore water volume is increased and during 
cooling conditions to retain its physical molecular dynamic water molecules 
tend to form weak hydrogen bonds with the solute molecules. When stirring 
is applied to the supersaturated solution of pca, sudden generation of 
metastable form II phase of pca occurs which proves the theory of 
crystallisation pathway that stable polymorphs are formed after generation of 
metastable phase which further in presence of crystallisation medium (water) 
gets converted to stable form I polymorph.  
When similar experiments were performed using conventional heating 
method it is observed that in 5% and 10% w/v solution concentration of pca 
takes 2-hrs and 8-mins respectively and concentration above 15%w/v 
doesn‘t form a clear solution and on further heating pink coloration was 
developed due to degradation of pca. In MASCW process clear solutions are 
formed at all the concentrations but faint pink coloration was observed in 25 
and 30%w/v solution concentration of pca due to degradation of pca. All the 
saturated pca solutions obtained from MASCW process acidic pH compared 
to conventional heated pca solutions. Based on the previous finding pca is 
stable at acidic pH range between 4 to 5 and on further increase in pH 
oxidation of pca into 4-aminophenols occurs (Liming Yang 2008). Based on 
the HPLC analysis higher solution state degradation of pca in conventional 
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heating was observed than MASCW process (refer Figure 5.9), this is 
attributed to the supersaturated solution concentrations of pca and type of 
heating conditions. 
This solubility curve can be compared with the MSZW where supersaturated 
solubility is obtained at 30%w/v of pca in SCW, upon further increase in the 
concentration degradation of pca solution occurs. Compared to the 
conventional heating supersaturated solubility is less than 15%w/v of pca in 
water at (95°C), and upon increase in the concentration no clear solution is 
formed. The longer solution stability of 10%w/v of pca in SCW can be 
correlated to the larger MSZW of microwave heated SCW and no equilibrium 









Table 5.3 Summary of crystallisation time vs solution concentration for MASCW process and conventional heating 
experiments 





%P Images Observation T (°C) S (mg) T (mins) pH % P Image Observation 
500 5.88 30hrs 96.72 
 
clear solution gets 
converted to pink 
colour after 24hrs 
95-100 500 120  6.06 95.35 
 
after 90 mins small 
crystal starts inducing 
1000 5.67 24hrs 98.98 
 
clear solution 95-100 1000 8 6.24 92.54 
 
 
small crystals started 
inducing out in 8mins  
1500 5.53 6hrs 99.44 
 
clear solution formed 95-100 1500 5 6.50 96.05 
 
ICO, no clear solution 
is formed 
2000 5.47 25mins 102.93 
 
clear solution formed 95-100 2000 3 6.52 98.86 
 
ICO, no clear solution 
is formed 
2500 5.22 13mins 98.66 
 
clear solution formed 95-100 2500 2.5 6.50 97.22 
 
ICO, no clear solution 
is formed 




95-100 3000 2 6.39 96.72 
 
ICO, no clear solution 
is formed 
T= time required to induce crystals, ICO= immediate crystallisation observed, FC= filtration solution concentration 
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Thus based on the aqueous solubility of pca in water (14mg/ml), higher 
supersaturated stable solutions concentration (100mg/ml) of pca is 
generated using MASCW process compared to conventional heating 
techniques. This proves the significance of this technology for generation of 
stable supersaturated solutions and enhancement of solubility of 
hydrophobic components.  
This investigation provided us a new pathway of processing as when the 
supersaturated solutions are stable for 1-day, the crystallisation kinetics 
using PAT tools like Raman spectroscopy can be used. During crystallisation 
the crystal phase can be manipulated by addition of certain additives.  
Table 5.4 Summary percent purity of pca solutions using SCWT and 
conventional heating 
 
5.2.2.1 SEM images 
Morphological properties like crystal shape, surface smoothness and crystal 
habit of all pca powdered samples is analysed using SEM analyser. Below 
Figure 5.5 represents the SEM images of MASCW treated and 
conventionally treated pca powdered samples collected from different 
solution concentrations at 1000X magnifications.  MASCW processed 




Figure 5.5 SEM images of paracetamol crystallised from the MASCW 




5.2.3 Crystallisation kinetic data 
In this study, the crystallisation pathway of 10%w/v supersaturated solution 
of pca over 24-hrs using off-line Raman spectroscopy is studied. In this study 
10% (w/v) of pca solution is prepared using MASCW process and left for 
cooling to ambient conditions. Once the solution temperature comes to 
ambient conditions a drop of 100µL volume is placed on the sample holder 
and further crystallisation kinetics is monitored under Raman spectroscopic 
analyser. Below Figure 5.6 represents the Raman spectral overlay of pca 
solution over 24hrs. 
 
Figure 5.6 Overlay of Raman spectra spotting the characteristic peak of 
pca form II (1623cm-1) and form I (1565 cm-1) polymorph. 
In the above spectral overlay, initial spectra red, blue and green represent 
the spectra for blank water + pca in solution and 30-mins and 45-mins 
respectively, no crystallisation is observed till 90-mins and after 90-mins 
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crystals started inducing out as spectral peaks were tracked. On analysing 
the peaks it is found that the peaks at 1623, 1120 and 1245 cm-1 resembles 
the characteristic peaks of metastable form II pca. It is confirmed that form I 
and form III polymorphs of pca is absent due to absence of characteristic 
peaks at 837cm-1, 1234 cm-1, 1565 cm-1 for the form I and absence of a peak 
at 1321cm-1 which is the characteristic peak of form III polymorph of pca. The 
intensity of from II characteristic peaks went on increasing at further 
accumulation for 18-hrs, after 18-hrs at 22nd hour of spectral scan presence 
of both form I and form II polymorphs of pca is observed. 
In the above experiment polymorphic transformation of paracetamol from 
metastable form II to stable form I polymorph is tracked using off-line 
spectroscopic technique. This transformation of metastable polymorph to 
stable polymorph is absent in case of conventional heating experiment. 
5.2.4 Effect of the solvent mixture on the dielectric constant of solution 
and crystallisation of paracetamol 
In this section, the change in the dielectric constant of solution using solvent 
mixture and in presence of solute (pca 1g), for method refer to section 
(4.2.1.D) is analysed. Below Table 5.5 demonstrates the change in dielectric 







Table 5.5 Dielectric constant values of different solvent mixtures at RT 
 
It is observed that the dielectric constant of every solvent decreases with 
increase in organic solvent concentration thus increasing the solubility 
parameter of solute in the solvent mixture. Below Figure 5.6 represents the 




Figure 5.7 Graphical presentation of the dielectric constant of solvent 
mixtures from 10 to 100%v/v concentrations 
Based on the above graph ethanol pure solvent and solvent mixture retains 
minimum dielectric values so theoretically the solubility capacity of this 
solvent mixture is high compared to other solvent mixtures. Later based on 
the above study added 1g of pca in pure water was added and individual 
solvent mixtures of total volume 10 ml and processed using MASCW process 
and checked the change in the dielectric constant of water after MASCW 
treatment and due to the addition of pca. Below table 5.6 represents the 
dielectric constant of pure solvents, pure water, and solvent mixtures after 






Table 5.6 Summary of the dielectric constant of the pure solvents and 
solvent mixtures with paracetamol solute after MASCW treatment 
 
Based on the above tabular data it is observed that the dielectric constant 
values of blank solvent mixtures is further reduced due to the presence of 
pca this is because of the hydrogen bond association of pca molecules with 
solvent molecules. The dielectric constant of solvent mixture solutions was 
analysed before and after MASCW processing and by addition of pca as a 
solute molecule. Below Figure 5.8, 5.9, 5.10 and 5.11 represents the bar 
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graph for change in dielectric constants of the solution with and without pca 
moiety. 
 
Figure 5.8 Dielectric constant values for: water-MeOH blank and water- 
MeOH-pca solution at 10, 20 and 30% v/v concentration of MeOH -water. 
 
Figure 5.9 Dielectric constant values for water-ACN blank and water-




Figure 5.10 Dielectric constant values for water-EtOH blank and water- 
EtOH -pca solution at 10, 20 and 30% v/v concentration of EtOH -water. 
 
Figure 5.11 Dielectric constant values for water-ACE blank and water- 
ACE –pca solution at 10, 20 and 30% v/v concentration of ACE -water. 
When pca is added to the solvent mixture the dielectric constant values of 
methanol-water drastically reduced compared with another solvent system. 
This can be attributed to hydrogen bonding association between methanol-
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water and pca. After investigating the change in the dielectric constant of 
water further investigation of the effect of a change in dielectric constant of 
solvent mixtures on equilibrium solubility of pca before and after MASCW 
treatment is studied. Below Table 5.7 represents the equilibrium solubility of 
pca in all the solvent mixtures under MASCW treated and untreated 
conditions. 
Table 5.7 Equilibrium solubility of: paracetamol in solvent mixtures 
when treated using MASCW process and conventional temperatures 
















ES UT= Equilibrium solubility of untreated pca solutions 
ES T= Equilibrium solubility of treated pca solutions 
Solvent mixture ES 
UT(1ml) 
ES T(1ml) %P of MASCW 
treated 
Water 13.52 15.57 99.44 
MeOH 100% 191.28 -  
M+W+P (10%) 17.37 19.76 94.21 
M+W+P (20%) 23.01 37.05 94.39 
M+W+P (30%) 34.26 58.74 96.17 
EtOH 100% 130.80   
E+W+P (10%) 19.51 39.46 97.38 
E+W+P (20%) 27.12 58.63 99.37 
E+W+P (30%) 46.71 82.57 99.06 
ACN raw 20.69   
ACN +W+P (10%) 24.57 28.03 94.86 
ACN +W+P (20%) 48.56 53.16 95.61 
ACN +W+P (30%) 84.59 85.96 95.99 
Acetone 100% 71.56   
A+W+P (10%) 25.11 31.44 96.09 
A+W+P (20%) 47.82 53.06 94.72 
A+W+P (30%) 80.54 85.28 97.02 
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Below Figure 5.12 represents the solubility variation of all the solvent mixture 
with and without MASCW treatment. 
 
Figure 5.12 Equilibrium solubility (mg/ml) of pca in untreated and 
MASCW treated solvent mixtures. 
Based on the above graph it is observed that the solubility of pca increases 
in MASCW treated batches compared to ionisation capacity and 
supersaturation limits of the individual solvent system before and after 
MASCW treatment. The increase in the solubility of the pca is large in case 
of methanol and ethanol solvent mixtures and percent purity of pca solid 
material crystallised from these solutions are in the acceptable ranges 
according to USP standards.  
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Investigation of crystal form of pca crystallised from the above solvent 
mixtures using PXRD, DSC and Raman spectroscopy is performed. Below 
Figure no 5.13, 5.14 and 5.15 represents the PXRD, DSC, and Raman data 
for all the batches respectively. 
5.2.4.1 PXRD data 
                     
Figure 5.13 PXRD pattern of A- Par raw form I, B- Par form II, C- 10% 
ACE-water, D-20% ACE-water, E- 30% ACE-water 
 
Figure 5.14 PXRD pattern of A- Par raw form I, B- Par form II, C- 10% 
ACN-water, D-20% ACN-water, E- 30% ACN-water 
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Figure 5.15 PXRD pattern of A- Par raw form I, B- Par form II, C- 10% 
EtOH-water, D-20% EtOH-water, E- 30% EtOH-water 
      
Figure 5.16 PXRD pattern of A- Par raw form I, B- Par form II, C- 10% 
MeOH-water, D-20% MeOH-water, E- 30% MeOH-water 
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5.2.4.2 DSC data 
 
Figure 5.17 DSC thermogram overlays of all pca crystals obtained from 
all solvent mixtures. 
In all the above DSC overlay of thermograms of all solvent mixture, reveals 
the presence of single endotherm at 169±2°C representing characteristic 
peaks of form I polymorph of pca. Thus based on DSC data it can confirm 
that form I stable polymorph of pca is formed. Based on the above 
thermogram no hydrate formation is observed. 
5.2.4.3 Raman data 
Raman spectroscopic analysis is performed to investigate the phase purity of 
pca processed batches. Based on the Raman data characteristic spectra of 
form I pca polymorph at wavelength 837 cm-1, 1234 cm-1 and 1565 cm-1 is 
observed. A characteristic peak of form II polymorph is not observed, thus it 
is confirmed that all the processed samples are the pure form I pca. Below 
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Figure 5.18, 5.19, 5.20 and 5.21 represent the Raman spectra for all pca 
batches. 
 
Figure 5.18 Raman spectra overlay for raw pca form I, solid materials 
obtained from 10%, 20% and 30% MeOH-water solvent mixtures 
 
Figure 5.19 Raman spectra overlay for raw pca form I, solid materials 
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Figure 5.20 Raman spectra overlay for raw pca form I, solid materials 
obtained from 10%, 20% and 30% EtOH-water solvent mixtures 
 
Figure 5.21 Raman spectra overlay for raw pca form I, solid materials 
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The effect of different process and experimental parameters on 
morphological and chemical properties of pca polymorphism was reported.  
Correlation between solution concentrations of pca and the processing 
temperature where the clear solution is formed is derived, further quantitative 
analysis of the process samples is analysed by calculating percent purity 
using HPLC analyser. Crystallisation kinetics of MASCW processed pca 
solution is analysed using Raman spectroscopy. Comparative studies were 
performed to investigate the crystallisation time for MASCW process and 
conventional heating pca solutions. Experimental correlation data is 
generated to explain the correlation between the dielectric constant of 
solvent system and solubility of pca in the solvent system using water itself 
and by using solvent mixtures of different organic solvents at varied 
temperature conditions. Further, the solution state stability of pca solute in all 
solvents mixtures at different temperature conditions is reported using HPLC 
analyser.  
Thus, based on all the above experiment conditions investigation between 
effect of different process parameters and solvent mixtures on crystallisation 




Chapter 6: Application of MASCW technology in 
cocrystallisation process 
In this chapter, application of MASCW process for the generation of 
congruent and incongruent cocrystal pairs is explored. Based on congruency 
theory between API and coformer this chapter is further categorised into two 
sections: section 1: Includes screening experiment to understand the effect 
of different process parameters in the cocrystallisation process, this includes 
formation of congruent cocrystal pairs of CBZ: SAC, SMT: SAC and SMZ: 
SAC in 1:1 stoichiometric ratio. In the second chapter, CAF and 4-HBA pair 
is selected as incongruent cocrystal pair and application of solvent mixture in 
MASCW technology is studied to form pure anhydrous cocrystal phase of 
CAF: 4-HBA in 1:1 stoichiometric ratio. 
6.1 Introduction 
Cocrystals are the complex molecules consists of two or more chemical 
moieties combined together via non-covalent interactions. Cocrystal complex 
consists of active pharmaceutical ingredient and co-crystal former also called 
coformer which undergoes chemical interactions to form a single co-crystal 
complex with enhanced physicochemical properties as compared to 
individual components. To generate phase pure cocrystal pairs with 
enhanced physical and chemical properties various pharmaceutical process 
industries and research groups have developed various novel techniques of 
cocrystallisation, all the new technologies of crystallisation retain certain 
potential limitations like use of different organic solvents which may cause 
side effects, generation of unstable cocrystals, phase impurities in co-crystal 
and solvate formation due to use of solvent systems (formed when 
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mechanochemical method is used). Recently Padrela and co-workers, 2015 
have proposed the new mechanism of cocrystallisation using supercritical 
solvents, these solvents include ethanol, supercritical carbon dioxide. 
(Padrela et al., 2015), this technology is based on the principle of antisolvent 
crystallisation using organic solvents as the bridging liquid to provide 
molecular mobility and form covalent bond between the two reacting 
components, this technique is subjected to organic solvents for the 
production of co-crystals and very stringent process parameters are used. 
This technology also contains certain limitations such as phase impurities, 
use of organic solvent so it‘s not a green technology; due to stringent 
process conditions the crystallinity and chemical stability of active ingredients 
is reduced. Therefore to surmount all such challenges during the processing 
of pharmaceutical ingredients it is very much desired to develop new novel 
crystallisation technology which is preferably green. In the present chapter 
MASCW technology is implemented as the screening tool for the generation 
of stable cocrystals, for this congruent cocrystal pairs with almost similar 
solubility in water were selected. CBZ is generally used for the treatment of 
epilepsy and neuropathic pain. SAC is referred as an artificial sweetener 
which is a substituent added in the formulation as a pharmaceutical excipient 
for the purpose of taste masking. Carbamazepine and saccharin exist in the 
form of two polymorphs, form I and II. Form II is the metastable form which 
gets converted into a stable form I polymorph in a very short period of time 
(Porter et al., 2008), CBZ has the propensity to form dihydrate when 
subjected to crystallization (Hickey et al., 2007). It is proposed that the 
scalability of CBZ/SAC by solution crystallisation has resulted in the 
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formation of CBZ dehydrate, which is stable in presence of water. For the 
first time, the metastable cocrystal polymorph of CBZ/SAC is proposed by 
Matzger‘s group (Porter et al., 2008). CBZ/SAC form I is generated recently 
using antisolvent crystallisation method (Wang et al., 2013). Reddy and co-
workers proposed the potential of the rotary evaporator for the generation of 
CBZ/SAC form I and II (Bag et al., 2011). Ragar and Hilfiker used ultrasound 
technique for the generation of CBZ/SAC cocrystals (Hilfiker 2006). Certain 
researchers have proposed the generation of metastable form by using 
higher moles of saccharin. Recently Aher et al have proposed phase 
diagram for generation of metastable form by using an excess amount of 
cocrystal former in case of caffeine/maleic acid cocrystals. (Aher et al., 2010) 
In the present chapter, formation of CBZ: SAC form I and form II cocrystal 
phase and formation of SMT and SMZ cocrystal with SAC as coformer is 
reported. The effect of different process parameters like temperature, level of 
supersaturation, microwave energy and heating rate over the end cocrystal 
phase is elucidated using CBZ: SAC as cocrystal components.  
6.2 Results and Discussion 
The result section is divided into two sections where the first section 
represents the process understanding using CBZ: SAC as cocrystal pair and 
the second section corresponds to screening experimental data for SMZ: 
SAC and SMT: SAC cocrystal pairs. 
6.2.1 Preliminary experiments of cocrystallisation 
This section includes the results obtained by varying different process 
parameters of MASCW technology and generation of CBZ: SAC form II 
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metastable phase using a solvent mixture. Different characterisation tools 
are used to analyse phase purity and form of cocrystal pairs. 
6.2.1. a) PXRD data 
PXRD instrument is used to identify the cocrystal form produced between 
CBZ: SAC cocrystal pair by varying different process parameters. 
The below Table 6.1 represents the brief overview and experimental 
variables and the PXRD results of the solid complex obtained, CBZ and SAC 
were selected in 1:1 stoichiometric ratio, for a method of crystallisation see 
section (4.2.2.1.2). 
In the MASCW process the heating temperature or the sub-critical 
temperature is altered initially keeping the concentration of solute in 10ml 
solvent and other parameters constant, at lower temperature range 110°C no 
clear solution is formed and further as the temperature is increased to 115 
and 120°C formation of clear solution is observed, below Figure 6.1 
represents the PXRD pattern of CBZ: SAC cocrystal pair at two different 
temperatures. 
 




Table 6.1 Result summary of: cocrystal phase obtained by altering different process parameters. 
Constant 
parameter 
Variable parameters  





Amount of solvent (ml) 
Microwave 
power  (watts) 
Rate of heating 
(mins) 
PXRD results 
350 (1:1) 110 10 300 5 No clear solution formed 
350 (1:1) 115 10 300 5 cocrystal form I 
350 (1:1) 120 10 300 5 cocrystal form I 
350 (1:1) 115 10 300 5 cocrystal form I 
350 (1:1) 115 12.5 300 5 cocrystal form I + CBZD 
350 (1:1) 115 15 300 5 cocrystal form I +CBZD 
350 (1:1) 115 10 200 5 
target temperature is not obtained 
(no clear solution) 
350 (1:1) 115 10 300 5 cocrystal form I 
350 (1:1) 115 10 400 5 cocrystal form I 
350 (1:1) 115 10 300 5 cocrystal form I 
350 (1:1) 115 10 300 2.5 cocrystal form I 
350 (1:1.5) 115 12.5 300 5 cocrystal FI + CBZD 
350 (1:1.5) 115 15 300 5 cocrystal FI+ CBZD 
350 (1:2) 115 12.5 300 5 cocrystal FI + CBZD 
350 (1:2) 115 15 300 5 cocrystal FI+ CBZD 
350 (1:1) 115 5ml MeOH and 5ml H20 300 5 cocrystal form II 
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Based on the PXRD patterns of CBZ: SAC cocrystal pair at two different 
temperatures, they rightly match with the form I stable phase of CBZ: SAC 
cocrystal (Rodríguez-Hornedo et al.,2008). 
Next parameter which is analysed is the effect of solvent concentration on 
the end product, below Figure 6.2 represents the PXRD pattern of MASCW 
processed samples at different solvent concentrations. Based on the 
specification and minimum requirement of the instrument the minimum 
amount of solvent which needs to be used based on the concentration of 
solute is 10ml, therefore 10ml water as the minimum volume of solvent is 
maintained. 
 
Figure 6.2 PXRD data of experiments carried with A- 10mL, B- 12.5mL 
and C- 15mL water as solvent system. 
Based on the above PXRD data it is concluded that as the concentration of 
solvent system is varied, phase purity and crystal form of the cocrystal 
complex also changed. At 10ml water volume form I CBZ: SAC cocrystal 
phase is obtained and when 12.5 mL and 15 mL solvent concentration is 
used formation of CBZ/SAC form I cocrystal along with CBZ dihydrate as 
impurity is observed. Based on the previously published data the impure 
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phase formed is coinciding with CBZ dihydrate phase (Robin K. Harris and 
Caiyun Ma 2005). At the 2θ° scale the peak present at 7.5 theta degrees 
represents dihydrate peak which is obtained at 12.5 and 15 mL of solvent 
volume. Further formation of dihydrate is confirmed using thermal analysis 
study. 
The third process parameter which is altered is the microwave power; this 
data is used to understand the effect of microwave energies on the end 
product. Below Figure 6.3 represents the PXRD patterns of CBZ: SAC 
cocrystal sample at different microwave energies. 
 
Figure 6.3 PXRD patterns of batches carried out at A-300W and B-400W. 
Based on the above PXRD pattern it is observed that the microwave power 
does not have any effect on the end product phase purity and only affect the 
rate of heating. When 200 watts microwave energy is used no clear solution 
is formed as the targeted temperature of 115°C did not reach so further the 
experiments were performed at 300 and 400 watts of energy. At two different 




The fourth parameter is the rate of heating, it the time required to reach the 
targeted temperature (temperature where the clear solution is formed). Two 
different heating rates were selected to reach the targeted temperature of 
115°C and they are 23°C/min and 46°C /min respectively. Below Figure 6.4 
represents the PXRD pattern of CBZ: SAC sample at two corresponding 
rates of heating. 
 
Figure 6.4 PXRD patterns of samples processed at different heating 
rates A) 26 °C/minute and B) 46 °C/minute. 
Based on the PXRD pattern obtained it is concluded that the rate of heating 
doesn‘t affect the cocrystal phase, as generation of form I cocrystal of CBZ: 
SAC cocrystal pair took place. Later the effect of the stoichiometric ratio of 
solute and volume of water at constant temperature, microwave energy, and 
heating rate is investigated. Below Figure 6.5 represents the PXRD pattern 
of CBZ: SAC at different stoichiometric ratio in 12.5ml and 15ml water as 
solvent system respectively. 
Based on the below PXRD pattern the formation of CBZ/ SAC form I 
cocrystal and CBZ dihydrate as an impurity in all the samples is observed. 
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This result proves that the concentration of coformer (CF) has no correlation 
with solvent volume to prevent the formation of dihydrate. 
 
Figure 6.5 PXRD pattern of: A) CBZ: SAC 1:1.5_12.5ml water, B) CBZ: 
SAC 1:1.5_15ml, C) CBZ: SAC 1:2_12.5ml water and D) CBZ: SAC 
1:2_15ml water 
Based on the results obtained in the previous experiments using water as a 
solvent system generation of CBZ/SAC form I pure stable phase is obtained 
but no metastable form II is generated. Thus dielectric constant of solvent 
system plays an important role in monitoring crystallisation pathway so to 
investigate the effect of change of dielectric constant on crystal form the use 
a mixture of solvents as the solvent system is used to further reduce the 
dielectric constant of the solvent system. Recently various research group 
has shown their interest in generating from II metastable phase of CBZ: SAC 
cocrystal and to prevent CBZ dihydrate formation, (Hilfiker 2006) 
demonstrated the process of solvent mixture to prevent the formation of CBZ 
dihydrate. (Childs et al., 2008) they have crystallised cocrystal of CBZ/SAC 
using water as a solvent but they have used different molar ratios of CBZ 
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and SAC and were successful in producing form I cocrystal and preventing 
the formation of dihydrate by increasing the molar concentration of coformer. 
In the present study, solvent mixture of methanol-water (50-50) in total 10 mL 
for the crystallisation is used. Below Figure 6.6 represents the PXRD 
patterns of form I and form II cocrystal phases of CBZ: SAC 1:1 cocrystal 
pair. 
 
Figure 6.6 PXRD pattern of A- CBZ/SAC FII CSD data, B- CBZ/SAC FII 
MASCW processed, C- CBZ/SAC FI CSD data and D-CBZ/SAC FI 
MASCW processed. 
Based on the PXRD pattern generated sample B correlates with the standard 
CSD pattern of form II cocrystal phase of CBZ: SAC. Based on the CSD data 
characteristic peak at 5 2(θ°) represents the formation of metastable form II 
phase of CBZ: SAC cocrystal. This peak is observed in the sample which is 
treated by continuous stirring and solvent mixture. In this process of 
cocrystallisation by continuous stirring of the sub-critically treated solution 
external stress is applied which prevents the formation of stable crystal 
phase and gets precipitated out as metastable phase.  
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Below Table 6.2 represents the summary of experimental results obtained 
during crystallisation of CBZ: SAC 1:1 cocrystal pair using solvent mixture 
under different crystallisation techniques. 
Table 6.2 Summary of CBZ: SAC cocrystal phase obtained during 
crystallisation and the technique used. 
Wt of CBZ/SAC( 1:1) 
molar ratio 
5ml MeOH + 5mL 
water as solvent mix 
PXRD and DSC 
data results 
350mg 5 mL MeOH + 5 mL 
Water 
Form I pure on 
controlled cooling. 
350mg 5 mL MeOH + 5 mL 
Water 




Formation of CBZ/SAC form II phase pure cocrystal were generated 
successfully when solvent mixture of methanol water is used as solvent 
system. Further, during the cooling step the processed solution is suddenly 
cooled accompanied by continuous stirring so the crystals started inducing 
out in the form of solid mass, but with controlled cooling and no stirring form I 
cocrystal formation took place. 
To confirm the results obtained from the PXRD analysis further 
characterisation is performed thermal analysis using DSC analyser and 
spectroscopic analysis. 
6.2.1. b) DSC thermogram 
Diffraction scanning calorimetric analysis is performed for all the samples to 
study the phase transformation, the presence of any residual water content 
and understand and reveal the crystallinity of the cocrystal complex formed. 
Below Figure 6.6, 6.8, 6.9, 6.10 and 6.11 represents the thermogram 
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obtained for CBZ: SAC 1:1 cocrystal when different parameters like target 
temperature, amount of solvent, microwave power, heating rate and solute 
stoichiometric ratio vs solvent volume were analysed respectively. 
 
Figure 6.7 DSC thermograms of batches carried at different process 
temperatures. 
Based on the literature value the melting point of CBZ, SAC and CBZ: SAC 
form I cocrystal is 189-193°C, 228°C and 175-177°C respectively. In the 
above thermogram obtained at different process temperatures a distinct 
endotherm at 176°C is observed which is attributed to form I cocrystal of 
CBZ: SAC cocrystal pair and a small endotherm at 160°C is the phase 
transition taking place between metastable form II to form I under high-




Figure 6.8 DSC thermograms of experiments performed at different 
amount of water. 
In the above thermogram at different solvent concentrations, formation of 
CBZ: SAC form I cocrystal dihydrate at 12.5 and 15ml volumes of water is 
observed. In 10ml the endotherm is corresponding to form I cocrystal 
whereas in 12.5 and 15ml samples endotherm shifted towards lower degrees 
due to phase impurities and the broadness of the endotherm is attributed to 
the bounded water impurities. 
Below Figure 6.9 and 6.10 represents the thermogram for CBZ: SAC 
cocrystal at different microwave energies and heating rate. In both the 
experiments generation of CBZ: SAC form I cocrystal took place. At the fast 
heating rate, some impurities of cocrystal and CBZ starting material based 
on the melting points is observed, in this thermogram presence of broad 





Figure 6.9 DSC endotherm of batches carried out at 300W and 400W. 
 
Figure 6.10 DSC thermograms of two cocrystal batches at different 
heating rates. 
Based on the thermogram below (Figure 6.11) a minor broad endothermic 
event between 80-110°C  is observed which is attributed to residual moisture 
and further phase transition endotherm from form II to form I in the region 




Figure 6.11 DSC thermograms of A) CBZ: SAC 1:1.5_12.5ml water, B) 
CBZ: SAC 1:1.5_15ml water, C) CBZ: SAC 1:2_12.5ml water and D) CBZ: 
SAC 1:2_15ml water 
Figure 6.12 represents the DSC thermogram for CBZ: SAC form II cocrystal 
processed using a solvent mixture. 
 
Figure 6.12 DSC thermograms of CBZ/SAC Form I and FII processed by 
MASCW. 
Based on the above DSC thermogram comparison of two different cocrystal 
samples is represented. The melting endotherm at 164.7°C represents to 
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form II cocrystal of CBZ: SAC which is a metastable phase and melting 
endotherm at 172.45°C represents to form I stable cocrystal phase.  
6.2.1. c) HPLC analysis 
Quantitative analysis of MASCW processed CBZ: SAC cocrystals were done 
as there are subjected to high temperature and pressure conditions and 
during performing experiments certain coloration of the supersaturated 
solution after microwave treatment is observed. CBZ undergoes oxidation 
reaction in presence of solvent system to give rise to iminostilbene. The 
initial steps consist of the preparation of calibration curve for various 
concentrations of iminostilbene and from the equation received from the 
graph the percentage concentration of iminostilbene present in an unknown 
sample of CBZ/SAC cocrystals process in MASCW process. The calibration 
curve for iminostilbene is displayed below in Figure 6.13 
 
Figure 6.13 Calibration curve for iminostilbene 
Both CBZ standard and iminostilbene standards were isolated using the 
isocratic method, below Figure 6.14 represents the chromatogram 





Figure 6.14 Chromatogram representing the separation of CBZ and 
iminostilbene. 
Below Table 6.3 represents the percent essay of iminostilbene for all the 
samples processed at different process parameters and form I and form II 
polymorphs of CBZ: SAC cocrystals. 
Table 6.3 Percent degradation of MASCW processed CBZ: SAC 
cocrystal samples using different parameters 
Processing variable  Process 
parameters 
% iminostilbene 
Solvent amount 10 mL 0.1366 
12.5 mL 0.2136 
15 mL 0.1518 
Temperature 110 °C 0.2958 
115 °C 0.1366 
120 °C 0.1993 
Microwave power 200 W 0.1790 
300 W 0.1366 
400 W 0.1947 
CBZ/SAC form I cocrystal - 0.1122 
CBZ/SAC form II cocrystal - 0.1024 
Based on the degradation study performed, it is observed that samples 
which were treated at an elevated temperature, high microwave power and 
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for a prolonged period of time contain a higher concentration of iminostilbene 
as potential degradant. Above table showed an acceptable amount of 
degradation according to USP guidelines. Thus based on the degradation 
study the optimum process parameters quantified for this cocrystallisation 
experiment is temperature 115°C, 300W power, 10mL solvent system and 5 
minutes heating rate to reach the target temperature. 
6.2.1. d) Scanning electron microscopy 
As all the cocrystals samples were exposed to high temperature and 
pressure condition using water as the solvent system, change in the 
morphological properties of cocrystal samples processed using MASCW 
process and solution crystallisation is reported in the below Figure 6.15 and 
6.16 respectively. Change in the crystal habits of two different form of CBZ: 




Figure 6.15 SEM images of CBZ/SAC cocrystal form I process from 
MASCW at optimum process parameters; A-40X, B-100X, C-400X and D-
1000X magnifications. 
 
Figure 6.16 SEM images of CBZ / SAC co-crystal Form I obtained from 





Figure 6.17 SEM images of CBZ/SAC cocrystal form II process from 
MASCW at optimum process parameters: A-100X, B- 300X, C-1000X, 
and D-2000X magnifications. 
SEM images of MASCW processed samples are compared with reference 
i.e. CBZ/SAC form I produced from conventional solution crystallisation 
process. The samples processed by MASCW show smooth surfaces plate-
like structure with minimum crystal defects. The CBZ/SAC form II cocrystals 
produced from a MASCW process show very drastic change in the 
morphology. This may be due to the growth of secondary nuclei which are 
based on primary nuclei. The plate-like crystal morphology of CBZ/SAC form 
I is previously reported in the literature (Rodríguez-Hornedo et al., 2008; 
Porter et al., 2008; Shariare et al., 2012). Shariare and co-workers proposed 
the change in the crystal structure due to change in the solvent system so 
the change in the crystal structure can be attributed to the process methods 
and the solvent system used. The cocrystal form II size is relatively smaller 
than form I cocrystal which can be correlated to the process parameters and 
phase properties. 
6.2.1. e) Surface Energy Analysis (SEA) 
Based on the SEM images the change in the crystal habit of MASCW 
processed cocrystal samples were observed compared to conventional 
solution crystallisation samples, therefore to study the change in the surface 
properties we have reported dispersive surface energies of all the samples at 
different surface coverage‘s (methods see Section 4.2.2.1.4). Various 
literature reviews are present which represent the change in the surface 
energy with the morphology, Peter York, and group demonstrated the 
174 
 
solubility variations observed with difference in morphology of Ibuprofen 
crystals, they demonstrated that plate-shaped crystals generated from 
ethanol have higher solubility and needle-shaped crystals obtained from 
hexane solvent  (Shariare et al., 2012). (Heng et al., 2006) has represented 
the change in the surface energy with the presence of impurities in 
paracetamol crystals. All the samples selected retain similar particle size 
distribution. Figure 6.18 represents the dispersive surface energies of CBZ: 
SAC form I cocrystal solution crystallised, CBZ: SAC form I and form II 
MASCW processed cocrystal samples. 
 
Figure 6.18 Dispersive surface energy plot for CBZ/SAC cocrystal FI 
and FII obtained from the MASCW process and CBZ/SAC FI obtained 
from solution crystallisation. 
The above plot reading is based on different percent surface coverage of 
samples obtained when series of alkane gas molecules are passed through 
the sample column. The dispersive surface energy is calculated by using 
Dorris/Gray approach with peak max as result parameter using SMS Cirrus 
Plus analysis software. Figure 6.16 represents that the crystals obtained 
using MASCW process have greater surface energy than the crystals 
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obtained from solution crystallisation. CBZ/SAC FII as discussed before as 
metastable phase retain highest surface energy than the FI crystals obtained 
from the same MASCW process. The surface energy is the analysis of the 
type of interaction between the molecules on the surface and bulk region, it 
indicates the presence of active sites on the surface and the bulk of the 
sample. They showed the retention of probe solvents on the bulk and surface 
of the material which depends on the interactions between the sample 
materials and the solvent probes passed through it. In the present study non-
polar solvents displayed higher surface energy values which indicate the 
presence of less polar functional group on the surface and bulk of the sample 
mass. Less surface energy for the crystals obtained from solution 
crystallisation is observed which indicates the presence of more polar 
functional groups on the bulk and surface of the sample materials. The 
change in the surface energies is attributed to crystal habit and presence of 
active sites on the surface of the cocrystals.  
6.2.1. f) Solubility data 
Due to the variation observed in the different forms of CBZ: SAC cocrystals 
investigation of solubility properties of the cocrystal is performed by studying 
the equilibrium solubility of the samples at different temperature conditions. 
Figure 6.19 represents the solubility profile of CBZ: SAC form I and form II at 




Figure 6.19 Solubility vs temperature profile for CBZ: SAC form I and 
form II cocrystal phase. 
Based on the solubility vs temperature curve an increase in the solubility of 
metastable form II phase of CBZ: SAC cocrystal compared to form I is 
observed. This increase in the solubility is attributed to the surface energy of 
metastable form II phase, crystal habit and dimorphic crystal lattice 
arrangement of cocrystal components. 
6.2.2 Screening experiment: cocrystallisation of SMT: SAC and SMZ: 
SAC cocrystal pairs 
In this section, MASCW process as the screening tool is implemented for the 
generation of SMT: SAC and SMZ: SAC cocrystal pairs in 1:1 stoichiometric 
ratio using water as the solvent system. The process parameters selected for 
these experiments are optimised in our previous studies (for method see 
Section 4.2.2.2.2). Previously (Fu et al., 2016) and the group had produced 
cocrystal complexes of sulfamethazine and saccharine in 1:1 stoichiometric 
ratio to study the formation of cocrystal salt or cocrystal based on the 
intermolecular interaction sites.  
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6.2.2. a) PXRD data 
The PXRD analysis is performed on all the samples processed using 
MASCW technology. Below Figure 6.20 represents the comparison of PXRD 
pattern for SMT and SAC cocrystals with starting materials and CSD 
standard PXRD pattern. 
Based on the PXRD data it is observe that the XRD peaks of SMT: SAC 1:1 
cocrystal sample is different from the raw starting materials and similar with 
the distinct characteristic peaks of SMT: SAC 1:1 CSD (XOBCOH) reference 
standard. According to the standard CSD pattern, two distinct peaks at 7.5 θ° 
and 12.5 2θ° can be distinguished which attributes to cocrystal phase. These 
two characteristic peaks are present in the processed sample of SMT: SAC 
cocrystal pair in 1:1 stoichiometric ratio (Fu et al., 2016). Thus formation of 
SMT: SAC 1:1 cocrystal is confirmed. 
  
Figure 6.20 PXRD patterns of : A) SMT_SAC 1:1 CSD-(XOBCOH), B) 
SMT raw, C) SAC raw and D) SMT: SAC 1:1 cocrystal 
In a similar manner, SMZ: SAC 1:1 cocrystal pair is selected and processed 
using the MASCW process to study the formation of cocrystal solid phase. 
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Figure 6.21 represents the comparison of PXRD pattern for raw and 
processed samples of SMZ and SAC. 
 
Figure 6.21 PXRD patterns of A) SMZ raw, B) SAC raw and C) SMZ: SAC 
1:1 cocrystal 
From the above PXRD pattern, new peaks at 17.5 and 19.2 2θ° is observed 
which may be corresponding to the formation of a new phase which could be 
cocrystal phase. Characteristic peak of SMZ and SAC raw materials are 
disappeared, which can be attributed to the interactions between SMZ and 
SAC during crystallisation or processing. To confirm the presences of new 
solid phase DSC analysis was performed.  
6.2.2.b) DSC data 
Based on the data obtained from PXRD studies thermal analysis of the 
processed samples is conducted to confirm the presence of any water 
molecule and new solid phase transitions. Below Figure 6.22 summarises 
the DSC endotherm of SMT, SAC raw materials, the physical mixture in 1:1 




Figure 6.22 DSC endotherms of A) SMT raw, B) SAC raw, C) SMT/SAC 
1:1 physical mixture and D) SMT/SAC 1:1 cocrystal 
Based on the DSC endotherm it is observed that the melting endotherm of 
processed samples is less than the melting points of raw materials, which 
confirms the new phase generation. In the physical mixture, very small 
endotherm at 167°C is observed further followed by broad degradation peak 
which can be attributed to phase impurities. Based on the previous literature 
findings the melting endotherm between 175°C and 179°C corresponds to 
cocrystal phase of SMT: SAC 1:1 cocrystal (Padrela et al., 2010). 
The similar ramp method is used to analyse the formation of SMZ: SAC 1:1 
cocrystal phase, Figure 6.23 represents the DSC endotherm of SMZ, SAC 




Figure 6.23 DSC endotherms of A) SMZ raw, B) SAC raw, C) SMZ/SAC 
1:1 physical mixture and D) SMZ/SAC 1:1 cocrystal 
Based on the above DSC patterns, the processed samples show new 
melting peak at 189.96°C which does not correlate to melting endotherms of 
starting materials. In the physical mixture, small melting event at 190.24°C is 
observed followed by a broad melting event at 220.77°C which can be 
attributed to the cocrystal peak and saccharin impurities. Thus based on the 
melting points, in the processed samples the melting point is lower than raw 
materials. Therefore generation of new crystal phase is confirmed which may 
be cocrystal. The absence of any broad or distinct endotherm between 60°C 
-110° C further confirms the absence of hydrate formation.  
6.2.3 Cocrystallisation of CAF – 4-HBA acid using MASCW process 
6.2.3.1 Introduction 
In the present chapter, application of MASCW process and solvent mixture is 
explored for the generation of incongruent cocrystal pair of caffeine (CAF) 
and para-hydroxybenzoic acid (4HBA) in 1:1 stoichiometric ratios. Various 
studies have been performed for the generation of cocrystals with enhanced 
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properties but the real challenge lies when the predicted results are not 
reflected experimentally when the stoichiometric ratios of the starting two 
components are not similar to the stoichiometric ratios of cocrystals formed. 
Aitipamula‘s group have analysed the study to predict the hidden cocrystal 
hydrates of caffeine and piracetam with 4-hydroxybenzoic acid (Aitipamula et 
al., 2012), they revealed the presence of CAF-4HBA (1:1) hydrate. The 
findings were able to generate 1:2 and 2:1 cocrystals of CAF/4HBA which is 
earlier studied by McGillivray‘s group, 2009. Recently (Dejan-Kresimir Bucar 
2008) have used cocrystallisation of caffeine with regioisomers of 
hydroxybenzoic acids (2, 3 and 4) to understand the product variability which 
is referred as an incongruent pair. The hydroxybenzoic acids have the 
capacity to form three different components of cocrystals with caffeine with 
different crystal properties. Recently, Price‘s group tried to study the 
cocrystallisation of CAF/4HBA in 1:1, 1:2 and 2:1 stoichiometric ratios based 
on its lattice energy and capacity to form hydrogen bonding between these 
two cocrystal components, this group has postulated that based on the 
crystal lattice energies and arrangements formation of CAF/4HBA in 1:1 is 
practically not possible (L. Sarah Price, 2014). Caffeine has in total three 
sites of a functional group which retain hydrogen bonding capacity, N-atom 
on imidazole, the other two are based on oxygen atom present on carbonyl 
group of urea and an amide moiety (Dejan-Kresimir Bucar 2008). So various 
studies were performed to study the heterosynthon in caffeine based 
cocrystallisation, (Dejan-Kresimir Bucar 2008) is able to produce CAF/4HBA 
1:2 and 2:1 cocrystals but failed in generation of 1:1 cocrystal of CAF/4HBA 
due to formation of concomitant impurities of  2:1 CAF/4HBA cocrystal, there 
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were successful in reporting the formation of hydrates of CAF and multi-
substituted HBA cocrystals when water and organic solvent (acetonitrile) is 
used as solvent media for cocrystallisation. Based on this screening 
experiment performed by (Dejan-Kresimir Bucar 2008) it is proved that it is 
practically difficult to produce 1:1 cocrystal of CAF/4HBA due to its 
incongruence. Hence, the present study aims in the production of anhydrous 
phase of CAF/4HBA cocrystal in 1:1 stoichiometry using MASCW process, 
(for method see Section 4.2.1.3.2). For the reference purpose, CAF/4HBA 
cocrystal at different stoichiometric ratios was produced using slow 
evaporation solution crystallisation.  
6.3.2.2 Results and discussion 
6.3.2.2. a Summary of experimental data 
As discussed by (Dejan-Kresimir Bucar 2008) the unpredictable enormous 
behavior of 4HBA with CAF, when 1:1 stoichiometric ratio of CAF/4HBA is 
subjected to crystallisation they induce out as CAF/4HBA 2:1 cocrystals 
instead of 1:1 cocrystals. CAF/4HBA in 1:1 molar ratios was subjected to 
MASCW process and analysed the resultant product stoichiometry using X-
ray diffraction analysis. Below Table 6.4 summarises the results obtained at 
different experimental conditions. 




Weight of 4HBA 
(mg)(2.5mmol) 







485 345 1:1 water 135 Mixture of 
1:2 and 
2:1cc 
485 690 1:2 water 135 1:2 cc 
970 345 2:1 water 135 2:1 cc 
485 345 1:1 5mLMeOH 
+5mLH2O 
135 1:1 cc 
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Generation of cocrystal pairs at different stoichiometric ratio is analysed and 
observed the formation of either 1:2 or 2:1 stoichiometric ratio of CAF/4HBA. 
When 1:1 molar ration of CAF/4HBA is subjected to processing based on 
PXRD data concomitant mixture of 1:2 and 2:1 stoichiometric ratios of 
CAF/4HBA is observed.  
6.3.2.2. b PXRD data 
Using solution crystallisation technique and methanol as the solvent system 
generation of CAF/4HBA cocrystals in different stoichiometric ratios is 
reported. The below Figure 6.24 summarises the PXRD results of CAF/4HBA 
cocrystals with different stoichiometric ratios. 
Based on the solution crystallisation PXRD result when 1:1 molar 
concentration of CAF and 4HBA is subjected to solution crystallisation using 
methanol as solvent, concomitant impurities of 2:1 CAF/4HBA cocrystals 
have induced out. CAF/4HBA 1:2 and 2:1 cocrystal results are in similar 
stoichiometric ratios as the initial molar ratios of caffeine and 4-
hydroxybenzoic acid. These results are in good agreement with results 




Figure 6.24 PXRD patterns of solution crystallisation pattern of 
CAF/4HBA cocrystals A-CAF-4HBA (1:1) CSD, B-CAF-4HBA (1:2) CSD, 
C-CAF-4HBA (2:1) CSD, D- CAF-4HBA (2:1) solcryst, E-CAF-4HBA (1:2) 
solcryst and F-CAF-4HBA (1:1) solcryst. 
Below Figure 6.25 represents the PXRD patterns of CAF-4HBA cocrystal 
pairs at different stoichiometric ratios using water as the solvent system. 
 
Figure 6.25 PXRD patterns of MASCW process batches of CAF/4HBA cc 
A-CAF-4HBA (1:1) CSD, B- CAF-4HBA (1:2) CSD, C- CAF-4HBA 
(2:1)CSD, D-CAF-4HBA(1:1)-SCWP, E-CAF-4HBA(1:2)-SCWP and F-
CAF-4HBA (2:1) – SCWP. 
Below Figure 6.26 represents the formation of 1:1 cocrystal pair of CAF-





Figure 6.26 PXRD patterns of CAF/4HBA 1:1 cocrystals produced from 
a MASCW process using a solvent mixture (50%-50% MeOH-water) as a 
solvent. A-CAF/4HBA 1:1 cocrystals produced from MASCW, B- CAF-
4HBA (1:1) CSD, C- CAF-4HBA (1:2) CSD, D- CAF-4HBA (2:1) CSD. 
As concomitant impurities of 2:1 CAF/4HBA when 1:1 molar concentrations 
of two components were obtained when subjected to solution crystallisation. 
The effect of the MASCW process in the molar ratios of initial components 
and final cocrystal product was studies using 10 mL water as the solvent 
system. Figure 6.25 represents the PXRD results of CAF/4HBA cocrystals 
obtained using MASCW process using water as the solvent system. As a 
result, this experiment failed as there is no 1:1 stoichiometric ratio of 
CAF/4HBA cocrystals is formed, same results similar to solution 
crystallisation observed in this process as well.  
These results made us consider the dielectric constant of solvent at elevated 
temperatures so a solvent mixture (5 mL water + 5 mL methanol) as a 
solvent system was used so the dielectric constant is further reduced at 
elevated temperatures which increase its polarity. Figure 6.26 represents the 
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PXRD patterns of CAF/4HBA 1:1 cocrystal obtained using MASCW process 
using solvent mixtures as the solvent system. The peak at 6.8 2θ degrees is 
the characteristic peak which corresponds to 1:1 stoichiometric ratio of 
CAF/4HBA cocrystal. The PXRD pattern of CAF/4HBA 1:1 cocrystals very 
correctly matches with CAF/4HBA 1:1 cocrystal pattern generated from 
crystal structure data (CSD). 
6.3.2.2. c Thermal analysis data 
Thermal analysis using DSC and TGA is performed to the hit sample of CAF-
4HBA 1:1 produced from a MASCW process using the solvent mixture to 
analyse the presence of hydrate due to the hygroscopic property of caffeine 
and hydroxybenzoic acid. 
Based on the DSC analysis the endotherm observed at melting point 
150.99˚C corresponds to the melting point of CAF: 4HBA 1:1 ratio observed 
by Aitipamula‘s and group. The absence of broad endotherm between 70°C-
110°C further confirms the absence of residual water molecule. The TGA 
thermogram contains only single linear event and doesn‘t show any loss in 
weight at 70°C-110°C which confirms the absence of water molecule. The 
only event present is around 150°C corresponds to the melting of CAF: 
4HBA co-crystal. Molecular association of hydrogen bonds involved in 
cocrystals of CAF-4HBA 1:1 stoichiometry is further confirmed by using 1H 
NMR which provided the complete description regarding stoichiometric ratios 




Figure 6.27 Overlay of DSC and TGA thermogram of CAF/4HBA 1:1 
processed using MASCW process. 
6.3.2.2. c 1H-NMR- spectra 
Successful determination of CAF: 4HBA cocrystal complex by thermal and X-
ray diffraction then is monitored by 1H-NMR, processed cocrystal pair of 
CAF: 4HBA is dissolved in d6-DMSO solvent before analysis, based on the 
integrated area ratios extracted from deconvolution of experimental 1H-NMR 
spectra (peak fitting) that particularly considering the signal fraction of 




Figure 6.28 NMR spectral comparison of CAF: 4HBA 1:1 cocrystal in d6-
DMSO 
Upon inspection of 1H-NMR spectra for CAF: 4HBA cocrystal, it is observed 
that all the chemical shifts representing the protons of either CAF or 4HBA 
are well separated. Based on the peak picking analysis; 4-HBA is present in 
three different proton environments based on the chemical structural 
environment, peak at 12.5 ppm can be labelled as 23 represents the proton 
corresponding to –COOH group of 4-HBA, peak at 10.3 ppm labelled as 21 
correspond to –OH group of 4HBA, peak at 7.8 and 6.8 labelled as 16a, 20a 
and 17a, 19a respectively corresponds to four aromatic –CH protons of 
4HBA.  CAF is present in chemically four different environments and 10 
protons are present in total based on the molecular structure; peak at 8 ppm 
labeled as 6a corresponds to one hydrogen atom of imidazole C-H, and 
peaks between 3 to 3.8 ppm represent three –N-CH3 protons which belong 
to 1, 3 and 7 nitrogen atoms. Peaks at 2.5 and 3.3 ppm represents to solvent 
(DMSO) residual peak and water respectively.  
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Next, the peak integration was evaluated for each of these chemical shifts 
using peak area values. As per NMR spectra, peak area for one proton 
(0.04), the integrated area ratios for (–COOH: -OH: -CH) groups of 4HBA are 
(1:1:4) and integrated area ratios of (–H: -N-CH3) groups of CAF are (1: 9) 
was determined. Finally upon considering the peak area ratios of all 
hydrogen‘s present in CAF and 4HBA, it is in excellent agreement with 1:1 
stoichiometry. 
6.2.4 Conclusion 
Microwave assisted subcritical water process have successfully 
demonstrated the potency to generate cocrystal (metastable phase) with 
minimum degradation with enhanced surface free energy and solubility 
compared to cocrystals generated from conventional solution crystallisation 
process. Demonstration of the effect of different process parameters and 
phase purity of end products was reported. The generation of further two 
cocrystals of SMT: SAC and SMZ: SAC using water as solvent system was 
reported, thus MASCW process is novel green technology which can be 
used as high throughput screening tool as it is less time consuming, efficient 
in controlling the process parameters and cause minimum chemical 
degradation to the processed samples.  
For the first time in this research work, the application of MASCW process for 
generation of incongruent pair cocrystals of CAF: 4HBA in 1:1 stoichiometric 





Chapter 7: Application of MASCW process in polymorphism 
In this chapter, application of the MASCW process in particle engineering of 
pharmaceutical ingredients is investigated. This chapter is further divided into 
two sections- 1) less compressible pharmaceutical ingredient like 
paracetamol (pca) and processed using MASCW technique for the 
generation of the metastable polymorphic phase of pca with enhanced 
compressibility and physicochemical properties.2) In the second section, 
application of the MASCW process for the generation of micro-sized 
theophylline particles with stable physicochemical and enhanced 
aerodynamic properties is investigated. 
7.1 Generation of metastable paracetamol form II polymorph using 
MASCW process 
7.1.1 Introduction 
Two chemical compounds which are chemically similar but differ in the 
crystal lattice arrangement than they are said to exhibit polymorphism 
(Williams, 2006). Most of the chemical entities virtually exhibit polymorphism; 
they exhibit different crystal structure arrangement in terms of unit cell 
spacing, angles or crystal system but are similar in the chemical composition. 
Polymorphism has gained its importance in the pharmaceutical industry 
because of different polymorphs of same chemical component exhibit 
different physical and chemical properties such as stability, melting point, 
process compatibility, solubility, particle flow. (Burley et al., 2007).  In the 
pharmaceutical industry, they are various groups of APIs which exhibit 
polymorphism up to 10 polymorphs. Groups such as barbiturates, steroids, 
and sulphonamide exhibit polymorphism (Tsapatsaris et al., 2014). 
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Controlled polymorphism is the new approach used in industry to obtain 
suitable polymorphs with advanced physicochemical properties. The most 
difficult task considered by researchers in the study of polymorphism is 
understanding and identification of thermodynamically stable polymorph. 
Most of the process parameters and experimental conditions are considered 
while identification and synthesis of polymorphs, parameters need to be 
considered are degree of supersaturation during crystallisation, solvent 
properties, process temperature and pressure. In recent years very good 
understanding of polymorphs have been developed via computational 
structural data study (Perrin et al., 2009). This process of polymorphism is 
exemplified by Acetaminophen (4-acetaminophen; paracetamol) which is 
rigorously studied antipyretic pharmaceutical ingredient which exhibits 
polymorphism. Paracetamol exists in three polymorphic crystal structures, 
pca form I is most stable and form III is most metastable crystal form. The 
relative thermodynamic stability of pca polymorphs in I>II>III and the inter 
conversion of the transformation of these polymorphs follow reverse order 
kinetics (Matthew L. Peterson 2003). Various studies have been performed 
to understand and isolate the polymorphic crystal structures of pca to 
generate metastable phase. (Matthew L. Peterson 2003) and group 
demonstrated the production of a trihydrate of polymorphs form I and II by 
ice-cold aqueous suspension approach. They demonstrated that the 
trihydrate form of polymorph is more metastable lath-shaped crystalline 
structure. Polymorphs of pca exhibit enantiotropic behavior which undergoes 
a phase transformation from metastable phase to stable phase. The most 
thermodynamically stable polymorph of pca is the monoclinic form I and 
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metastable form II which is orthorhombic form in ambient conditions. Despite 
various methods and studies the crystal structure of pca form III is difficult to 
isolate, it is postulated to be very unstable based on the crystal lattice energy 
(Etienne Joiris 1997). In the formulation aspects, pca is commonly used for 
the manufacturing of tablet dosage forms, commercially available stable 
polymorph form I is very poorly compressible due to its low densification 
property and crystal lattice arrangement (Etienne Joiris 1997). Pca 
monoclinic form generally represents high elastic deformation, particle 
fragmentation resulting tablet capping problem so it became very important 
to produce a metastable form of pca with enhanced compressibility property 
so the addition of external binders and pharmaceutical excipients can be 
avoided. And to avoid granulation step prior to compression Burley‘s group is 
able to isolate metastable form I and II of pca by implementing Oswald‘s rule 
of states (Burley et al., 2007). They proposed that in the process of 
crystallisation the system transforms from state of high energy to state of low 
energy via a minimum change of free energy so this study confirms than less 
stable polymorphs should get isolated first. This process is explored by using 
hot stage microscopy; they have produced by the heating glassy state rather 
than cooling the solution. Martino and group studied the molecular mobility of 
pca amorphous form using DSC instrumental analysis and proposed that the 
metastable forms are generated from the melt (Piera Di MARTINO 2000). 
Compression behavior of orthorhombic form of pca is studied and analysed 
by Joiris and co-workers. They have recrystallised the monoclinic form of pca 
and proposed that orthorhombic form II has higher compressibility due to its 
sliding structural planes (Etienne Joiris 1997). Gary Nichols proposed that 
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quantitative crystallisation of pca form II is possible only using polycrystalline 
material from fused form I. It is stated that form II orthorhombic polymorph 
undergoes plastic deformation and which is suitable for direct compression 
into tablets (Frampton 1998). The only method used for crystallisation of form 
II polymorph is by seeding the supersaturated solution of monoclinic form I 
with orthorhombic form II (Frampton 1998). Various studies were performed 
to generate cocrystals of pca which have enhanced compressibility 
properties than commercially available stable form I pca. Cocrystals of pca 
with trimethylglycine in 1:1 stoichiometry is generated which retains good 
compressibility property, later trimethylglycine replaced by oxalic acid as a 
coformer based on the compressibility property (Maeno et al., 2014). Crystal 
structure determination of pca form III is performed by Perrin and group 
using crystal structure prediction and powder X-ray diffraction technique 
(Perrin et al., 2009). Due to high requirement and greater need of metastable 
form II of pca in industrial level MASCW technology was implemented to 
generate stable pca form II polymorph. Further, this technology is transferred 
to the scalable level with our industrial partner where pca is used as the 
model component for generation of stable metastable phase with enhanced 
physicochemical properties. 
7.1.2 Results and discussion 
7.1.2.1 MASCW crystallisation of commercial paracetamol 
Using MASCW technology generation of form I and form II polymorphs of 
pca was successfully performed in the lab scale as well as industrial scale. 




Table 7.1 Experimental results of MASCW treated pca 
 
Based on experimental data formation of form I stable and form II metastable 
phase of pca is reported at different experimental conditions. When 10% w/v 
supersaturated solution of pca is processed using MASCW technology and 
implemented different crystallisation techniques different pca polymorphs 
were identified. When the supersaturated solution is not disturbed during 
controlled cooling and sudden cooling form I polymorph is obtained. When 
the solution under controlled cooling step is disturbed by applying external 
shear than immediate crystal start inducing which results form I polymorph 
with form II impurities. To obtain pure metastable polymorphic phase the 
supersaturated solution is suddenly cooled by applying shear (stirring) 
immediate crystals start inducing resulting generation of form II orthorhombic 
polymorphic phase of paracetamol. The generation of metastable form II 
phase of pca is attributed to the supersaturation level of the solution and 
importantly the water hydrogen bonding property, when sub-critically treated 
solution of pca in water is disturbed during the cooling step we are inhibiting 
water to retain its hydrogen bonding structure and based on the dielectric 
energy difference of the solution and solubility of pca in water generation 
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metastable phase of pca is occurred. The phase purity of the processed pca 
is further confirmed using spectroscopic studies. 
7.1.2.2 PXRD data 
Below Figure 7.1 represents the PXRD patterns of pca samples MASCW 
processed and raw commercial pca form I as the reference. 
 
Figure 7.1 PXRD patterns of: A- pca FI CSD, B- pca FII CSD, C-pca-raw, 
D- pca FII MASCW processed and E – pca FI MASCW processed. 
Based on the PXRD patterns MASCW processed samples of pca are in good 
agreement with pca FII CSD calculated patterns and pca FI calculated 
pattern. Characteristic peak at 10 theta degrees in pca form II CSD pattern 
(D) is in good agreement with PXRD pattern D. Pattern E which is MASCW 
processed samples proved to be pca form I similar to starting material and 
pattern A. Only difference in the process between D and E is the batches (D) 
which is subjected to continuous stirring and rapid cooling step whereas 
batch E is subjected to control cooling without stirring action. The decrease 
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in the crystallinity can be attributed to decrease in particle size and 
generation of amorphous fraction of processed samples. 
7.1.2.3 Raman spectroscopic data 
Based on the previous literature studies pca exists in three polymorphic 
phases form I,II and III out of which form II and III are the metastable phase 
and were studied using DSC coupled with Raman spectroscopy (Kauffman 
et al., 2008) . Figure 7.2 represents the base line corrected and normalised 
Raman spectra of raw and processed pca samples. 
A)  
  B)   
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Figure 7.2 A) Full range spectra of pca raw form I, MASCW processed 
form I and MASCW processed form II and B) Zoomed spectral region 
marking the charecteristic distinct peak marking of form II polymorph 
of pca . 
Form I polymorph exhibits its characteristic spectral peaks at 1234 and 1325 
cm-1, form II display a weak peaks at 1220 and 1245 cm-1and a strong peak 
at 1329cm-1 and based on the literature study form III polymorph  of pca 
show well resolved peaks at 1500-1700cm-1 range. From the above spectral 
data it is confirmed that form III polymorph is absent as there are no 
characteristic peaks representing form III polymorph. PCA form I obtained 
from MASCW process rightly coincides with the characteristics peak of form I 
polymorph. In the form II polymorph characteristic peaks at 1220 and 1245 
cm-1 is observed. Comparatively strong peak at 1329 cm-1 which correctly 
correlates with literature values for form II pca (Kauffman et al., 2008) is 
identified. Thus based on the Raman spectra it is concluded that successful 
generation of form II polymorph of pca which is phase pure has occurred 
using this technology. Table 7.2 represents the measured peak positions of 
form I, II and III of pca polymorphs. 
Table 7.2 Measured peak positions of all polymorphs of pca 
Form I (cm
-1
) Form II (cm
-1
) Form III (cm
-1
) 
654 650 650 
837 - - 
854 862 862 
- 1220 - 
1234 - - 
- 1245 1245 
1565 1576 1561 
1615 1611 1611 
- 1623 - 
1650 1650 1646 
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7.1.2.4 Differential Scanning Calorimetry 
 
Figure 7.3 Practical DSC thermogram of pca FII processed. 
 
Figure 7.4 Practical DSC thermogram of pca FI processed. 
Thermogram of form I pca show single endothermic peak at 171°C (onset 
168°C) refer Figure 7.4 which is similar to the DSC data generated by Gary 
and co-workers (Frampton 1998). FII pca gave thermogram with three 
endothermic peaks at 128°C (weak broad peak), 157°C (weak sharp peak) 
and 171.6°C (strong and sharp peak) refer Figure 7.3. All these three events 
are similar to the events observed in previous publications. The thermally 
induced events for FII thermogram is interpreted as a solid state conversion 
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of FII to FI as the temperature is increased. As the crystals are obtained from 
melt solution crystallisation it may have many structural defects and may 
thermally promote the conversion of FII to FI. As reported before that FII 
generated from melt crystallisation generally produces sharp peak at 157°C. 
Based on the Raman spectra, XRD pattern and DSC thermogram it is found 
that phase pure form I and form II polymorph of pca was generated and 
further thermal study provides the absence of water molecule in pca 
processed samples.  
7.1.2.5 Degradation study of MASCW processed pca samples 
As the pca raw material is subjected to high temperature and pressure 
conditions and decolouration of samples is observed when treated at high 
temperature. To quantitatively analyse the percent purity of pca samples 
degradation studies using HPLC analyser is done. Initially calibration curve 
for potential degradant of pca i.e. 4-aminophenol is determined at different 
concentrations. The slope equation obtained by plotting a calibration graph 
between concentration and area under curve is used to analyse the unknown 
concentration of 4-aminophenol present in MASCW processed pca samples. 
Below Figure 7.5 represents the chromatogram of elution peaks of pca and 
4-aminophenol separately; this confirms the sensitivity of the method 





Figure 7.5 HPLC chromatogram of: distinctive peaks of pca and 4-
aminophenol raw  
 
Figure 7.6 Calibration curve plot of: 4-aminophenol. 
Based on the calibration curve obtained and slope equation percent essay is 
calculated to various MASCW processed samples of pca. Analysis of 
degradation profile of all pca samples which are MASCW treated and 
conventionally heated is performed. Below Table 7.3 summarises the 






Table 7.3 Percent assay of pca treated at high temperatures 
Name of sample Percent assay (%) 
Para MASCW treated  99.50±0.29 
Para conventional heating 96.23±0.46 
 
Based on the HPLC analysis very negligible amount of degradation is 
observed in MASCW process pca samples as compared to conventional 
heating process. As per literature review it is concluded that upon storage in 
solution state, potential degradant product of pca which is 4-amino phenol 
undergo further oxidation to give rise to quinoeimine derivatives which are 
under detection limit using HPLC technique. According to literature the pink 
colorations to pca sample in solid state or darkening of solution is due to 
quinoeimine (Francois Dietlin 1998), (Jouyban et al.,2004). 
7.1.2.6 Scanning Electron Microscopy 
Due to the exposure of pca samples to high pressure and temperature 
conditions using water as solvent system SEM analysis was performed to 
study the change in morphology and crystal habits of the processed 
samples. Figure 7.7 represents the SEM images of pca raw and MASCW 
treated at different magnifications. 
Based on the SEM images it is observed that the morphological changes 
were observed when raw pca is treated by MASCW process to give rise to 
plate like orthorhombic structures on continuous stirring using magnetic 
stirrer, this structure represents the form II polymorphic structure of pca and 
when the supersaturated solution is left for cooling without stirring large 
prism shaped agglomerated of pca were obtained which coincides with the 
monoclinic crystal structure of form I pca. The particle size of form II pca is 
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reduced as compared to form I pca which is attributed to implementation of 
shear while crystallisation is taking place. 
 
Figure 7.7 SEM images of pca raw, pca FII MASCW processed pca FI 
MASCW processed. 
7.1.2.7 Surface Energy Analysis 
Based on the SEM data as the morphological properties like crystal habit, 
surface roughness, size of processed pca are changed, further investigation 
of change in the bulk surface properties is performed using MASCW 
processed form I, form II and raw paracetamol samples (reference). All the 
samples selected retain similar particle size distribution. Initially BET surface 
area is determined and based on the BET results further surface 





Table  7.4  BET surface area of raw and processed pca 
 
The surface area of pca form II polymorph is higher than pca form I 
processed and raw samples. Even though the particle size of all the samples 
are similar the surface area of MASCW processed form I polymorph is 
greater than raw form I polymorph of pca this is due to crystal habit and 
increase number of active sites of the processes form I pca and polymorph 
form II is metastable phase it retains higher specific surface area.  Below 
Table 7.5, 7.6 and 7.7 represents the tabular format of dispersive surface 
energy, acid-base surface energy and total surface energy of paracetamol 
raw, paracetamol form I and form II respectively.  
Table 7.5 Summary  of Dispersive surface energy (γs
D), acid base 
surface energy (γs
AB) and total surface energy (γS










0.008 43.63 ± 0.68 4.73 ± 0.23 48.36 ± 0.91 
0.01 43.13 ± 0.04 4.52 ± 0.16 47.66 ± 0.20 
0.02 41.11 ± 0.16 3.92 ± 0.06 45.03 ± 0.21 
0.04 38.23 ± 0.34 2.71 ± 0.08 40.94 ± 0.42 
0.06 37.09 ± 0.13 1.40 ± 0.05 38.50 ± 0.18 
0.08 35.21 ± 0.89 1.70 ± 0.04 36.91 ± 0.92 





Table 7.6 Summary  of Dispersive surface energy (γs
D), acid base 
surface energy (γs
AB) and total surface energy (γS
T) of paracetamol form 









0.008 50.61 ± 1.45 8.40 ± 0.11 59.00 ± 1.56 
0.01 51.77 ± 0.31 8.31 ± 0.07 60.08 ± 0.24 
0.02 51.18 ± 0.09 8.01 ± 0.03 59.19 ± 0.13 
0.04 49.45 ± 0.28 7.28 ± 0.23 56.73 ± 0.52 
0.06 49.50 ± 0.40 7.17 ± 0.24 56.67 ± 0.64 
0.08 50.09 ± 0.80 7.25 ± 0.18 57.34 ± 0.98 
0.1 51.02 ± 0.28 7.17 ± 0.23 57.94 ± 0.15 
 
Table 7.7 Summary  of Dispersive surface energy (γs
D), acid base 
surface energy (γs
AB) and total surface energy (γS
T) of paracetamol form 









0.008 64.35 ± 0.16 9.02 ± 0.04 73.37 ± 0.11 
0.01 65.23 ± 0.16 9.15 ± 0.21  74.38 ± 0.37 
0.02 67.20 ± 0.27 9.64 ± 0.13 76.84 ± 0.40 
0.04 64.74 ± 0.02 8.77 ± 0.02 73.50 ± 0.00 
0.06 61.90 ± 0.53 8.05 ± 0.00 69.95 ± 0.53 
0.08 60.14 ± 0.64 7.56 ± 0.06 67.70 ± 0.59 
0.1 59.31 ± 0.45 7.07 ± 0.11 66.38 ± 0.56 
 
Below Figure 7.8a, 7.8b and 7.8c represents the graphical comparison of 
dispersive surface energy, acid base surface energy and total surface energy 




Figure 7.8a Comparative profile of dispersive surface energies of pca 
raw form I, MASCW processed form I and form II 
 
Figure 7.8b Comparative profile of dispersive surface energies of pca 




Figure 7.8c Comparative profile of total surface energies of pca raw 
form I, MASCW processed form I and form II 
The dispersive, specific and total surface energy readings of pca form II 
polymorphs is greater than form I processed and raw form I pca which can 
be attributed to the surface morphologies and crystal habit. Based on the 
literature review the particles with greater surface area and surface energy 
display greater kinetic properties thus in the results obtained form II 
polymoprh displayed higher surface energy than form I polymorph. The 
increase in the surface energy of paractamol form II polymorph can be 
attributed to planar deformation of crystals and prescence of charged moities 
on the surface of the particles. Due to increase in the charges molecules on 
the surface of form II polymorph further solubility and intrinsic dissolution 
experiments were performed to analyse the differece in the kinetic properties 
of pca processed and raw samples. 
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7.1.2.8 Solubility analysis of MASCW processed pca samples 
Based on the morphological and surface energy results of the processed pca 
samples equilibrium solubility experiments were performed to analyse the 
aqueous solubility of pca raw and processed at constant temperature and 
different time points. Below Figure 7.9 represents the solubility profile of pca 
from I and II processed and raw form I samples (refer Section 4.2.2.4.5).  
Table 7.8 Summary of aqueous solubility of pca form I and II MASCW 
treated versus commercial pca sample form I. 
                 
Based on the solubility data obtained there is increase in the solubility of 
MASCW processed pca samples compared to raw material. Paracetamol 
form II polymorph displayed higher (12%w/v) solubility compare to pca raw 
material, followed by form I MASCW processed sample showed (6%w/v) 
increase in solubility compared to raw form I sample. This increase in the 
solubility correlates with the increase in the surface energies, polymorphic 





Figure 7.9 Solubility profile of raw and MASCW process pca in water at 
ambient conditions. 
7.1.2.9 Drug dissolution data 
The dissolution profile of pca raw and MASCW treated samples of form I and 
form II pca polymorph is analysed using intrinsic dissolution apparatus (USP 
II apparatus). All the samples are shifted trough 35 µm sieve and particles 
size distribution is determined using Sympatec particle size analyser (Table 
7.9).  
Table 7.9 PSD of pca raw form I, MASCW processed form I and form II 
Sample code X10 (µm) X50 (µm) X90 (µm) 
pca raw form I 1± 0.03 5.92 ± 0.11 21.34 ± 0.39 
pca form I  1.74 ± 0.08  15.42 ± 0.61 28.52 ± 0.20 




Figure 7.10 describes the drug release profile for pca form I raw and 
MASCW generated pca form I and II powdered samples. Below table no 7.10 
IDR dissolution data for pca samples.  
Table 7.10 IDR dissolution data for pca raw, processed F I and F II 
 
In the below Figure 7.10 it is observed that form I pca and MASCW 
processed form I polymorph sample display negligible release difference up 
to 90mins time points but latter MASCW processed form I sample displayed 
increase in release rate followed by form I raw sample. The interesting profile 
is shown by MASCW processed form II polymorph with higher release rate 
from 10mins time point and after 360 mins it showed 60% increase in release 
rate compared to raw and form I processed samples. This enhancement in 
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the release rate can be attributed to surface energies, metastable phase of 
pca form II. 
 
Figure 7.10 Drug release profile of pca raw and MASCW processed. 
To further confirm the stability of pca form II in phosphate buffer (dissolution 
media) stability analysis of pca in phosphate solution is performed to  track 
the polymorphic transformation of metastable pca form II to form I using 





Figure 7.11 Raman spectral data for pca form II suspension a) full range 
spectra and B) magnified view of Raman shift between  (1150-1300cm-1) 
highlighting presence of pca form II characteristic peak at 1220 and 
1245cm-1 
As previously discussed in Raman crystallisation kinetics data regarding the 
characteristic peak of form II pca at 1220 and 1245cm-1 and form I peak at 
1234 and 1325 cm-1 respectively. Based on the above Raman data reflects 
the presence of form II pure spectral peaks and absence of form I peaks 
throughout the experiment for 22hours proving the stability of form II 
polymorph of pca in solution over 22hours.  
7.1.3 Conclusion 
Therefore the application of MASCW technolgy for the generation of phase 
pure stable metastable orthorhombic polymorph of paracetamol is reproted. 
This results was supported by performing dissolution data which displays 
enhanced intrinsic dissolution profile of orthorhombic polymorph using USP-II 
dissolution apparatus. Effect of crystallisation technique for the generation of 
metastable phase is investigated. 
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7.2 Pharmaceutical analysis and in-vitro aerodynamic characterisation 
of inhaled theophylline formulations generated by Microwave Assisted 
Sub-Critical water process 
In this present work MASCW process is implemented to explore its 
application in the field of crystal engineering for the generation of micro sized 
particles for inhalation drug delivery system. Anhydrous theophylline (THF) is 
selected as the model component to investigate the aerodynamic 
performance of MASCW processed samples.  
7.2.1 Introduction 
Theophylline (THF) is very well established antiasthma drug administered 
through oral and intravenous routes. Due to its low solubility in water it has 
restricted its clinical application. The prominent drawbacks of this API are 
related to its narrow therapeutic index and certain side effects, i.e. nausea, 
dizziness, headache and vomiting (Banner 1994). Various studies have 
reported regarding THF that at lower plasma concentration it has significant 
anti-inflammatory effect in chronic pulmonary disease (Barnes 2005). With 
the aim to attenuate the side effect and exploit the anti-inflammatory 
advantages of THF different potential formulations are developed, among 
these the most successful formulation is inhalation drug delivery system 
using dry powder inhaler (DPI) (Zhu et al., 2015). Thought this route of 
administration scientist has reported good aerosolisation and cell results, the 
only disadvantage of this delivery system is that the dose is limited to few 
micrograms (Zhu et al., 2015). 
For the inhalation drug delivery system particle size, morphological and 
structural configuration of API play very prominent role in the therapeutic 
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behaviour of the substance especially in respiratory drug delivery system. 
Therefore, production of micro- and nano- sized particles with controlled 
properties is very important steps during formulation of inhalable 
pharmaceutical actives and excipients. Various studies and techniques are 
been reported which are implemented for generation inhalable drugs with 
enhanced aerodynamic properties (Alhalaweh et al., 2013; Korang-Yeboah 
et al., 2016). All the technologies used retain certain drawback like use of 
organic solvent in case of antisolvent crystallisation process, solution state 
degradation of API in solution crystallisation, use of carbon dioxide at 
supercritical temperatures in case of supercritical fluid technology in the 
present study keeping in mind the drawbacks related to process and API 
water is used as green solvent for crystallisation implementing MASCW 
crystallisation process as quick crystallisation technique with negligible 
chemical degradation. 
In the present work nano- and micro- sized THF particles were generated 
and its aerodynamic properties was analysed using Next Generation 
Impactor (NGI) and Foradil as dry powder inhaler. Anhydrous theophylline 
was processed using MASCW process, once the clear theophylline solution 
was formed the recrystallisation of the particle was done using different 
crystallisation techniques like manual stirring, antisolvent technique, effect of 
external shear using ultrasound and Ultraturrax. Based on the particle size 
generated from different crystallisation techniques further NGI experiments 
were performed. Theophylline is process using conventional spray drying 
technique is kept as reference to understand and compare the effect of 
aerodynamic properties of theophylline between conventional and newly 
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developed MASCW process. Several important processed parameters are 
been identified in our previous studies (see chapter 5) are considered during 
crystallisation of THF using MASCW process.   
7.2.2 Results and discussion 
7.2.2.1 Re-crystallisation process and particle size distribution 
Pure anhydrous theophylline (1g) solution is prepared using water (10ml) as 
solvent and further this solution is processed using MASCW process at high 
temperature and pressure conditions till clear solution is formed. 
Crystallisation of the supersaturated THF solution is done using four different 
techniques; manual stirring, antisolvent method, ultrasound and Ultraturrax. 
For the method of recrystallisation (see Section 4.2.2.5.2) 
Below Table no 7.11 represents the PSD results for the powdered THF 
samples process using different crystallisation techniques. Anhydrous THF 
(SD1) is processed using conventional spray drying process (method see 
Section 4.2.2.5.3). All the samples are analysed in triplicates. 
Table 7.11 Mean particle size distribution data for raw and processed 
theophylline samples using different crystallisation techniques.  
 
Based on the above results the PSD data, prominent reduction in the particle 
size of MASCW processed THF as compared to raw THF is observed, the 
PSD of processed THF using antisolvent crystallisation process and spray 
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drying process are below 5 µm which is the recommended particle size for 
inhalation study. Thus based on the above results antisolvent technique of 
crystallisation is finalised for further studies in this chapter. 
7.2.2.2 Scanning Electron Microscopy 
The morphological properties of all processed and raw samples were 
analysed using SEM microscopy. Below Figure 7.12 represents the 
microscopic images of gold coated samples under 1000X magnifications. 
                                 
                                                              THF raw S1                                                        
        
                 THF-S2                                                   THF S3                                                         
        




             Figure 7.12 SEM images of THF S1 raw theophylline, THF S2 antisolvent 
treated,   THF S3 ultrasound treated, THF S4 manually treated and THF 
S5 spray dried THF. 
All the samples processed using MASCW process have smoother surface as 
compared to raw theophylline samples, crystal habit of the processed 
powder samples are changed from large cylindrical particles to small rod 
shaped agglomerates. In the spray dried samples, formation of small 
spheres are observed. 
7.2.2.3 Powder X-ray diffraction data 
X-ray diffraction study is performed to analyse the crystal structure and 
crystal phase of all processed and raw THF powder samples. Below Figure 
7.13 represents the PXRD patterns for all the samples. 
Based on the literature review theophylline exists in different polymorphic 
forms like anhydrous and hydrate form, where the anhydrous form is further 
classified into form I stable, form I metastable and form II polymorphs 
(Phadnis and Suryanarayanan 1997). The XRD pattern of the unprocessed 
samples reflects characteristic peaks at 2 theta degrees 7°, 12.5° and 14.5° 
which matches with literature patterns of anhydrous theophylline.  
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Figure 7.13 PXRD pattern for all processed and raw THF samples. 
Processed THF samples also show similar XRD pattern which confirms that 
the samples are anhydrous THF. The intensity of the processed samples is 
less which depends on the variation in precipitation process, crystallinity, 
level of supersaturation and crystal growth. 
7.2.2.4 Thermal analysis of THF 
Thermal response of theophylline raw and MASCW process samples were 
studied using DSC and TGA at a heating rate of 10°C/min between 25°C and 
300°C. Figure 7.14 represents the melting endotherms for raw THF and 
processed THF samples. All the powdered samples in the DSC data showed 
an endotherm melting point at approximately at 271°C, which is 
corresponding to the melting point of the raw anhydrous theophylline 




Figure 7.14 DSC thermogram of; THF raw and processed powder 
samples 
Below Table 7.12 represents the melting point and enthalpy of all samples. 
Based on the enthalpy values there is decreased in the enthalpy of the 
processed samples compared to unprocessed samples which reveals that 
there is decrease in the crystallinity of the processed samples over 
unprocessed. 
Table 7.12 Description of melting point and enthalpy values for all THF 
samples. 
 
All the samples are crystalline as there is no exothermic peak observed 
below 150°C. Furthermore, there is no endothermic peak observed at the 
temperatures between 70°C and 110°C, indicating that there is no residual 
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moisture present in the powdered samples thus all the samples are 
anhydrous theophylline. To confirm the presence of residual moisture 
content TGA analysis is performed, Figure 7.15 represents the TGA 
thermograms for all theophylline samples. 
 
Figure 7.15 TGA thermograms of raw and processed THF samples 
Table 7.13 Transition temperatures of THF samples 
 
The transition temperatures of the processed THF samples are less than the 
raw THF which is attributed to decrease in the particle size of the processed 
theophylline samples, due to decrease in the particle size the surface area of 
the particles is increase and thus they require lower temperature to 
decompose. The loss in weight in TGA thermogram is minimum (<0.01%w/w; 
data not shown) which indicates that the samples are anhydrous in nature. 
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Thus, based on the thermal analysis data using DSC and TGA it is confirmed 
that the THF samples are anhydrous in nature. 
7.2.2.5 FTIR spectroscopy data 
Spectroscopic analysis is performed to exploit and monitor the phase 
transition which is taking place in the MASCW processed samples. Below 
Figure 7.16 and Table 7.14 represents the IR-spectra for all the batches and 
correlation between the IR-peaks and structural information respectively. 
 
Figure 7.16 FTIR spectra for theophylline raw and processed samples. 
Table 7.14 IR-band range index and structural properties of anhydrous 
theophylline. 
Band range (cm-1) Relation with chemical structure 
3448 N-H bond stretch of amine 
2998 C-H stretch 
1718, 1668 C=O stretch 
1610, 1566 C=C and C=N stretch 
1314,1286,1240 C-N stretching 
927 N-CH3 stretching 
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Based on the IR spectral data the spectra of processed theophylline samples 
are in complete agreement with raw anhydrous theophylline thus there is no 
structural transition occurring during processing of theophylline using 
different crystallisation techniques. 
Based on the data generated from PXRD, thermal analysis and FTIR spectra 
it is concluded that the processed samples are anhydrous theophylline. 
Based on the particle size antisolvent crystallisation a technique was 
selected to study the aerodynamic performance of MASCW treated 
theophylline. Quantitative analysis of the processed samples is performed 
using HPLC analysis (see Section 4.2.2.5.5). 
7.2.2.6 Inverse gas chromatography  
Gas chromatography is performed to analyse the surface properties of all the 
theophylline samples. This study provides us with different surface properties 
like total surface energy, work of cohesion between same molecules and 
work of adhesion between two different molecules. All the samples analysed 
retain similar mean particle size distribution. Figure 7.17 provides the 





Figure 7.17 Total surface energy of THF raw, THF MASCW and THF SD 
Based on the above surface energy data THF raw demonstrated maximum 
total surface energy followed by spray dried THF and MASCW treated THF. 
This variation in the surface property is attributed to amorphous nature of 
processed samples, and crystal surface roughness. MASCW THF sample 
retains minimum surface energy as compared to spray dried sample this is 
due to surface smoothness and more crystalline property of theophylline 
processed using MASCW process. Spray dried THF crystals are spherical 
shaped with surface roughness thus more charged groups are exposed so 
the total surface energy is high. 
More the charged particles more is the surface energy and more the work of 
cohesion between the particles, Figure 7.18 represents the thermodynamic 




Figure 7.18 Thermodynamic work of cohesion (mJ/m2) of THF raw, THF 
MASCW and THF SD processed. 
Based on the literature review the particle with high total surface energy 
undergoes agglomeration as compared with less total surface energy 
particles. Thus, thermodynamic work of cohesion data rightly correlates with 
the total surface energy data. The aerodynamic performance of drugs is 
based on the work of cohesion, solid materials with high work of cohesion 
display less aerodynamic performance in case of dry powder inhalation as 
there is chances of forming agglomerates and high air flow is required to 
break the agglomerates. From the about data MASCW theophylline sample 
show minimum work of cohesion than spray dried and raw theophylline 
samples, thus based on this data aerodynamic performance theoretically 
should be more in case of MASCW processed theophylline than others. 
In dry powder inhalation formulations apart from active pharmaceutical 
ingredient there is also pharmaceutical excipient present which will be acting 
as a carrier to enhance the lung deposition of drug. To analyse the 
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interaction between the API and excipient work of adhesion between them is 
analysed, in the present study determination of the thermodynamic work of 
adhesion between the theophylline and lactose inhalation grade blend in 1:1 
w/w ration is performed. Figure 7.19 represents the work of adhesion 
between THF and lactose IG sample blends. 
 
Figure 7.19 Thermodynamic work of adhesion (mJ/m2) between THF 
and Lac IG blend. 
The above data displayed that MASCW THF SCW-Lac IG blend retains 
minimum thermodynamic work of adhesion as compared to THF-SD-Lac IG 
and THF raw-Lac IG powder blend. Thus the blends with maximum work of 




7.2.2.7 In-vitro evaluation of the aerodynamic performance of MASCW 
processed theophylline using NGI 
Prepared DPI formulations were subjected to in vitro cascade impactor using 
Next generation impactor (NGI) in order to evaluate aerodynamic 
performance of theophylline powder sample and blend of theophylline and 
lactose monohydrate. All the blends of anhydrous theophylline and lactose 
are prepared using turbula mixer for 5 mins and the quantitative analysis of 
the samples were studies using HPLC to maintain equilibrium distribution of 
API and excipient in the blend. The dose of pure THF used is 25mg in soft 
gelatine capsules. Copley Inhaler testing data analysis software (CITDAS 
version 2.0) is used to calculate aerodynamic parameters of all processed 
and blends of theophylline formulations. The result provided gave an idea 
regarding aerodynamic performance of theophylline processed using 
MASCW technique against spray dried theophylline as reference. Samples 
retrieved from THF S2 and THF S5 batches were selected for the analysis. 
7.2.2.7. A) Determination of total emitted dose of THF S2 and THF S5 
batches 
Table 7.11 represents the total emitted dose per shot, fine particle 
distribution; fine particle fraction (%), MMAD and GSD antisolvent MASCW 
processed and spray dried theophylline samples. Figure 7.20 represents the 
graphical pattern for the deposition of theophylline samples in different 
stages of impactor. Table 7.15 represents the summary of emitted dose of 





Table 7.15 Description of emitted dose of theophylline samples 
 
Based on the data obtained for the pure theophylline samples, NGI shows 
that for MASCW process THF samples produced using antisolvent technique 
show about 30% of total dose (20mg) of THF deposition in the throat and 
preseperator and 50% in the NGI stages and rest in the filter, the amount of 
drug loss is more in the filter region due to the particle size of THF processed 




Figure 7.20 Graphical representation of amount deposition of 
theophylline dose in different stages of NGI 
The spray dried pure THF samples displayed maximum deposition (40%) in 
the throat and preseperator region and minimum (20%) deposition in the NGI 
stages as compared to THF S2 sample. The maximum drug loss in the 
preseperator and throat region can be attributed to the fact that pure 
powdered samples without carrier may stick with each other and need higher 
inhalation flow rate to be de-aggregated into fine particles. Thus, based on 
the above data it is proved that the percent deposition of theophylline dose is 
more for MASCW processed samples compared to conventional spay dried 
theophylline. In THF S2 batch high average FPD and FPF % 5.93 and 35.48 
respectively is observed and in THF S5 we can see low FPD and FPF % 
1.86 and 15.96 respectively is observed. These results are in complete 
agreement with the SEM images and particle size analysis 4.60 for THF S2 
and 4.80 for THF S5 respectively. Therefore THF S2 with smaller particle 
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size and smooth surface (small rod shaped) show better aerodynamic 
properties than spray dried theophylline THF S5 which are larger in size and 
spherical in shape. Thus the shape of the particle is also an important factor 
in DPI formulations as the particles with rod shaped structure can easy thick 
to the walls of the stage and do not escape with the flow rate where as in 
THF S5 as the particles are spherical in shape they flow along with air and 
show minimum decomposition in the lungs.  Lactose is commonly used as a 
carrier as it can accomplish many of the ideal requirements; this is 
chemically and physically stable and inert to the drug substance. 
Furthermore, lactose can be easily cleared from the airway without causing 
any harm to the respiratory tract. Lactose is available in two form alpha and 
beta lactose, α-lactose monohydrate is thermodynamically stable phase and 
it is commonly used as carrier in DPI formulations. The physical properties of 
the lactose like size, shape and surface texture has shown to effect the 
dispersion and de-aggregation of the self-adhered drug particles. Thus, 
based on the aerodynamic data retrieved for pure THF samples THF S2 had 
showed good aerodynamic property than THF S5 sample. In MASCW 
process theophylline sample displayed 50% of the dose deposition in the 
lungs as compared to conventionally prepared THF samples. 
7.2.2.7. B) Determination of total emitted dose of theophylline and 
lactose blends 
Based on the data obtained for pure theophylline samples it was decided to 
analyse the effect of standard inhalable lactose monohydrate as carrier over 
aerodynamic properties of the drug. Standard inhalable lactose monohydrate 
with mean particle size of 50µm was selected as carrier mass. Blends of 
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theophylline 50% and lactose inhalation grade (IG) 50% were prepared using 
turbula mixer and the equilibrium distribution of drug in the blend is pre 
analysed using HPLC, 20mg of theophylline dose is selected with 20mg of 
lactose to analyse the aerodynamic performance of THF using NGI. Below 
Table 7.16 and Figure 7.21 represents the amount of API deposited in 
different stages of NGI and tabular format of different parameters of THF S2 
50% + lactose inhalation grade 50%. 
Table 7.16 Total emitted dose of THF and lactose (IG) blend 
Particle size distribution of 50% THF S2 and S5 with 50 % Lactose IG (20mg) 
  SCW THF S2 SD THF S5 
Stage no (mg) Trial 1 Trail 2 Trial 3 Trial 1 Trail 2 Trial 3 
Throat 7.54 7.77 7.52 10.25 9.27 9.76 
Preseperator 2.24 1.24 1.36 1.99 3.54 2.77 
Stage 1 2.42 2.56 2.48 1.59 1.89 1.74 
Stage 2 2.5 2.42 2.32 0.71 1.01 0.86 
Stage 3 0.88 0.90 0.86 0.20 0.16 0.18 
Stage 4 0.35 0.40 0.42 0.10 0.07 0.09 
Stage 5 0.12 0.18 0.22 0.03 0.02 0.03 
Stage 6 0.03 0.06 0.07 0.01 0.01 0.01 
Stage 7 0 0 0.01 0 0.01 0.01 
Stage 8 0 0 0 0 0 0 
No of doses to NGI 1 1 1 1 1 1 
TED  16.08 15.53 15.26 14.88 15.98 15.43 
TED per shot (mg) 16.08 15.53 15.26 14.88 15.98 15.43 
FPD (mg) 3.0 3.12 3.10 0.75 0.82 0.78 
FPF (%) 18.68 20.07 20.29 5.05 5.11 5.08 
MMAD (µm) 5.16 5.16 5.11 6.80 6.76 6.78 




Figure 7.21 Graphical representation of: amount deposition of 
theophylline-lactose IG blend formulations in different stages of NGI. 
The fine particle dispersion of inhaled drug is dependent on the particle size 
of the powder API, based on the literature particle size of the API influences 
the extent, distribution and site of the inhaled drug deposition within the 
airways. In the present study two formulations with similar particle size 
distribution but differ in the surface texture and crystal habit were selected. 
The NGI results of THF and lactose blend illustrates the aerodynamic 
performance and deposition profile of the inhaled particles.  Based on the 
results SCW THF S2 with smoother surfaces and rod shaped structure, 
provides maximum FPD, FPF and minimum MMAD and GSD as compared 
to THF S5 with rough surface and spherical structure. This result proved that 
apart from particle size, particles shape and crystal habit also plays an 
important role in deposition of drug in the lungs. Based on the results it can 
be found that maximum deposition of drug on the throat and preseperator 
region this can be related to the particle surface energy and work of 
adhesion between the THF powder and lactose powder. The graph 
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illustrated that THF S2 show maximum deposition in the first 4 stages of NGI 
which can be correlated to lung deposition, but minimum deposition of drug 
in the lung region is observed when added with carrier lactose, this is 
attributed to the agglomeration between lactose and THF due to surface 
energies and thus preventing the powder to flow through NGI. Thus based 
on the NGI results it is observed that maximum deposition of drug is 
observed only when the drug is injected individually as compared with the 
blend of theophylline and lactose, this is attributed to the greater adhesive 
energy between the theophylline and lactose there is formation of 
agglomerated thus less drug deposition is observed in the NGI stages. The 
results obtained from IGC also show greater adhesive energy between the 
theophylline and lactose moiety so based on the results it is concluded that 
as there is required amount of dose deposited in the lungs, in the case 
observed for THF S2 pure samples there is no carrier needed to enhance the 
aerodynamic property of MASCW processed theophylline. Below table 7.17 
represents the summary of inhalation property of pure theophylline and blend 
of theophylline and lactose monohydrate 





In the present study description regarding the application of MASCW process 
for the development of micro sized particles of theophylline with enhanced 
aerodynamic properties as compared to standard spray dried theophylline 
powder sample as reference standard. THF MASCW treated THF S2 
showed high FPD and FPF fraction from 5.93 mg, 35.48% respectively. THF 
spray dried showed low FPD and FPF fraction from 1.86 mg, 16% 
respectively, thus pure theophylline processed using MASCW process 
showed higher aerodynamic and suitable physico-chemical properties for 
lung delivery, as confirmed by the morphology, surface properties and in-
vitro aerodynamic performance studies. 
The FPD and FPF of THF SCW treated showed high deposition rate 
compared to conventional THF SD, therefore reasonable good THF dose 
can be achieved with the patients having difficulties in generating high level 











Chapter 8: A Green route for the synthesis of API-loaded 
nano-crystalline hydroxyapatite 
In this chapter, MASCW technology was implemented as the green 
technology for the synthesis of nanocrystalline hydroxyapatite and further 
explored on the prospects of combining nanoHA with a pharmaceutically 
active component like ibuprofen to enhance the clinical performance of the 
biologically active complex in the treatment of various bone-related diseases 
in the human body. The possibility of the attachment of ibuprofen to the 
surface of nanoHA via the formation of the hydrogen-bonded complex was 
designed and investigated. 
8.1 Introduction 
Hydroxyapatite (HA), with its chemical formula Ca10(PO4)6(OH)2, is a major 
inorganic component of bone and along with collagen fibrils, it accounts for 
up to 65% of the hard tissue of vertebrates. Hydroxyapatite is the inorganic 
biomaterials which are nano-sized, non-stoichiometric, calcium deficient 
carbonated ceramic material with low crystallinity which mimics the bone 
composition (Vallet-Regí and González-Calbet 2004). Nanocrystalline 
hydroxyapatite implants are used in the market for the treatment of various 
bone defects resulting from trauma or surgery as it possesses excellent 
biocompatibility and osteoconductivity properties (Ogilvie et al., 1987). This 
biocompatible property of HA had gained significant importance in bone 
tissue engineering, implant osseointegration, and drug delivery. 
During the last decades, HA complexes with polymers, ceramics or 
hydrogels are very extensively studied, in all these studies HA is used as the 
drug carrier, in turn, have been particularly studied as prospective drug 
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delivery systems for the treatment of various bone infections. Osteoarthritis 
and rheumatoid arthritis, despite having different causes behind the 
diseases, share similar symptoms of chronic pain due to associated 
peripheral inflammation (Ma et al., 2008). Both are considered an important 
public health concern, with osteoarthritis being the most common cause of 
total hip or knee replacement. 
One of the most common analgesic anti-inflammatory non-steroidal drugs 
used for relief of pain symptoms in arthritic patients is ibuprofen (Boureau et 
al., 2004). Ibuprofen, or 2-(4-isobutylphenyl) propanoic acid (Fig. 8.1a), 
exists as a cyclic hydrogen-bonded dimer in a solid state (Fig. 8.1b) and its 
anti-inflammatory and analgesic activity is assigned to the mono-carboxyl 
groups of an ibuprofen monomer (Smeyers et al., 1985). Based on this, it is 
beneficial to introduce ibuprofen into the body as a monomer, for instance as 
a sodium salt, for an improved performance due to a higher drug solubility.  
 
Figure 8.1 Structures of (a) ibuprofen monomer, 2-(4-isobutylphenyl) 
propanoic acid, and (b) dimer of ibuprofen highlighting the hydrogen 
bond between carboxyl groups. 
Several attempts have been made to combine hydroxyapatite and ibuprofen 





achieve the desired drug dissolution rates (Qi et al., 2012) (Melville et al., 
2008). These studies attempt to relate the prolonged retention times and 
drug release either with the geometry of the materials (Sambudi et al., 2016) 
or with the porosity of ceramics in combination with hydrogen bonding effects 
between hydroxyapatite and ibuprofen monomer. Whereas the majority of 
studies produced materials using a trial-and-error approach to find the best 
possible combination of an API and an excipient, they did not focus on the 
mechanism of the API adsorption and release, but rather on the final 
formulation with certain characteristics. However, to the best of our 
knowledge, there are currently no insights into the physical chemistry behind 
the ibuprofen loading onto the surface of hydroxyapatite and its release. In 
the present study, for the first time mechanistic studies describing the 
adsorption of ibuprofen on the surface of hydroxyapatite is reported and 
propose a possible mechanism for the interaction of ibuprofen and 
hydroxyapatite at the molecular level. The understanding of the surface 
properties of ceramics and its influence on the API dissolution rates may 
provide a useful conceptual platform for the rational development and design 
of formulations with the desired controlled and sustained drug release. 
8.2 Results 
8.2.1 Characterisation of synthesised hydroxyapatite 
8.2.1 (a) PXRD results  
Several characterisation techniques were employed to verify whether the 
synthesised HA using two different methods mimic the bone composition. 
Figure 8.2 represents the PXRD pattern comparison between HA 
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synthesised using conventional mixing method and MASCW process 
method. 
 
Figure 8.2 PXRD pattern of A) HA synthesised using conventional 
mixing method and B) HA synthesised using MASCW process 
Based on the PXRD pattern in Figure 8.2, HA synthesised using 
conventional mixing process is not stoichiometrically similar to the bone 
composition. Impurities of tricalcium phosphate were produced which 
correlated with the peak at 18 2θ° represented as a star (*) in Figure 8.2 A. 
This characteristic peak is absent in the HA batch synthesised using 
MASCW process technology, thus MASCW process was selected over 
conventional method for sysnthesis of HA complex. Figure 8.3 represents the 
XRD patterns for HA raw or as prepared (a) and calcined HA at 1000°C 
overnight (b). Peak broadening of raw material is characteristic of poorly 
crystalline nano-dimensional hydroxyapatite, the second phase of tri-calcium 
phosphate is detected after calcination (major reflections not overlapping 
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with that of HA are marked as * symbol), thus indirectly proving non-
stoichiometry of HA. 
 
Figure 8.3 PXRD patterns of a) raw, or as-prepared, hydroxyapatite, b) 
hydroxyapatite calcined at 1000 °C. 
Based on the results the XRD pattern of raw HA is in complete correlation 
with standard HA phase reported in JCPDS entry 9-432 (mineral powder 
diffraction file data book). There is broadening of the peak at region 20 and 
50° 2θ are usually characteristic of either partially amorphous or nano-
particulate material. Interestingly, Figure 8.2b reveals the thermal 
decomposition of non-stoichiometric HA into tricalcium phosphate (TCP) 
after calcination of the synthesised HA there is a decrease in the peak 
volume and increase in the crystallinity of the HA material. This extra phase 
of TCP is confirmed by comparing the XRD pattern with the standard JCPDS 
entry 9-169  (Liao et al., 1999). Crystallinity calculations, in turn, showed that 
the raw, or as-prepared HA, is made of ca. 35% crystalline component, 
whereas the crystallinity of the calcined HA expectedly reached ca. 96% after 
a prolonged heat treatment (Table 8.1). 
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Table 8.1 Unit cell parameters from Rietveld refinement and crystallinity 
evaluations of nano-hydroxyapatite as-synthesised and calcined at 
1000 °C. 
 
Contraction of the unit cell upon calcination is observed as well as increase 
in crystallinity. A second phase, namely tri-calcium phosphate or TCP, has 
also been detected after thermal treatment, showing non-stoichiometry of the 
as-prepared HA. (*) 23 Wt% attributed to the tri-calcium phosphate (JCPDS 
entry 9-169). According to the Rietveld refinement results for the lattice 
parameters, the calculated unit cell of the raw hydroxyapatite is 531.4 ± 1.1 
Å3 whereas for the calcined material it is 526.5 ± 1.1 Å3, while the proportion 
of the second phase of tri-calcium phosphate (TCP) is 23 wt. %.  
The Scherrer equation (Cullity 2001), allowed us to evaluate the crystallite 
size which appeared to be 13 nm for raw HA and 79 nm for calcined HA. 
Decomposition of HA into TCP after thermal treatment and reduction of the 
unit cell volume is indirect evidence of its non-stoichiometry, whereas its 
particle (crystallite) size lies within a nanometre range, thus proving that the 
HA used for this study is indeed a non-stoichiometric nano-sized material 
with poor crystallinity.  
8.2.1 (b) FTIR spectral results  
To further analyse the similarity between the synthesised HA and bone 
attenuated total reflectance (ATR) FTIR technique as XRD alone was 
implemented. ATR-FTIR being a bulk method it cannot reveal the details of 
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the HA composition, especially for the layers of solids close to its surface. In 
this technique, the IR beam is directed on the particular sample and the 
further reflected signals are recorded using detector (Gulley-Stahl et al., 
2010). This technique is often regarded as the surface method with a 
penetration depth in a range of 0.5 to 3µm. However, considering that our HA 
is present in the form of agglomerates ranging from 20 to 200 µm and that 
ibuprofen is also in a similar range, the use of ATR-FTIR as a surface 
method can be ascribed, but with a large penetration depth. This particular 
aspect of the technique will be important also for the investigation of the 
mechanism of adsorption of ibuprofen to the HA surface.  Below Figure 8.4 
reveals the ATR-FTIR spectrum of raw HA, the main active band, and 
corresponding regions are described in table 8.2. 
   





Table 8.2 FTIR active sites and corresponding structural regions of raw 
HA 
 
Thus based on the FTIR results, surface carbonate formation occurred 
during the preparation despite the fact that carbonate anions were not 
deliberately introduced into the system. This is a known phenomenon where 
CO2 capture from the atmosphere may occur when one of the solutions has 
high pH values (Viswanath and Ravishankar 2008) or a strongly basic 
surface in the presence of moisture. Overall, the presence of small amounts 
of carbonate groups on the surface of HA is characteristic for the wet 
precipitation preparation method. However, our results are slightly different 
from previously reported studies where it has been suggested that A-type 
carbonate substitution (CO3
2- for OH-) occurs at lower temperatures, whereas 
B-type substitution is a feature of the materials prepared at elevated 
temperature ranges (Kumar et al., 2004). Only a slightly detectable A-type 
substitution with the B-type dominating was observed, thus suggesting that 
the material mostly mimics the young bone tissue (Gibson and Bonfield 
2002) as the ratio of A/B types is age-dependent and also influences the HA 
crystallinity and solubility (Ibrahim et al., 2011). 
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8.2.2 Characterisation of Ibuprofen/ HA complex formation 
8.2.2.a PXRD data 
In order to prepare ibuprofen-hydroxyapatite complex, SCW was used as the 
dissolution solvent for the IBU and subsequent stirring for 1hrs to facilitate 
absorption of ibuprofen molecule on the surface of HA and further vacuum 
filtration of the powdered complex and drying at ambient conditions. Water 
as the green solvent is used to minimise environmental impact in chemical 
reaction as compared with widely used hexane which degrades IBU 
(Chevalier et al., 2010), stirring of the suspension after MASCW process 
allows controlled loading of API molecule on HA molecule. Using PXRD it 
was described that the homogeneity of the attachment of ibuprofen on the 
surface of HA, Figure 8.5 describes the PXRD patterns of raw HA, 
commercial IBU, commercial IBU recrystallised from ethanol and IBU/HA 
complex. Based on the detection capacity of the instrument 20% w/w IBU/HA 
complex was selected. 
 
Figure 8.5 XRPD patterns of a) raw hydroxyapatite, b) commercial, or as 
received, ibuprofen from the supplier, c) commercial ibuprofen 
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recrystallised in ethanol, d) ibuprofen/hydroxyapatite (ibuprofen/HA) 
complex. 
Based on the above PXRD pattern characteristic peak of ibuprofen in 
IBU/HA complex was not observed, this is due to the low crystallinity of 
ibuprofen, the particle size of ibuprofen less than 5µm and formation of a 
highly dispersed thin layer of ibuprofen on the surface of HA (Jouyban et al.,, 
2004). 
8.2.2.b Scanning electron microscopy images  
SEM images also reveal very interesting results, Figure 8.6 describes the 
microscopic images of a) raw HA, b) commercial ibuprofen, c) IBU 
recrystallised from ethanol and d) IBU/HA complex. 
 
Figure 8.6 SEM micrographs of a) raw hydroxyapatite, b) commercial, 
or as received, ibuprofen from the supplier, c) commercial ibuprofen 






Similar particle shapes and sizes were observed for as-prepared HA (a) and 
ibuprofen/HA complex (d). It can be seen that raw HA consists of reasonably 
large agglomerates of ca. 200 µm and some smaller clusters of 10-20 µm. 
Commercial ibuprofen showed rod-shaped particles of ca. 50-200 µm, 
whereas water-recrystallised ibuprofen particles are randomly shaped with 
the average size ranging from 10 to 250 µm. It cannot be excluded that the 
possibility of the formation of rod-shaped particles with larger dimensions 
during the recrystallisation of ibuprofen, as the recrystallised sample is 
crushed in a mortar and pestle prior to analysis, and this may not be a 
complete representation of the particle shape and size. However, it is 
important to compare the water treated ibuprofen specimen with the 
ibuprofen/HA complex that has also been ground to reach a powder form, 
and we believe the comparison between two SEM micrographs for these 
materials is valid in this case. 
Another interesting feature observed during SEM analysis is specimen 
destruction under the electron beam see Figure 8.7. Structural damage upon 
irradiating the sample with the beam of electrons is a well-known 
phenomenon and may happen not just with organic samples (Talmon 1987) 
but also with ceramics, though at much higher accelerated voltages and 
current densities. Trial were done to exploit this feature to try to visualise the 




Figure 8.7 SEM micrographs of a) as received ibuprofen, b) same as a 
but after approx. 4 min exposure to electron beam radiation; c) 
ibuprofen/HA complex, d) same as c but after approx. 4 min exposure 
to electron beam radiation. 
It is observed that when pure ibuprofen is subjected under electron beam 
noticeable destruction of the sample is taking place whereas no such 
changes are visible in the microimages of IBU/HA complex, thus suggesting 
the homogenous distribution of ibuprofen on the surface of HA. 
8.2.2. c ATR-FTIR spectral data 
Further, formation of IBU/ HA complex using ATR-FTIR spectroscopy was 
studied, Figure 8.8 reveals the spectra for IBU/HA complex (a) and water 
treated IBU (b). 
Upon close inspection of the spectra, small shift in the carbonyl region of 
ibuprofen/HA complex to higher wavenumber (1717 cm-1) compared to pure 







Figure 8.8 ATR-FTIR spectra of a) ibuprofen/HA complex and b) 
ibuprofen recrystallised in water. 
Majority of the active bands are observed in the range of 1800 to 500 cm-1 
and 3200 to 2400 cm-1 with the former assigned to carbonyl group, tertiary 
and quaternary carbon atoms and OH bending vibrations and the latter to the 
C-H and C-C bond stretching. Interestingly, overlapping of the two spectra 
(see inset on Fig. 8.8) clearly shows the shift of the ibuprofen C=O group 
stretching to the higher wavenumbers from the 1707 to 1717 cm-1. Similar 
shifts have been reported in the literature and they are usually explained, yet 
not proved, by the hydrogen bonding between the hydroxyl groups of HA and 
the carbonyl group of ibuprofen. However, the degree of this deviation is 
variable from study to study, ranging from 1720 cm-1(Öner et al., 2011) to 
1547 cm-1 (Sambudi et al., 2016). This large variability in literature data, as 
well as the lack of direct evidence on the actual nature of molecular bond 
interactions between ibuprofen and HA prompted us to investigate this issue 
in more detail. 
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8.2.3 Analysis of ibuprofen monomer, dimer and attached species 
using ATR-FTIR spectroscopy 
Firstly, the behavior of ibuprofen in ethanol solution based on the greater 
solubility of IBU in ethanol is observed. Based on the previous literature it is 
reported that ibuprofen exists in a hydrogen-bonded cyclic dimeric form 
which is stable in both solution and solid phases. Our objective is to identify 
the monomeric form of ibuprofen in ethanol solution as ethanol is used as the 
solvent system to dissolve ibuprofen. To perform this experiment known 
quantity of ibuprofen is dissolved in ethanol solution based on its solubility in 
organic ethanol and the resulting solution is subjected under ATR crystal of 
ATR-FTIR spectrometer and allowed it to dry at ambient conditions recording 
the spectra in the initial and final time points. Below Figure 8.9 represents the 
IR spectra of ibuprofen in ethanolic solution. 
 
Figure 8.9 ATR-FTIR spectra of a) Ibuprofen in ethanol on the ATR 
crystal, b) same as a) but dried on the ATR crystal for 4 hours. 
Figure 8.9 a) shows the IR spectrum at the zero time point measurement in 
the presence of ethanol, whereas Fig. 8.9 b) shows the spectrum of 
ibuprofen after 4 hours when the ethanol had completely evaporated (as 
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indicated by the absence of ethanol‘s most active bands at 880, 1046 and 
1087 cm-1 and a broad band between 3600 and 3000 cm-1). What is 
immediately apparent is the presence of a broad shoulder in the region 
between 1760 and 1720 cm-1 in the spectrum corresponding to the 
ibuprofen dissolved in ethanol (Fig. 8.9 a). Deconvolution of this part of the 
spectrum (see inset in Fig. 8.9) allowed us to determine the peak position of 
a second species which appeared to be at ca. 1735 cm-1 and has been 
assigned as the C=O stretching vibration of monomer ibuprofen affected by 
H-bonding with ethanol (further confirmed by the computational studies). 
Thus it has been proved that ibuprofen may exist in both dimeric and 
monomeric forms when ethanol is present in the system. 
Thus as the presence of monomer in the ethanol solution is proved,  the next 
step of the analysis is to investigate the presence of monomer, dimer and 
attached species in IBU/HA complex generated using MASCW technology. 
Below Figure 8.10 shows the presence of monomer, dimer and attached 
species of IBU in IBU/HA complex. 
 
Figure 8.10:  Area of the FTIR spectra characteristic of H-bonding 
attachment: (---) pure Ibuprofen, (---) physical mixture of Ibuprofen and 
HA and (---) microwave-assisted synthesis of Ibuprofen/HA complex. 
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Based on the above Figure it is observed that IBU in monomer, dimer and in 
attached state with HA molecules, at 1740 cm-1 wavelength region where 
formation of monomer species is seen and it can be seen at C=0 bond 
vibrations at 1735 cm-1 corresponding to hydrogen bonding generated due to 
water molecule,   thus proving the formation of bonding between IBU and HA 
using MASCW process. 
Thus the presence of ibuprofen monomer in the ethanol solution and in water 
suspension has been assessed, the next step of analysis is to evaluate the 
presence of dimer, monomer and attached species in the synthesised 
IBU/HA complex using time-on-line IR spectroscopy. Various in situ 
experiments were performed on synthesised IBU/HA complex which is 
directly transferred from the synthesis flask onto the ATR crystal of 
spectrometer. Measurements were recorded at different time points (6 to 
180minutes) and peak at 1717 cm-1 was not observed (as in Figure 8.7 
above), this band we believed that corresponds to absorbed monomeric 
ibuprofen species. To further investigate the results further ex situ 
experiments where the sample complex is directly collected from the 
synthesis flask every time at different time points and transferred on to the 




Figure 8.11 Kinetics of the ibuprofen/HA complex formation, ex-situ 
ATR-FTIR measurements of the carbonyl region of ibuprofen between 6 
and 180 min, showing the evolution of the peak assigned as attached 
species, and the signal decay of the dimer and monomer peaks. 
This is different from the previous, in situ, IR experiment as in the first case 
the specimen is always the same across the experiment, whereas in this 
second case the specimens are different at every measurement time point, 
though still originating from the same ibuprofen/HA sample (flask). 
Interestingly, in the case of ex situ kinetic studies, we were able to observe a 
peak at 1717 cm-1 instead. This suggests that keeping a specimen between 
the force applicator and the ATR crystal for the whole duration of the in situ 
experiment (180 min) prevents the formation of the adsorbed species, 
leading only to the re-crystallisation of the ibuprofen dimer. 
8.2.4 Dissolution studies 
Finally, dissolution experiments was performed to study the drug release 
properties of ibuprofen which is absorbed on the surface of HA nanocrystals. 
Figure 8.11 shows the drug release profiles of pure ibuprofen (as a control), 
a physical mixture of ibuprofen and HA, and ibuprofen/HA complex which 


















was proved to be made up of a hydrogen-bonded API monomer weakly 
attached to the surface of HA. Fig. 8.11 demonstrates that the release of 
drug from the physical mixture and pure ibuprofen is similar whereas the 
drug release profile for HA loaded IBU complex is statistically slower at the 
initial time points (between 5 and 180 mins) but then equalizes by the 4 
hours measurements. This could possibly be explained by the fact that the 
main cause of the retardation of ibuprofen release is due to weak 
intermolecular bonding between the API and the carrier, and not the 
geometry of the HA.  
The intense drug release at the early time points of the dissolution is 
normally associated with the concentration gradients on the surface where 
diffusion pathways are short, followed by the decrease of the drug release 
rate due to the increase in the diffusion pathways from the bulk. Such 
formulations are referred to as diffusion-controlled drug delivery system, and 
the kinetics is based on the known cylindrical geometry of the tablets and 




Figure 8.12 Drug release profile of: as received ibuprofen (■), physical 
mixture of ibuprofen and hydroxyapatite (●) and hydrogen bonded 
ibuprofen-hydroxyapatite complex (ibuprofen/HA) (▲). 
In our case, however, no tablet was made, and therefore ibuprofen that 
formed a thin layer on the surface of the HA powder is readily released 
mostly from the surface rather than the bulk, thus suggesting that the profile 
observed in Fig. 8.12 is not fully diffusion controlled. The slower release rate 
for the ibuprofen/HA complex can be clearly noted, whereas raw ibuprofen 
and a physical mixture of ibuprofen and HA present similar dissolution rates. 
This slower, and desirable, drug release was related to the adsorption of the 
API compared to the bi-phasic physical mixture where the two components 
are not bonded to one another, thus proving that the intra-molecular bonding 
effect between the API and a carrier is an important factor when designing 
materials with controlled drug release properties. The majority of the studies 
on combining ceramics and anti-inflammatory concentrate their attention on 
prolonged drug release, whereas for the treatment of arthritic patients a 
―burst‖ drug release may be required at a point of need followed by a 
prolonged drug release afterward (Hite et al., 2007). Our study suggests that 
when ibuprofen and HA form a hydrogen-bonded complex it may be more 
difficult to obtain an immediate release due to an API-carrier interaction, in 
turn impeding design of materials with dual properties when using the 





In this study, application of MASCW process as green route for the synthesis 
of nano-crystalline HA which is stoichiometrically similar to bone composition 
is explored and further elucidation of mechanism of the IBU adsorption onto 
the surface of nano-HA and its effects on the drug dissolution rate, explaining 
earlier findings on the shift of the FTIR signal of the carbonyl group of the 
API in the presence of ceramics. Herein, using an array of characterisation 
tools it is demonstrated that when synthesising an ibuprofen/ceramic 
complex, a hydrogen bonding occurs between the carbonyl group of the API 
and a calcium centre of hydroxyapatite. The process of surface-attachment 
follows the steps: (i) ibuprofen dimer partial dissolution in a solvent, (Williams 
W. Porter III) formation of a monomer/solvent complex from a dimer, 
(Williams W. Porter III) subsequent preferential attachment of the ibuprofen 
monomer to the hydroxyapatite. The latter is represented by a hydrogen 
bond between the hydroxyl group of ibuprofen and one of the hydroxyl 
groups of the hydroxyapatite, along with an interaction between the carbonyl 
group of ibuprofen and a calcium centre of HA. The formation of this complex 
occurs by means of a first order kinetics. Furthermore, the influence of such 
non-covalent bonding on the release/dissolution rate of the drug was also 
investigated. Through investigation of the behavior of the intramolecular 
bonded system ibuprofen-hydroxyapatite under physiological conditions 
(Ghosh et al., 2011) and comparing it with the bi-phasic mixture of the two 
components it is shown that the initial API release rate from the complex is 
influenced by the hydrogen bond induced attachment of the ibuprofen to the 
surface of nano-hydroxyapatite.  
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Chapter 9:  Global Conclusions 
In the present research work, for the first time a novel ―Microwave Assisted 
Sub-Critical Water‖ to dissolve hydrophobic organic molecules and further 
explored the application of this novel technology in the fields of particle 
engineering and pharmaceutical processing is studied. In this process, high 
supersaturated solution of water and solute is prepared and further on 
cooling step based on the aqueous solubility of solute narrow particle size 
crystals induce out. 
Chapter 5:  In this chapter, process understanding and validation of MASCW 
technology is reported by generating a correlation between solute/solution 
concentrations (w/v) and processing temperatures of the MASCW process. 
Raman spectroscopy is used to track the crystallisation kinetics and 
polymorphic transformation of paracetamol solution from metastable phase 
form II to stable form I polymorph. Initially, till 90 mins of analysis no 
crystallisation is occured which is latter followed by generation of metastable 
phase of pca crystals which remained stable till 18 hrs and   then conversion 
of metastable polymorphs to stable polymorph is observed. This proved the 
theory of Gibbs free energy that in solution state the polymorphic phase with 
higher free energy crystallises first followed by stable less free energy 
polymorphic phase. To understand the role of dielectric constant of water 
and solvent mixtures of water and organic solvents on solubility of solute at 
sub-critical state correlation between the change in the dielectric constant of 
solvent and solubility of solute is investigated. As there is decrease in the 
dielectric constant of solvent solubilising property of solvent enhances 
simultaneous resulting in producing highly supersaturated solutions of 
254 
 
hydrophobic APIs. Difference between conventional heating temperatures 
and sub-critical water heating temperatures is investigated by tracking the 
crystallisation time for the crystals to induce out is calculated. In this stability 
of supersaturated solutions of paracetamol solution is reported. In the 10% 
w/v aqueous solution of pca in sub-critically treated water remained stable for 
more than 24 hrs compared to conventional pca solution which is stable for 
three hours. This experimental observation indicates that on treating water at 
sub-critical state more water hydrogen bonds are broken compared to 
conventionally treated water molecules.  All the solute crystals generated are 
analysed for its percent purity using HPLC technique. 
Chapter 6: provided an evidence regarding the application of the MASCW 
process in cocrystallisation, based on the congruency of the cocrystal pairs 
used this chapter is further divided into three sections 
Chapter 6.2.1: In this chapter, based on aqueous solubility of API and 
coformer congruent pairs (CBZ: SAC, SMT: SAC and SMZ: SAC) in 1:1 
stoichiometric ratio is selected. Experimental design approach is used to 
understand the effect of different process and experimental parameters on 
end crystal phase is investigated. Generation of stable form I and metastable 
form II cocrystal phase of CBZ: SAC in 1:1 ratio from water is reported. SEM 
images have provided additional data regarding the change in crystal 
morphology and crystal habit of different cocrystal polymorph, the surface 
energy data explained the differences between the specific surface energies 
of CBZ: SAC form I (solution crystallised), CBZ: SAC form I and metastable 
form II (MASCW processed),  the increase in the surface properties of the 
MASCW generated cocrystal has been reported which is further linked with 
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the study of kinetic properties (solubility) of these samples. Thermal analysis 
data has provided the information regarding the thermodynamic monotropic 
relationship between form I and form II transitions of CBZ: SAC cocrystals. 
PXRD and Raman spectra have elucidated the phase purity of the cocrystals 
formed. Minimum degradation of MASCW processed samples using HPLC 
analysis was observed.  
Chapter 6.2.2: In this chapter, high throughput screening is done for 
generation of congruent cocrystal pairs of SMT: SAC, SMZ: SAC in 1:1 
stoichiometric using water as solvent systems. X-ray diffraction and thermal 
analysis data has confirmed the formation of cocrystal based on the previous 
literature review. 
Chapter 6.2.3: In this section, incongruent cocrystal pair of CAF: 4HBA in 1:1 
stoichiometric ratios is selected for generation of anhydrous cocrystal of 
CAF: 4HBA in 1:1 stoichiometric ratio. The effect of decrease in dielectric 
properties of solvent system by using a solvent mixtures of (50% methanol + 
50% water) on increase in solubility of molar concentration weight CAF: 
4HBA cocrystal pairs in 1:1 ratio under subcritical environment is reported. 
PXRD, DSC and NMR data provides the formation of anhydrous phase of 
CAF: 4HBA cocrystal in 1:1 stoichiometric ratio. These results were 
practically generated for the first time using MASCW process. 
Chapter 7: This chapter demonstrated the application of the MASCW 
process in the field of particle engineering. Based on the drug dosage form 




Chapter 7.1: This section includes the application of MASCW technology for 
generation of metastable polymorph of paracetamol using water as solvent 
system. Paracetamol commercial phase (form I) has a serious issue of 
compressibility during tableting. This issue can be attributed to the crystal 
lattice arrangements, crystal form, and crystal habit. PXRD, thermal analysis, 
and Raman spectroscopic data reveal the formation of metastable and stable 
polymorphs of pca using water as the solvent system. The SEM images 
reveal the change in the crystal habit and surface smoothness of MASCW 
processed samples compared to conventional commercial form I pca 
samples. Enhanced surface properties like specific surface area, dispersive 
surface energy are observed in the processed samples compared to raw 
pca, this surface energetic data attribute to increase in the compressibility 
and pharmacokinetic properties of MASCW processed a form I and form II 
polymorph of pca. Intrinsic dissolution data demonstrated that there is an 
increase in the solubility of MASCW processed form I polymorph of pca 
compared to raw which is attributed to the crystal habit and surface energies 
of the samples. The HPLC analysis provided the information regarding the 
chemical stability of MASCW processed samples as compared to 
conventional heating of pca in water at high temperatures. 
In this chapter, the scalability of this technology with the help of external 
pharmaceutical processing industry was investigated and further obtained 
the similar results with enhancing kinetic properties and minimum chemical 
degradation. 
Chapter 7.2: In the process of MASCW process sub-critical treated 
supersaturated solution is quenched in cold water which induced out crystal 
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with narrow particle size distribution for the generation of inhalable drug 
particles using dry powder inhaler. Anhydrous theophylline and lactose 
inhalation grade were selected as API and carrier model respectively based 
on their applications in nasal delivery system using DPI. The aerodynamic 
performance of the powdered samples is elucidated using next generation 
impactor (NGI). Spray dried theophylline is used as reference powder 
sample for analysis of aerodynamic performance. PXRD, DSC, TGA and 
FTIR data demonstrated the formation of stable anhydrous form I 
theophylline using MASCW process. Correlation between supersaturated 
concentration of solute and different crystallisation techniques on crystal size 
and morphology is investigated. iGC analysis demonstrated the surface 
properties, thermodynamic work of adhesion and cohesion between MASCW 
processed THF and spray dried THF with inhalation grade lactose. 
THF MASCW treated THF S2 showed high FPD and FPF fraction from 
5.93mg, 35.48% respectively. THF spray dried showed low FPD and FPF 
fraction from 1.86, 16% respectively, thus pure theophylline processed using 
MASCW process showed higher aerodynamic and suitable physicochemical 
properties for lung delivery, as confirmed by the morphology, surface 
properties, and in-vitro aerodynamic performance studies. The FPD and FPF 
of THF SCW treated showed high deposition rate compared to conventional 
THF SD, therefore reasonable good THF dose can be achieved with the 
patients having difficulties in generating a high level of inhalation flow such 
as children‘s and elderly. 
Chapter 8: In this chapter, description of the application of the MASCW 
process for the synthesis of inorganic nano-crystalline HA and formation of 
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IBU/HA complex is reported for the first time. Further, in-depth understanding 
regarding the mechanism of hydrogen-bonded complex formation between 
ibuprofen and nano-crystalline hydroxyapatite is explained. Herein, using 
different characterisation tools the synthesis of IBU-HA complex was 
reported, the formation of hydrogen bonding between carbonyl moiety of API 
and calcium center HA. ATR-FTIR is used to track the kinetics of hydrogen 
bonding between IBU-HA complexes. Furthermore, the influence of such 



















Chapter 10: Suggestions for future work 
 Development of a computational molecular dynamics model for sub-
critical water to elucidate the structural and physical properties of 
water at different processing conditions. 
 To study the influence of activation energy of microwaves over the 
structural vibrations of water and solute molecules. 
 To study the influence of different additives (surfactants, antioxidants) 
in the dissociation of hydrophobic organic molecules using this 
technology. 
 To generate computational models to differentiate different crystal 
phase transition regions during processing organic molecules at 
different processing conditions. 
 To study the effect of the solvent mixture on the dielectric and 
dissolution properties of water which will affect the crystal form and 
crystallisation pathway of the molecule obtained using this technology. 
 To analyse the compressibility or mechanical properties of the crystal 
generated from this technology and analyse its influence in post 
formulation performance. 
 To study the effect of water dielectric constant over the solubility of the 
solute molecules using M-UNIFAC software. 
 To develop an in-line tool to track different phases of crystallisation 
during processing at different temperature and pressure conditions.  
 Study the application of this technology in polymer process industry, 
generation of stable solid dispersion of different drugs with enhanced 
chemical and physical stability. 
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